Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3410586,t 1/2,"In CHF patients t 1/2 of total epinine was significantly higher than in NS (4.1 +/- 0.2 h vs 3.1 +/- 0.2 h, mean +/- SE).",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),h,4.1,778,DB00668,Epinephrine
,3410586,t 1/2,"In CHF patients t 1/2 of total epinine was significantly higher than in NS (4.1 +/- 0.2 h vs 3.1 +/- 0.2 h, mean +/- SE).",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),h,3.1,779,DB00668,Epinephrine
,3410586,total urinary recoveries,"The mean +/- SE total urinary recoveries in the 24 h after dosing, expressed as percentages of the administered dose, were 60 +/- 3 in CHF patients and 69 +/- 4 in NS.",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),,60,780,DB00668,Epinephrine
,3410586,total urinary recoveries,"The mean +/- SE total urinary recoveries in the 24 h after dosing, expressed as percentages of the administered dose, were 60 +/- 3 in CHF patients and 69 +/- 4 in NS.",Ibopamine kinetics after a single oral dose in patients with congestive heart failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3410586/),,69,781,DB00668,Epinephrine
≤,33125516,time to reach maximum plasma concentration,"Vericiguat (≤ 10.0 mg, IR tablets) was rapidly absorbed (median time to reach maximum plasma concentration ≤ 2.5 h [fasted]) with a mean half-life of about 22.0 h (range 17.9-27.0 h for single and multiple doses).","Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125516/),h,2.5,3456,DB00668,Epinephrine
,33125516,half-life,"Vericiguat (≤ 10.0 mg, IR tablets) was rapidly absorbed (median time to reach maximum plasma concentration ≤ 2.5 h [fasted]) with a mean half-life of about 22.0 h (range 17.9-27.0 h for single and multiple doses).","Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33125516/),h,22.0,3457,DB00668,Epinephrine
,2368893,steady-state peak plasma concentration,"The mean steady-state peak plasma concentration was 2.3 mg/l (range 1.2-3.1 mg/l); however, in three of the eight patients peak plasma concentrations were greater than 3 mg/l.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),[mg] / [l],2.3,4612,DB00668,Epinephrine
greater,2368893,peak plasma concentrations,"The mean steady-state peak plasma concentration was 2.3 mg/l (range 1.2-3.1 mg/l); however, in three of the eight patients peak plasma concentrations were greater than 3 mg/l.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),[mg] / [l],3,4613,DB00668,Epinephrine
,2368893,accumulation ratio,"The mean accumulation ratio was found to be 1.6 (range 0.99-2.49), with steady-state occurring within the first 24 hours of drug administration.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),,1.6,4614,DB00668,Epinephrine
,2368893,apparent systemic plasma clearance,"Mean apparent systemic plasma clearance was 0.16 +/- 0.07 l/kg/h with a mean terminal half-life of 5.8 +/- 2.3 hours measured at steady-state, values which were not significantly different (P greater than 0.05) from those values obtained following single interpleural bolus dose administration.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),[l] / [h·kg],0.16,4615,DB00668,Epinephrine
,2368893,terminal half-life,"Mean apparent systemic plasma clearance was 0.16 +/- 0.07 l/kg/h with a mean terminal half-life of 5.8 +/- 2.3 hours measured at steady-state, values which were not significantly different (P greater than 0.05) from those values obtained following single interpleural bolus dose administration.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),h,5.8,4616,DB00668,Epinephrine
,21080867,maximal rate,"Management included mechanical ventilation (80%), 8.4% sodium bicarbonate (66%), epinephrine [73%, maximal rate: 2.8 mg/h (0.8-5.0)], and extracorporeal life support (16%).",Blood concentrations are better predictors of chioroquine poisoning severity than plasma concentrations: a prospective study with modeling of the concentration/effect relationships. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21080867/),[mg] / [h],2.8,5449,DB00668,Epinephrine
,7639374,steady-state concentration (Css),The infusion led to a high steady-state concentration (Css) of 5.91 +/- 2.46 mg/mL in Group TD-.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),[mg] / [ml],5.91,6020,DB00668,Epinephrine
,7639374,VAS score,The VAS score was slightly reduced after the bolus (6.6 +/- 1.0 vs 8.7 +/- 0.3; P < 0.05 vs the placebo group) but the cumulative doses of morphine were similar in both groups.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),,6.6,6021,DB00668,Epinephrine
,7639374,VAS score,The VAS score was slightly reduced after the bolus (6.6 +/- 1.0 vs 8.7 +/- 0.3; P < 0.05 vs the placebo group) but the cumulative doses of morphine were similar in both groups.,"Interpleural infusion of 2% lidocaine with 1:200,000 epinephrine for postthoracotomy analgesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7639374/),,8.7,6022,DB00668,Epinephrine
,7486614,volume of distribution,"CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours.",Clinical pharmacology of CNS 1102 in volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486614/),[l] / [kg],6.2,6419,DB00668,Epinephrine
,7486614,clearance,"CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours.",Clinical pharmacology of CNS 1102 in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486614/),[l] / [h],115,6420,DB00668,Epinephrine
,7486614,plasma half-life,"CNS 1102 has a large and variable volume of distribution (mean +/- standard deviation, 6.2 +/- 1.9 l/kg), variable clearance (115 +/- 77 l/h), and plasma half-life of approximately 4.5 hours.",Clinical pharmacology of CNS 1102 in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486614/),h,4.5,6421,DB00668,Epinephrine
,34223294,total CA duration,The mean(SD) total CA duration was 14.8(1.2) minutes.,Dose optimization of early high-dose valproic acid for neuroprotection in a swine cardiac arrest model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34223294/),min,14.8,6527,DB00668,Epinephrine
,11413527,time to attain maximum concentration,The time to attain maximum concentration of total Pt after intralesional injection was dose-dependent and ranged from 2-13 hours.,Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),h,2-13,7458,DB00668,Epinephrine
,11413527,initial half-life,The initial half-life for cisplatin doses < 15 mg was approximately 9 hours and the initial half-life at higher cisplatin doses (> 15 mg) was approximately 25 hours.,Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),h,9,7459,DB00668,Epinephrine
,11413527,initial half-life,The initial half-life for cisplatin doses < 15 mg was approximately 9 hours and the initial half-life at higher cisplatin doses (> 15 mg) was approximately 25 hours.,Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),h,25,7460,DB00668,Epinephrine
,11413527,area under the curve (AUC),The area under the curve (AUC) was dose-dependent with values ranging from 38-150 microm/mL x hour.,Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),[μm] / [h·ml],38-150,7461,DB00668,Epinephrine
,11413527,t-max,"After the intravenous infusion of cisplatin, the t-max for total and free Pt was 1.3 hours and 1.1 hours, respectively.",Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),h,1.3,7462,DB00668,Epinephrine
,11413527,t-max,"After the intravenous infusion of cisplatin, the t-max for total and free Pt was 1.3 hours and 1.1 hours, respectively.",Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),h,1.1,7463,DB00668,Epinephrine
,11413527,terminal half-life,"The terminal half-life and average AUC for total Pt was 194 hours and 247 microg/mL per hour, respectively, and its corresponding parameters for free Pt after intravenous infusion were much lower, similar to the findings for the intralesional injection.",Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),h,194,7464,DB00668,Epinephrine
,11413527,AUC,"The terminal half-life and average AUC for total Pt was 194 hours and 247 microg/mL per hour, respectively, and its corresponding parameters for free Pt after intravenous infusion were much lower, similar to the findings for the intralesional injection.",Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11413527/),[μg] / [h·ml],247,7465,DB00668,Epinephrine
,28435854,ΔAUC,"While in virtual healthy participants, the differences were calculated to be ΔAUC=2658 and ΔCmax=81 for 3-minute and 5-minute dosing frequencies.",A Clinical Trial Simulation Evaluating Epinephrine Pharmacokinetics at various Dosing Frequencies during Cardiopulmonary Resuscitation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435854/),,2658,7670,DB00668,Epinephrine
,28435854,ΔCmax,"While in virtual healthy participants, the differences were calculated to be ΔAUC=2658 and ΔCmax=81 for 3-minute and 5-minute dosing frequencies.",A Clinical Trial Simulation Evaluating Epinephrine Pharmacokinetics at various Dosing Frequencies during Cardiopulmonary Resuscitation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28435854/),,81,7671,DB00668,Epinephrine
,29439456,maximum plasma concentration (Cmax),The mean ± SEM maximum plasma concentration (Cmax) of 16.7 ± 1.9 ng/mL at peak time (Tmax) of 21 min after sublingual epinephrine 30 mg did not differ significantly (p > 0.05) from the Cmax of 18.8 ± 1.9 ng/mL at a Tmax of 36 min after IM epinephrine 0.15 mg.,Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439456/),[ng] / [ml],16.7,8106,DB00668,Epinephrine
,29439456,peak time (Tmax),The mean ± SEM maximum plasma concentration (Cmax) of 16.7 ± 1.9 ng/mL at peak time (Tmax) of 21 min after sublingual epinephrine 30 mg did not differ significantly (p > 0.05) from the Cmax of 18.8 ± 1.9 ng/mL at a Tmax of 36 min after IM epinephrine 0.15 mg.,Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439456/),min,21,8107,DB00668,Epinephrine
,29439456,Cmax,The mean ± SEM maximum plasma concentration (Cmax) of 16.7 ± 1.9 ng/mL at peak time (Tmax) of 21 min after sublingual epinephrine 30 mg did not differ significantly (p > 0.05) from the Cmax of 18.8 ± 1.9 ng/mL at a Tmax of 36 min after IM epinephrine 0.15 mg.,Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439456/),[ng] / [ml],18.8,8108,DB00668,Epinephrine
,29439456,Tmax,The mean ± SEM maximum plasma concentration (Cmax) of 16.7 ± 1.9 ng/mL at peak time (Tmax) of 21 min after sublingual epinephrine 30 mg did not differ significantly (p > 0.05) from the Cmax of 18.8 ± 1.9 ng/mL at a Tmax of 36 min after IM epinephrine 0.15 mg.,Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439456/),min,36,8109,DB00668,Epinephrine
,29439456,Cmax,The Cmax of both doses was significantly higher than the Cmax of 7.5 ± 1.7 ng/mL of endogenous epinephrine after placebo.,Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29439456/),[ng] / [ml],7.5,8110,DB00668,Epinephrine
,7687709,Peak plasma concentrations,"The interindividual pharmacokinetics of ibopamine varied considerably: Peak plasma concentrations of ibopamine in the three subjects were 2.8, 4.5, and 35.4 ng/ml, respectively.",Effects of ibopamine on postural hypotension in pure autonomic failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7687709/),[ng] / [ml],2.8,8616,DB00668,Epinephrine
,7687709,Peak plasma concentrations,"The interindividual pharmacokinetics of ibopamine varied considerably: Peak plasma concentrations of ibopamine in the three subjects were 2.8, 4.5, and 35.4 ng/ml, respectively.",Effects of ibopamine on postural hypotension in pure autonomic failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7687709/),[ng] / [ml],4.5,8617,DB00668,Epinephrine
,7687709,Peak plasma concentrations,"The interindividual pharmacokinetics of ibopamine varied considerably: Peak plasma concentrations of ibopamine in the three subjects were 2.8, 4.5, and 35.4 ng/ml, respectively.",Effects of ibopamine on postural hypotension in pure autonomic failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7687709/),[ng] / [ml],35.4,8618,DB00668,Epinephrine
,8008711,terminal half-life,"The mean terminal half-life was 118 +/- 36 min, the mean steady-state volume of distribution was 0.61 +/- 0.22 L/kg, and the mean plasma clearance was 8 +/- 2 mL/min/kg.","Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008711/),min,118,8812,DB00668,Epinephrine
,8008711,steady-state volume of distribution,"The mean terminal half-life was 118 +/- 36 min, the mean steady-state volume of distribution was 0.61 +/- 0.22 L/kg, and the mean plasma clearance was 8 +/- 2 mL/min/kg.","Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008711/),[l] / [kg],0.61,8813,DB00668,Epinephrine
,8008711,plasma clearance,"The mean terminal half-life was 118 +/- 36 min, the mean steady-state volume of distribution was 0.61 +/- 0.22 L/kg, and the mean plasma clearance was 8 +/- 2 mL/min/kg.","Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008711/),[ml] / [kg·min],8,8814,DB00668,Epinephrine
,8008711,C50,"The mean C50 was 44.4 +/- 6.0 ng/mL, and the mean Hill coefficient was 1.5 +/- 0.3.","Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008711/),[ng] / [ml],44.4,8815,DB00668,Epinephrine
,8008711,Hill coefficient,"The mean C50 was 44.4 +/- 6.0 ng/mL, and the mean Hill coefficient was 1.5 +/- 0.3.","Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008711/),,1.5,8816,DB00668,Epinephrine
,8008711,bioavailability,The mean bioavailability was 4.9 +/- 1.4% in dogs administered 2.0 mg/kg (p.o.).,"Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8008711/),%,4.9,8817,DB00668,Epinephrine
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,54,8991,DB00668,Epinephrine
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,63,8992,DB00668,Epinephrine
,8856481,Maximal inhibition,"Maximal inhibition of the systolic BP response was 54 +/- 3 (mean +/- SEM), 63 +/- 2, and 93 +/- 1% with 10, 40, and 80 mg LRB081, respectively.",Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),%,93,8993,DB00668,Epinephrine
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,3,8994,DB00668,Epinephrine
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,4,8995,DB00668,Epinephrine
,8856481,time to peak,The time to peak was 3 h for 6 subjects and 4 and 6 h for 2 others.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,6,8996,DB00668,Epinephrine
,8856481,plasma half-life (t1/2),Preliminary plasma half-life (t1/2) was calculated at 2 h.,Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8856481/),h,2,8997,DB00668,Epinephrine
,6995479,steady-state plasma epinephrine concentrations,"These 30 infusions resulted in steady-state plasma epinephrine concentrations ranging from 24 to 1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[pg] / [ml],"24 to 1,020",9497,DB00668,Epinephrine
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],52,9498,DB00668,Epinephrine
,6995479,plasma metabolic clearance rate,"At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/- 4 ml x min-1 x kg-1; this value rose to 89 +/- 6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml.",Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6995479/),[ml] / [kg·min],89,9499,DB00668,Epinephrine
,8400092,clearance rates,"Children with TOF had significantly faster clearance rates of morphine (1.39 +/- 0.37 L/kg/h) than children following the Fontan procedure (0.86 +/- 0.31 L/kg/h, P < 0.01).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],1.39,10254,DB00668,Epinephrine
,8400092,clearance rates,"Children with TOF had significantly faster clearance rates of morphine (1.39 +/- 0.37 L/kg/h) than children following the Fontan procedure (0.86 +/- 0.31 L/kg/h, P < 0.01).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],0.86,10255,DB00668,Epinephrine
,8400092,clearance rates,"When stratifying children by their postsurgical needs for inotropic support, those needing epinephrine, dopamine, or dobutamine at more than 10 micrograms/kg/min had significantly slower clearance rates (0.73 +/- 0.3 L/kg/h) when compared to the rest of the patients (1.5 +/- 0.41 L/kg/h, P < 0.05).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],0.73,10256,DB00668,Epinephrine
,8400092,clearance rates,"When stratifying children by their postsurgical needs for inotropic support, those needing epinephrine, dopamine, or dobutamine at more than 10 micrograms/kg/min had significantly slower clearance rates (0.73 +/- 0.3 L/kg/h) when compared to the rest of the patients (1.5 +/- 0.41 L/kg/h, P < 0.05).",Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8400092/),[l] / [h·kg],1.5,10257,DB00668,Epinephrine
,8910173,peak plasma lidocaine level,"In Group A, mean (+/- SD) peak plasma lidocaine level of 1.35 +/- 0.5 micrograms/ml (range 0.61 to 2.41 micrograms/ml) occurred 45 minutes after injection.",Lidocaine plasma levels following two techniques of obturator nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910173/),[μg] / [ml],1.35,11342,DB00668,Epinephrine
,8910173,peak,"In Group B, a peak of 3.63 +/- 2.07 micrograms/ml (0.75 to 7.21 micrograms/ml) occurred 15 minutes after injection.",Lidocaine plasma levels following two techniques of obturator nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910173/),[μg] / [ml],3.63,11343,DB00668,Epinephrine
,8910173,peak level,"Mean peak level in Group C of 2.08 +/- 0.77 micrograms/ml (0.84 to 3.21 micrograms/ml) occurred 60 minutes after injection Lidocaine concentrations were significantly higher in Groups B and C than in Group A, and they were higher in Group B than in Group C.",Lidocaine plasma levels following two techniques of obturator nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910173/),[μg] / [ml],2.08,11344,DB00668,Epinephrine
,2077146,half-life,"2) The blood concentration of captopril reached its peak in 2 h after medication, the mean value being 274 ng/ml and the half-life 3.16 h.",Effect of captopril on congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077146/),h,3.16,12750,DB00668,Epinephrine
,2809817,Maximum systemic concentrations,"Maximum systemic concentrations were seen at 20-30 min and ranged from 100 to 1,100 ng/ml, well below the toxic threshold of 5,000 ng/ml.",Plasma lidocaine levels following hematoma block for distal radius fractures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2809817/),[ng] / [ml],"100 to 1,100",13641,DB00668,Epinephrine
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),hg·mm,11.7,14939,DB00668,Epinephrine
,15060505,peak difference,"Ephedrine plus caffeine increased systolic blood pressure (peak difference, 11.7 +/- 9.4 mm Hg; compared with placebo, P =.0005) and heart rate (peak difference, 5.9 +/- 8.8 beats/min; compared with placebo, P =.001) and raised fasting glucose, insulin, free fatty acid, and lactate concentrations.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),[beats] / [min],5.9,14940,DB00668,Epinephrine
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,9.7,14941,DB00668,Epinephrine
,15060505,elimination half-life,"Women taking oral contraceptives had prolonged caffeine elimination (mean elimination half-life, 9.7 hours versus 5.0 hours in men; P =.05), but sex differences in pharmacodynamic responses were not seen.",Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060505/),h,5.0,14942,DB00668,Epinephrine
,29905628,peak ropivacaine concentration,"Median peak ropivacaine concentration was 1.16 μg/mL (IQR, 0.46); median peak unbound ropivacaine concentration was 0.05 μg/mL (IQR, 0.02).",Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905628/),[μg] / [ml],1.16,15282,DB00668,Epinephrine
,29905628,peak unbound ropivacaine concentration,"Median peak ropivacaine concentration was 1.16 μg/mL (IQR, 0.46); median peak unbound ropivacaine concentration was 0.05 μg/mL (IQR, 0.02).",Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905628/),[μg] / [ml],0.05,15283,DB00668,Epinephrine
,29905628,times to reach the maximum concentration,"The corresponding times to reach the maximum concentration for total and unbound ropivacaine were 360 (IQR, 240) and 360 (IQR, 360) minutes, respectively.",Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905628/),min,360,15284,DB00668,Epinephrine
,29905628,times to reach the maximum concentration,"The corresponding times to reach the maximum concentration for total and unbound ropivacaine were 360 (IQR, 240) and 360 (IQR, 360) minutes, respectively.",Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905628/),min,360,15285,DB00668,Epinephrine
,30399533,protein binding,Changes in bupivacaine plasma protein binding is of clinical relevance considering its high protein binding (approximately 95%) and its classification as an intermediate hepatic extraction ratio drug (E = 0.38).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,95,16533,DB00668,Epinephrine
,30399533,flow rate,"The separation of bupivacaine enantiomers was obtained on a Chirex® 3020 chiral stationary phase column using as a mobile phase a mixture of 95% n-hexane:ethanol (80:20, v/v) at a flow rate of 0.8 mL/min.",Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[ml] / [min],0.8,16534,DB00668,Epinephrine
,30399533,unbound concentration,The lower limit of quantification was 0.25 ng of each enantiomer/mL of plasma as the total concentration and 0.125 ng of each enantiomer/mL of plasma as the unbound concentration.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),ng,0.125,16535,DB00668,Epinephrine
,30399533,AUC0-∞,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[h·ng] / [ml],25.42,16536,DB00668,Epinephrine
,30399533,AUC0-∞,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[h·ng] / [ml],30.57,16537,DB00668,Epinephrine
,30399533,volume of distribution,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),l,841.96,16538,DB00668,Epinephrine
,30399533,volume of distribution,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),l,655.05,16539,DB00668,Epinephrine
,30399533,total clearance,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[l] / [h],98.34,16540,DB00668,Epinephrine
,30399533,total clearance,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[l] / [h],81.79,16541,DB00668,Epinephrine
,30399533,AUC(R)/(S) ratio,The pharmacokinetics of bupivacaine were enantioselective displaying a lower plasma proportion of the enantiomer R-bupivacaine (AUC(R)/(S) ratio equal to 0.83).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),,0.83,16542,DB00668,Epinephrine
,30399533,placental transfer,The placental transfer was approximately 60% for both bupivacaine enantiomers.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,60,16543,DB00668,Epinephrine
,30399533,unbound fraction (Fu),The unbound fraction (Fu) for the R-bupivacaine enantiomer was higher (10.84%) than the eutomer S-bupivacaine (6.29%).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,10.84,16544,DB00668,Epinephrine
,30399533,unbound fraction (Fu),The unbound fraction (Fu) for the R-bupivacaine enantiomer was higher (10.84%) than the eutomer S-bupivacaine (6.29%).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,6.29,16545,DB00668,Epinephrine
,12665159,peak plasma concentrations,The mean of the individual peak plasma concentrations of bupivacaine (C(max) was 0.74+/- 0.64 microg/ml.,"Steady state bupivacaine plasma concentrations and safety of a femoral ""3-in-1"" nerve block with bupivacaine in patients over 80 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665159/),[μg] / [ml],0.74,17288,DB00668,Epinephrine
,12665159,highest plasma concentration,The highest plasma concentration was 1.83 microg/ml.,"Steady state bupivacaine plasma concentrations and safety of a femoral ""3-in-1"" nerve block with bupivacaine in patients over 80 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665159/),[μg] / [ml],1.83,17289,DB00668,Epinephrine
,28844768,peak level (Cmax),"The mean peak level (Cmax) was 0.8 μg/mL (range, 0.4-1.2 μg/mL).",Systemic Safety of Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844768/),[μg] / [ml],0.8,19826,DB00668,Epinephrine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,4,19904,DB00668,Epinephrine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,5.5,19905,DB00668,Epinephrine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,5.3,19906,DB00668,Epinephrine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,9.8,19907,DB00668,Epinephrine
,2331063,Peak arterial plasma concentrations,Peak arterial plasma concentrations after IP injection (2.07 +/- 0.53 micrograms/mL) were significantly higher (P less than 0.005) than those after IC administration (1.36 +/- 0.48 micrograms/mL).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],2.07,19908,DB00668,Epinephrine
,2331063,Peak arterial plasma concentrations,Peak arterial plasma concentrations after IP injection (2.07 +/- 0.53 micrograms/mL) were significantly higher (P less than 0.005) than those after IC administration (1.36 +/- 0.48 micrograms/mL).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],1.36,19909,DB00668,Epinephrine
,2331063,Peak venous plasma concentrations,Peak venous plasma concentrations showed a similar difference (IP: 1.86 +/- 0.45 micrograms/mL; IC: 1.21 +/- 0.48 micrograms/mL; P less than 0.005).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],1.86,19910,DB00668,Epinephrine
,2331063,Peak venous plasma concentrations,Peak venous plasma concentrations showed a similar difference (IP: 1.86 +/- 0.45 micrograms/mL; IC: 1.21 +/- 0.48 micrograms/mL; P less than 0.005).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],1.21,19911,DB00668,Epinephrine
,10945316,renal clearance,"Steady-state plasma mecamylamine concentrations were twice as high (mean, 12.2 versus 6.3 ng/mL), consistent with lower renal clearance (2.1 versus 5.8 mL/min/kg) during alkaline compared with acidic urine conditions.",Nicotine-mecamylamine interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945316/),[ml] / [kg·min],2.1,21120,DB00668,Epinephrine
,10945316,renal clearance,"Steady-state plasma mecamylamine concentrations were twice as high (mean, 12.2 versus 6.3 ng/mL), consistent with lower renal clearance (2.1 versus 5.8 mL/min/kg) during alkaline compared with acidic urine conditions.",Nicotine-mecamylamine interactions. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10945316/),[ml] / [kg·min],5.8,21121,DB00668,Epinephrine
,27417947,absorption half-life,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,4.22,21818,DB00668,Epinephrine
,27417947,absorption half-life,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,7.02,21819,DB00668,Epinephrine
,27417947,relative bioavailability,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,0.,21820,DB00668,Epinephrine
,3777457,peak plasma concentrations,"Addition of epinephrine to the local anesthetic solutions reduced the mean peak plasma concentrations of lidocaine and bupivacaine from 2.2 to 1.7 micrograms/ml (23%) and from 0.73 to 0.53 microgram/ml (28%), respectively, but did not alter the times at which the peak concentrations were reached.",Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777457/),[μg] / [ml],2.2 to 1.7,23243,DB00668,Epinephrine
,3777457,peak plasma concentrations,"Addition of epinephrine to the local anesthetic solutions reduced the mean peak plasma concentrations of lidocaine and bupivacaine from 2.2 to 1.7 micrograms/ml (23%) and from 0.73 to 0.53 microgram/ml (28%), respectively, but did not alter the times at which the peak concentrations were reached.",Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777457/),[μg] / [ml],0.73 to 0.53,23244,DB00668,Epinephrine
,29197630,PCTA,Simulated maximum recommended dose regimen (7mg/kg) had a PCTA of 0%.,"Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29197630/),%,0,26414,DB00668,Epinephrine
,29197630,PCTA,"Simulated higher doses of 10mg/kg and 15mg/kg had a PCTA of 0% and about 1-4%, respectively.","Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29197630/),%,0,26415,DB00668,Epinephrine
,29197630,PCTA,"Simulated higher doses of 10mg/kg and 15mg/kg had a PCTA of 0% and about 1-4%, respectively.","Population pharmacokinetics of articaine with 1:200,000 epinephrine during third molar surgery and simulation of high-dose regimens. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29197630/),%,1-4,26416,DB00668,Epinephrine
,11237494,half-life,"Further, epinephrine half-life was 20.8+/-3.6 min in the peritoneal cavity of two laparotomized pigs.",Pre-clinical study of the epinephrine-cisplatin association for the treatment of intraperitoneal carcinomatosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11237494/),min,20.8,27651,DB00668,Epinephrine
,7720172,AUC,Area-under-the-curve (AUC0-24 h) calculations resulted in an AUC value of 146.4% h for the 5-FU/epi gel formulation as compared with 45.7% h for 5-FU solution.,Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720172/),%·h,146.4,28474,DB00668,Epinephrine
,7720172,AUC,Area-under-the-curve (AUC0-24 h) calculations resulted in an AUC value of 146.4% h for the 5-FU/epi gel formulation as compared with 45.7% h for 5-FU solution.,Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7720172/),%·h,45.7,28475,DB00668,Epinephrine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,379,29341,DB00668,Epinephrine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,32.9,29342,DB00668,Epinephrine
,1751170,daily excretion,"Catecholamine clearances from CHD (D:43.7 ml/min; NE: 43.5 ml/min; and E: 46.6 ml/min) resulted in daily excretion of only 379 micrograms D, 32.9 micrograms NE, and 37.2 micrograms E.",In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751170/),μg,37.2,29343,DB00668,Epinephrine
,3706800,peak whole blood arterial bupivacaine,"Doses of 2 mg/kg, 3 mg/kg, and 4 mg/kg resulted in peak whole blood arterial bupivacaine (base) concentrations (mean +/- SD) of 0.77 +/- 0.25 microgram/ml, 1.37 +/- 0.23 microgram/ml, and 1.87 +/- 0.53 microgram/ml, respectively.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[μg] / [ml],0.77,29433,DB00668,Epinephrine
,3706800,peak whole blood arterial bupivacaine,"Doses of 2 mg/kg, 3 mg/kg, and 4 mg/kg resulted in peak whole blood arterial bupivacaine (base) concentrations (mean +/- SD) of 0.77 +/- 0.25 microgram/ml, 1.37 +/- 0.23 microgram/ml, and 1.87 +/- 0.53 microgram/ml, respectively.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[μg] / [ml],1.37,29434,DB00668,Epinephrine
,3706800,peak whole blood arterial bupivacaine,"Doses of 2 mg/kg, 3 mg/kg, and 4 mg/kg resulted in peak whole blood arterial bupivacaine (base) concentrations (mean +/- SD) of 0.77 +/- 0.25 microgram/ml, 1.37 +/- 0.23 microgram/ml, and 1.87 +/- 0.53 microgram/ml, respectively.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[μg] / [ml],1.87,29435,DB00668,Epinephrine
,3706800,apparent volume of distribution (VD beta),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[l] / [kg],2.8,29436,DB00668,Epinephrine
,3706800,steady-state volume of distribution (VDss),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[l] / [kg],2.7,29437,DB00668,Epinephrine
,3706800,elimination half-life (t1/2 beta),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),min,147,29438,DB00668,Epinephrine
,3706800,total body clearance (Cl),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[ml] / [kg·min],16.0,29439,DB00668,Epinephrine
,3706800,total body clearance (Cl),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[ml] / [(m)^2·min],382,29440,DB00668,Epinephrine
,3706800,lambda,"Hematocrit in this group ranged from 30 to 59, and lambda varied from 0.47 to 0.82.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),,0.47 to 0.82,29441,DB00668,Epinephrine
,1686693,maximal plasma concentrations,200 mg ibopamine lead to maximal plasma concentrations of 60 to 100 nmol/l.,[Ibopamine--pharmacologic principles]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),[nM] / [l],60 to 100,29805,DB00668,Epinephrine
,1686693,plasma half-life,The plasma half-life of epinine amounts to about 45 min.,[Ibopamine--pharmacologic principles]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),min,45,29806,DB00668,Epinephrine
,1686693,affinity,"Investigations in isolated organs have shown that the action on DA1, DA2-receptors occurs in the range of 100-700 nmol/l), whereas stimulation of beta 1- and beta 2-receptors affords significantly higher levels (affinity to human cardiac beta 1- and beta 2-receptors 5-10 mumol/l).",[Ibopamine--pharmacologic principles]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1686693/),[μM] / [l],5-10,29807,DB00668,Epinephrine
,2961361,peak plasma venous concentration,"Mean peak plasma venous concentration achieved following 0.5% plain bupivacaine was 2.23 +/- 0.24 micrograms ml-1 (mean +/- SEM), while the mean peak concentration following 0.5% bupivacaine with adrenaline was 0.98 +/- 0.10 micrograms ml-1 (mean +/- SEM).",Venous plasma (total) bupivacaine concentrations following lower abdominal field block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2961361/),[μg] / [ml],2.23,31938,DB00668,Epinephrine
,2961361,peak concentration,"Mean peak plasma venous concentration achieved following 0.5% plain bupivacaine was 2.23 +/- 0.24 micrograms ml-1 (mean +/- SEM), while the mean peak concentration following 0.5% bupivacaine with adrenaline was 0.98 +/- 0.10 micrograms ml-1 (mean +/- SEM).",Venous plasma (total) bupivacaine concentrations following lower abdominal field block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2961361/),[μg] / [ml],0.98,31939,DB00668,Epinephrine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],39.8,32819,DB00668,Epinephrine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],28.3,32820,DB00668,Epinephrine
,9350366,plasma concentrations,"With sevoflurane, plasma concentrations of nicardipine, five minutes after administration, (39.8 +/- 3.5 ng.ml-1, mean +/- SEM) were higher (P < 0.05) than in the other two groups (28.3 +/- 2.9 ng.ml-1, 32.6 +/- 4.3 ng.ml-1, enflurane and isoflurane, respectively).","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[ng] / [ml],32.6,32821,DB00668,Epinephrine
,9350366,half-life,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),min,14,32822,DB00668,Epinephrine
,9350366,clearance,"With isoflurane, the approximated half-life of nicardipine (14 +/- 4 min) was shorter and clearance (2.1 +/- 0.3 l.min-1) more rapid.","Interactions between nicardipine and enflurane, isoflurane, and sevoflurane. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350366/),[l] / [min],2.1,32823,DB00668,Epinephrine
,15318058,total plasma epinephrine,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],323,35078,DB00668,Epinephrine
,15318058,total plasma epinephrine,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],24.8,35079,DB00668,Epinephrine
,15318058,peak,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],323,35080,DB00668,Epinephrine
,15318058,peak,"The total plasma epinephrine peak occurred at the final intraoperative reading (5 hours after induction) and was 323 pg/ml (24.8 pg/ml), three to four times maximum baseline resting levels.",Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],24.8,35081,DB00668,Epinephrine
,15318058,time to peak,Estimated time to peak exogenous epinephrine level ranged from 1 to 4 hours from the start of infiltration.,Pharmacokinetics and safety of epinephrine use in liposuction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),h,1 to 4,35082,DB00668,Epinephrine
,15318058,Area under the plasma concentration versus time curve,Area under the plasma concentration versus time curve was approximately 2089 to 2610 pg x hour/ml.,Pharmacokinetics and safety of epinephrine use in liposuction. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[h·pg] / [ml],2089 to 2610,35083,DB00668,Epinephrine
,15318058,Peak exogenous epinephrine concentration,Peak exogenous epinephrine concentration was estimated to be 286 to 335 pg/ml.,Pharmacokinetics and safety of epinephrine use in liposuction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[pg] / [ml],286 to 335,35084,DB00668,Epinephrine
,15318058,Clearance,"Clearance was 764,508 ml/hour and volume of distribution was 0.4 liter/kg (0.006 liter/kg).",Pharmacokinetics and safety of epinephrine use in liposuction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[ml] / [h],"764,508",35085,DB00668,Epinephrine
,15318058,volume of distribution,"Clearance was 764,508 ml/hour and volume of distribution was 0.4 liter/kg (0.006 liter/kg).",Pharmacokinetics and safety of epinephrine use in liposuction. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15318058/),[l] / [kg],0.4,35086,DB00668,Epinephrine
,32792847,Tgel,Tgel of DV-containing thermoresponsive-gels were between 35.1 and 38.9 °C and it was Poloxamers and CP concentrations dependent.,Thermoresponsive sol-gel improves ocular bioavailability of Dipivefrin hydrochloride and potentially reduces the elevated intraocular pressure in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32792847/),°c,35.1 and 38.9,37539,DB00668,Epinephrine
,32792847,Tgel,"The optimal formulation (F8), composed of 20% P407, 5% P188 and 0.15% CP (w/v), had a Tgel of 35 °C.",Thermoresponsive sol-gel improves ocular bioavailability of Dipivefrin hydrochloride and potentially reduces the elevated intraocular pressure in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32792847/),°c,35,37540,DB00668,Epinephrine
,4014356,initial half-life,"In both, the dopamine clearance was biphasic with an initial half-life of 1.5 minutes in fetal blood and 1.0 minute in maternal blood.",3H-dopamine clearance from the intravascular compartment of the maternal and fetal rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014356/),min,1.5,38925,DB00668,Epinephrine
,4014356,initial half-life,"In both, the dopamine clearance was biphasic with an initial half-life of 1.5 minutes in fetal blood and 1.0 minute in maternal blood.",3H-dopamine clearance from the intravascular compartment of the maternal and fetal rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4014356/),min,1.0,38926,DB00668,Epinephrine
>,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39088,DB00668,Epinephrine
<,15319342,(R)/(S) ratios,"(R)/(S) ratios both in plasma (0-48 h) and urine (0-72 h) for MDMA and MDA were >1 and <1, respectively.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),,1,39089,DB00668,Epinephrine
,15319342,elimination half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,4.8,39090,DB00668,Epinephrine
,15319342,half-life,"The short elimination half-life of (S)-MDMA (4.8 h) is consistent with the subjective effects and psychomotor performance reported in subjects exposed to MDMA, whereas the much longer half-life of the (R)-enantiomer (14.8 h) correlates with mood and cognitive effects experienced on the next days after MDMA use.","Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15319342/),h,14.8,39091,DB00668,Epinephrine
,28238945,brain/plasma ratio,"Following intravenous administration, the brain/plasma ratio for imatinib was calculated to be 2% and remained at this ratio for 30min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,2,40263,DB00668,Epinephrine
,28238945,brain/plasma ratio,"The brain/plasma ratio following intranasal administration, however, was found to be 5.3% and remained at this ratio for up to 90min.",Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28238945/),%,5.3,40264,DB00668,Epinephrine
,7076744,detection limit,The detection limit of the assay for plasma and urine samples is about 1 ng/ml.,High-performance liquid chromatographic method for the determination of plasma and urine metapramine after dansylation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7076744/),[ng] / [ml],1,40848,DB00668,Epinephrine
,33859140,plasma concentrations,"Mean plasma concentrations of lidocaine were not statistically different between groups, ranging from 0.245 to 2.28 ng/ml after administration of lidocaine with epinephrine (immediate post-iontophoresis to 230 min post-iontophoresis), compared with 1.35 to 2.14 ng/ml after administration of lidocaine alone.",Pharmacokinetics of Single Dose Lidocaine and Epinephrine Following Iontophoresis of the Tympanic Membrane in a Double-Blinded Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33859140/),[ng] / [ml],0.245 to 2.28,42078,DB00668,Epinephrine
,33859140,plasma concentrations,"Mean plasma concentrations of lidocaine were not statistically different between groups, ranging from 0.245 to 2.28 ng/ml after administration of lidocaine with epinephrine (immediate post-iontophoresis to 230 min post-iontophoresis), compared with 1.35 to 2.14 ng/ml after administration of lidocaine alone.",Pharmacokinetics of Single Dose Lidocaine and Epinephrine Following Iontophoresis of the Tympanic Membrane in a Double-Blinded Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33859140/),[ng] / [ml],1.35 to 2.14,42079,DB00668,Epinephrine
,33859140,Cmax,Lidocaine levels (Cmax 2.24 ng/ml) were approximately 2000-fold lower than the threshold for minor lidocaine toxicity.,Pharmacokinetics of Single Dose Lidocaine and Epinephrine Following Iontophoresis of the Tympanic Membrane in a Double-Blinded Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33859140/),[ng] / [ml],2.24,42080,DB00668,Epinephrine
,30032887,volume of distribution,Levobupivacaine volume of distribution after Caesarean section was higher than in healthy volunteers [172 L (70 kg)-1 (95% confidence interval: 137-207) vs 94.3 L (70 kg)-1 (95% CI: 62-128); P<0.01].,Pharmacokinetics of levobupivacaine with epinephrine in transversus abdominis plane block for postoperative analgesia after Caesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032887/),l,172,42369,DB00668,Epinephrine
,30032887,volume of distribution,Levobupivacaine volume of distribution after Caesarean section was higher than in healthy volunteers [172 L (70 kg)-1 (95% confidence interval: 137-207) vs 94.3 L (70 kg)-1 (95% CI: 62-128); P<0.01].,Pharmacokinetics of levobupivacaine with epinephrine in transversus abdominis plane block for postoperative analgesia after Caesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032887/),1/[kg],94.3,42370,DB00668,Epinephrine
,16192762,bioavailability,The median bioavailability of the rapid component was approximately 20% higher when epinephrine was not used.,Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),%,20,42423,DB00668,Epinephrine
,16192762,mean absorption times,"The mean absorption times were 7.8 min for the rapid absorption phase and 697 min for the slow absorption phase, with wide dispersion of the absorption function for the acute phase.",Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),min,7.8,42424,DB00668,Epinephrine
,16192762,mean absorption times,"The mean absorption times were 7.8 min for the rapid absorption phase and 697 min for the slow absorption phase, with wide dispersion of the absorption function for the acute phase.",Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),min,697,42425,DB00668,Epinephrine
,16192762,half-time,The half-time of arterial-venous equilibration was 1.5 min.,Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),min,1.5,42426,DB00668,Epinephrine
,31864721,flow rate,"Seven currently marketed syringe infusion pump assemblies were assessed in an in vitro study during start-up, vertical displacement manoeuvres, and infusion line occlusion at a set flow rate of 1 ml h-1.",Performance of modern syringe infusion pump assemblies at low infusion rates in the perioperative setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31864721/),[ml] / [h],1,43408,DB00668,Epinephrine
,31864721,time from starting the infusion pump to steady-state flow,The mean time from starting the infusion pump to steady-state flow varied from 89 to 1622 s.,Performance of modern syringe infusion pump assemblies at low infusion rates in the perioperative setting. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31864721/),s,89 to 1622,43409,DB00668,Epinephrine
,31864721,zero-drug delivery time,The zero-drug delivery time after lowering the pump ranged from 145 to 335 s.,Performance of modern syringe infusion pump assemblies at low infusion rates in the perioperative setting. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31864721/),s,145 to 335,43410,DB00668,Epinephrine
,10630270,elimination half-life,Plasma hydroxychloroquine level was 29.40 mumol/L (9.87 mg/L) 2 hours after ingestion and the elimination half-life of hydroxychloroquine was 22 hours.,Hydroxychloroquine overdose: toxicokinetics and management. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630270/),h,22,46844,DB00668,Epinephrine
,9349926,Initial pain intensity,"Initial pain intensity was 5.9 (arbitrary units) and 5.4 in the groups with and without signs of transmural myocardial damage, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),,5.9,48512,DB00668,Epinephrine
,9349926,Initial pain intensity,"Initial pain intensity was 5.9 (arbitrary units) and 5.4 in the groups with and without signs of transmural myocardial damage, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),,5.4,48513,DB00668,Epinephrine
,9349926,terminal half-life,The terminal half-life of unchanged metoprolol ranged from 2.5 to 8.5 h in group 1 and from 2.2 to 5.2 h in group 2.,Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,2.5 to 8.5,48514,DB00668,Epinephrine
,9349926,terminal half-life,The terminal half-life of unchanged metoprolol ranged from 2.5 to 8.5 h in group 1 and from 2.2 to 5.2 h in group 2.,Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,2.2 to 5.2,48515,DB00668,Epinephrine
,9349926,half-life,"In group 1, metoprolol half-life was 4.5 h and total plasma clearance (CL) 54.1 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,4.5,48516,DB00668,Epinephrine
,9349926,total plasma clearance (CL),"In group 1, metoprolol half-life was 4.5 h and total plasma clearance (CL) 54.1 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),[1] / [h],54.1,48517,DB00668,Epinephrine
,9349926,half-life,"In group 2, the metoprolol half-life was 3.7 h and total plasma clearance 75.4 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),h,3.7,48518,DB00668,Epinephrine
,9349926,total plasma clearance,"In group 2, the metoprolol half-life was 3.7 h and total plasma clearance 75.4 1.h-1.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),[1] / [h],75.4,48519,DB00668,Epinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,143,48520,DB00668,Epinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,135,48521,DB00668,Epinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,2830,48522,DB00668,Epinephrine
,9349926,maximal concentrations in plasma (Cmax),"In groups 1 and 2, maximal concentrations in plasma (Cmax) were 143 and 135 nmol.1(-1) for alpha-hydroxymetoprolol and 2830 and 1653 nmol.1(-1) for metoprolol, respectively.",Effects and pharmacokinetics of high dose metoprolol on chest pain in patients with suspected or definite acute myocardial infarction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9349926/),nM,1653,48523,DB00668,Epinephrine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00668,Epinephrine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00668,Epinephrine
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00668,Epinephrine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.6,55810,DB00668,Epinephrine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.4,55811,DB00668,Epinephrine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],1.2,55812,DB00668,Epinephrine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.8,55813,DB00668,Epinephrine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.6,55814,DB00668,Epinephrine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.4,55815,DB00668,Epinephrine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],1.2,55816,DB00668,Epinephrine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.8,55817,DB00668,Epinephrine
,10870098,Maximum plasma epinephrine concentrations,"Maximum plasma epinephrine concentrations were higher, and occurred more rapidly, after intramuscular injection than after subcutaneous injection or inhalation, and were 7719+/-3943 (S.E.M.) pg/mL at 32.5+/-6.6 min, 2692+/-863 pg/mL at 111.7+/-30.8 min and 1196+/-369 pg/mL at 45.",Epinephrine absorption after different routes of administration in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870098/),[pg] / [ml],7719,56598,DB00668,Epinephrine
,10870098,Maximum plasma epinephrine concentrations,"Maximum plasma epinephrine concentrations were higher, and occurred more rapidly, after intramuscular injection than after subcutaneous injection or inhalation, and were 7719+/-3943 (S.E.M.) pg/mL at 32.5+/-6.6 min, 2692+/-863 pg/mL at 111.7+/-30.8 min and 1196+/-369 pg/mL at 45.",Epinephrine absorption after different routes of administration in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870098/),[pg] / [ml],2692,56599,DB00668,Epinephrine
,10870098,Maximum plasma epinephrine concentrations,"Maximum plasma epinephrine concentrations were higher, and occurred more rapidly, after intramuscular injection than after subcutaneous injection or inhalation, and were 7719+/-3943 (S.E.M.) pg/mL at 32.5+/-6.6 min, 2692+/-863 pg/mL at 111.7+/-30.8 min and 1196+/-369 pg/mL at 45.",Epinephrine absorption after different routes of administration in an animal model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870098/),[pg] / [ml],1196,56600,DB00668,Epinephrine
,10870098,elimination half-life (t(1/2)),"Intravenous injection of epinephrine resulted in a plasma concentration of 3544+/-422 pg/mL at 5 min, and an elimination half-life (t(1/2)) of 11.0+/-2.5 min.",Epinephrine absorption after different routes of administration in an animal model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10870098/),min,11.0,56601,DB00668,Epinephrine
>,26895001,Cmax,"For any given milligram per kilogram dosage, the probability that Cmax >6 μg/mL, the threshold for mild lidocaine toxicity was estimated using tolerance interval analysis.",Estimated Maximal Safe Dosages of Tumescent Lidocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895001/),[μg] / [ml],6,57667,DB00668,Epinephrine
,26895001,maximum safe dosages,Preliminary estimates for maximum safe dosages of tumescent lidocaine are 28 mg/kg without liposuction and 45 mg/kg with liposuction.,Estimated Maximal Safe Dosages of Tumescent Lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895001/),[mg] / [kg],28,57668,DB00668,Epinephrine
,26895001,maximum safe dosages,Preliminary estimates for maximum safe dosages of tumescent lidocaine are 28 mg/kg without liposuction and 45 mg/kg with liposuction.,Estimated Maximal Safe Dosages of Tumescent Lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26895001/),mg,45,57669,DB00668,Epinephrine
,23886232,Cmax,Epinephrine peak concentration and total exposure were similar between Auvi-Q (Cmax = 0.486 ng/mL; AUC0-t = 0.536 ng·h/mL; AUCinf = 0.724 ng·h/mL) and EpiPen (Cmax = 0.520 ng/mL; AUC0-t = 0.466 ng·h/mL; AUCinf = 0.583 ng·h/mL).,Bioavailability of epinephrine from Auvi-Q compared with EpiPen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23886232/),[ng] / [ml],0.486,58950,DB00668,Epinephrine
,23886232,AUC0-t,Epinephrine peak concentration and total exposure were similar between Auvi-Q (Cmax = 0.486 ng/mL; AUC0-t = 0.536 ng·h/mL; AUCinf = 0.724 ng·h/mL) and EpiPen (Cmax = 0.520 ng/mL; AUC0-t = 0.466 ng·h/mL; AUCinf = 0.583 ng·h/mL).,Bioavailability of epinephrine from Auvi-Q compared with EpiPen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23886232/),[h·ng] / [ml],0.536,58951,DB00668,Epinephrine
,23886232,AUCinf,Epinephrine peak concentration and total exposure were similar between Auvi-Q (Cmax = 0.486 ng/mL; AUC0-t = 0.536 ng·h/mL; AUCinf = 0.724 ng·h/mL) and EpiPen (Cmax = 0.520 ng/mL; AUC0-t = 0.466 ng·h/mL; AUCinf = 0.583 ng·h/mL).,Bioavailability of epinephrine from Auvi-Q compared with EpiPen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23886232/),[h·ng] / [ml],0.724,58952,DB00668,Epinephrine
,23886232,Cmax,Epinephrine peak concentration and total exposure were similar between Auvi-Q (Cmax = 0.486 ng/mL; AUC0-t = 0.536 ng·h/mL; AUCinf = 0.724 ng·h/mL) and EpiPen (Cmax = 0.520 ng/mL; AUC0-t = 0.466 ng·h/mL; AUCinf = 0.583 ng·h/mL).,Bioavailability of epinephrine from Auvi-Q compared with EpiPen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23886232/),[ng] / [ml],0.520,58953,DB00668,Epinephrine
,23886232,AUC0-t,Epinephrine peak concentration and total exposure were similar between Auvi-Q (Cmax = 0.486 ng/mL; AUC0-t = 0.536 ng·h/mL; AUCinf = 0.724 ng·h/mL) and EpiPen (Cmax = 0.520 ng/mL; AUC0-t = 0.466 ng·h/mL; AUCinf = 0.583 ng·h/mL).,Bioavailability of epinephrine from Auvi-Q compared with EpiPen. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23886232/),[h·ng] / [ml],0.466,58954,DB00668,Epinephrine
,23886232,AUCinf,Epinephrine peak concentration and total exposure were similar between Auvi-Q (Cmax = 0.486 ng/mL; AUC0-t = 0.536 ng·h/mL; AUCinf = 0.724 ng·h/mL) and EpiPen (Cmax = 0.520 ng/mL; AUC0-t = 0.466 ng·h/mL; AUCinf = 0.583 ng·h/mL).,Bioavailability of epinephrine from Auvi-Q compared with EpiPen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23886232/),[h·ng] / [ml],0.583,58955,DB00668,Epinephrine
,2310001,maximum concentrations,"Median maximum concentrations of lidocaine after i.v. (3.2 range 1.3-9.6 micrograms/ml) and e.b. administration (3.1 range 1.1-8.6) were measured after 5.5 min (range i.v. = 4-10 min, e.b. = 3-7 min).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[μg] / [ml],3.2,59388,DB00668,Epinephrine
,2310001,maximum concentrations,"Median maximum concentrations of lidocaine after i.v. (3.2 range 1.3-9.6 micrograms/ml) and e.b. administration (3.1 range 1.1-8.6) were measured after 5.5 min (range i.v. = 4-10 min, e.b. = 3-7 min).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[μg] / [ml],3.1,59389,DB00668,Epinephrine
,2310001,absorption half-life,"The absorption half-life of e.b. lidocaine was 3.9 min, and mean bioavailability was 90%.",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),min,3.9,59390,DB00668,Epinephrine
,2310001,bioavailability,"The absorption half-life of e.b. lidocaine was 3.9 min, and mean bioavailability was 90%.",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),%,90,59391,DB00668,Epinephrine
,2310001,elimination half-lives,"Elimination pharmacokinetics of i.v. and e.b. lidocaine were nearly identical, with elimination half-lives of 25 min (e.b.) and 42 min (i.v.).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),min,25,59392,DB00668,Epinephrine
,2310001,elimination half-lives,"Elimination pharmacokinetics of i.v. and e.b. lidocaine were nearly identical, with elimination half-lives of 25 min (e.b.) and 42 min (i.v.).",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),min,42,59393,DB00668,Epinephrine
,2310001,Total body clearances,Total body clearances were 401 ml/min (e.b.) and 362 ml/min (i.v.).,[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[ml] / [min],401,59394,DB00668,Epinephrine
,2310001,Total body clearances,Total body clearances were 401 ml/min (e.b.) and 362 ml/min (i.v.).,[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[ml] / [min],362,59395,DB00668,Epinephrine
,2310001,minimum dosage,"During CPR without i.v. access the e.b. instillation of lidocaine can be recommended, but to ensure therapeutic concentrations a minimum dosage of 2 mg/kg is suggested.",[The pharmacokinetics of lidocaine in resuscitation conditions. Results of experimental studies on swine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310001/),[mg] / [kg],2,59396,DB00668,Epinephrine
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8878,61872,DB00668,Epinephrine
,12072587,rate-pressure product,"Salmeterol increased mean rate-pressure product by 5% (salmeterol 8878 +/- 1560 vs. placebo 8414 +/- 1440 bpm x mm Hg, p = 0.04), although no increase in plasma norepinephrine, epinephrine, plasma renin activity or ventricular ectopy was detected.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),bpm·hg·mm,8414,61873,DB00668,Epinephrine
,12072587,Tmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),min,5,61874,DB00668,Epinephrine
,12072587,Cmax,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),[pg] / [ml],715,61875,DB00668,Epinephrine
,12072587,half-life,"The Tmax, Cmax, and half-life of salmeterol at steady-state were 5 min, 715 pg/ml and 11.4 hours, respectively.",Chronically inhaled salmeterol improves pulmonary function in heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12072587/),h,11.4,61876,DB00668,Epinephrine
,8864326,Total body clearance,"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61881,DB00668,Epinephrine
,8864326,apparent volume of distribution,"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61882,DB00668,Epinephrine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],7.15,61883,DB00668,Epinephrine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],3.11,61884,DB00668,Epinephrine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],4.48,61885,DB00668,Epinephrine
,8864326,maximum observed concentration (Cmax),"Total body clearance and apparent volume of distribution were similar in the four groups, but the maximum observed concentration (Cmax) was markedly increased in the plain solution group as compared with the other groups; (plain lignocaine: 7.15 +/- 2.04 micrograms ml-1, lignocaine + adrenaline: 3.11 +/- 136 micrograms ml-1, lignocaine + clonidine: 4.48 +/- 1.26 micrograms ml-1, lignocaine + adrenaline + clonidine: 4.06 +/- 1.42 micrograms ml-1 [mean +/- s.d.]).",Clonidine and or adrenaline decrease lignocaine plasma peak concentration after epidural injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8864326/),[μg] / [ml],4.06,61886,DB00668,Epinephrine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,20.7,62422,DB00668,Epinephrine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,19.5,62423,DB00668,Epinephrine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,18.8,62424,DB00668,Epinephrine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,19.1,62425,DB00668,Epinephrine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,20.4,62426,DB00668,Epinephrine
,2271470,Cmax,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),[mg] / [l],4.22,62610,DB00668,Epinephrine
,2271470,Tmax,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),h,0.99,62611,DB00668,Epinephrine
,2271470,T1/2,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),h,3.25,62612,DB00668,Epinephrine
,2271470,CL,"Plasma pharmacokinetic variables of mepivacaine were as follows: Cmax: 4.22 mg.l-1 (SD, 1.28); Tmax: 0.99 hours (SD, 0.76); T1/2: 3.25 hours (SD, 1.12); CL 0.55 1.hour-1.kg-1.",Plasma concentrations after high doses of mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2271470/),[1] / [h·kg],0.55,62613,DB00668,Epinephrine
,3396545,maximum mean concentration (CPmax),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),[μg] / [ml],0.64,64483,DB00668,Epinephrine
,3396545,time to maximum concentration (Tmax),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),min,19.2,64484,DB00668,Epinephrine
,3396545,vascular absorption (T1/2 abs),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),min,4.3,64485,DB00668,Epinephrine
,3396545,terminal half-life (T1/2 beta),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),min,227,64486,DB00668,Epinephrine
,3396545,volume of distribution (Vd),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),1/[kg],3.4,64487,DB00668,Epinephrine
,3396545,total body clearance (Clt),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),[ml] / [kg·min],11.0,64488,DB00668,Epinephrine
,15300360,pKb,The pKb of metoprolol was similar in both groups of animals (SO: 7.49+/-0.20; ACo: 7.19+/-0.23).,Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,7.49,65932,DB00668,Epinephrine
,15300360,pKb,The pKb of metoprolol was similar in both groups of animals (SO: 7.49+/-0.20; ACo: 7.19+/-0.23).,Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,7.19,65933,DB00668,Epinephrine
,15300360,half-maximal effect (pEC50),"There were no differences in maximum response (Emax; SO: -28+/-2.0%, n=5; ACo: -27+/-4%, n=5) or the concentration eliciting a half-maximal effect (pEC50) (SO: 4.9+/-0.2, n=5; ACo: 5.2+/-0.2, n=5) between the experimental groups.",Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,4.9,65934,DB00668,Epinephrine
,15300360,half-maximal effect (pEC50),"There were no differences in maximum response (Emax; SO: -28+/-2.0%, n=5; ACo: -27+/-4%, n=5) or the concentration eliciting a half-maximal effect (pEC50) (SO: 4.9+/-0.2, n=5; ACo: 5.2+/-0.2, n=5) between the experimental groups.",Pharmacokinetic-pharmacodynamic properties of metoprolol in chronic aortic coarctated rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15300360/),,5.2,65935,DB00668,Epinephrine
,1836304,production rates,"The plasma epinephrine production rates did not vary significantly between fetuses less than 135 and greater than 135 days' gestation (15.4 +/- 1.5 vs 13.9 +/- 2.0 ng/min, p greater than 0.5).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ng] / [min],15.4,67087,DB00668,Epinephrine
,1836304,production rates,"The plasma epinephrine production rates did not vary significantly between fetuses less than 135 and greater than 135 days' gestation (15.4 +/- 1.5 vs 13.9 +/- 2.0 ng/min, p greater than 0.5).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ng] / [min],13.9,67088,DB00668,Epinephrine
,1836304,metabolic clearance rate,"The fetal metabolic clearance rate of epinephrine at early gestations (less than 135 days) was similar to that of the fetus of the nondiabetic ewe (35.3 +/- 3.4 vs 28.0 +/- 4.3 ml/min/kg, p greater than 0.2).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],35.3,67089,DB00668,Epinephrine
,1836304,metabolic clearance rate,"The fetal metabolic clearance rate of epinephrine at early gestations (less than 135 days) was similar to that of the fetus of the nondiabetic ewe (35.3 +/- 3.4 vs 28.0 +/- 4.3 ml/min/kg, p greater than 0.2).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],28.0,67090,DB00668,Epinephrine
,1836304,metabolic clearance rate,"However, at later gestations (greater than 135 days) the fetus of the diabetic ewe did not have the increase in the metabolic clearance rate previously published for the control fetus (32.0 +/- 4.6 vs 133.7 +/- 41.7 ml/min/kg, p less than 0.05).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],32.0,67091,DB00668,Epinephrine
,1836304,metabolic clearance rate,"However, at later gestations (greater than 135 days) the fetus of the diabetic ewe did not have the increase in the metabolic clearance rate previously published for the control fetus (32.0 +/- 4.6 vs 133.7 +/- 41.7 ml/min/kg, p less than 0.05).",The metabolic clearance rate of epinephrine in the fetus of the diabetic ewe. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1836304/),[ml] / [kg·min],133.7,67092,DB00668,Epinephrine
,3573880,bioavailability,The bioavailability of e.b.-administration of epinephrine was in the range of 80-85%.,[Endobronchial administration of adrenaline in cardiopulmonary resuscitation: pharmacokinetic and dynamic studies in the dog]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3573880/),%,80-85,68977,DB00668,Epinephrine
,32677407,Time to peak concerntration (Tmax),Time to peak concerntration (Tmax) ranged from 12 to 13 min.,[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32677407/),min,12 to 13,70619,DB00668,Epinephrine
,32677407,Half-time of elimination (t1/2),"Half-time of elimination (t1/2) ranged from 3.84 to 4.07 h, with a clearance (CL) of 190 L/h.",[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32677407/),h,3.84 to 4.07,70620,DB00668,Epinephrine
,32677407,clearance (CL),"Half-time of elimination (t1/2) ranged from 3.84 to 4.07 h, with a clearance (CL) of 190 L/h.",[Pharmacokinetics Study of Phentolamine Mesylate Injection in Healthy Volunteers]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32677407/),[l] / [h],190,70621,DB00668,Epinephrine
,3100310,pulmonary arterial-systemic arterial extraction ratio,"The pulmonary arterial-systemic arterial extraction ratio of NA was mean 0.08 (n = 9) as compared to that of 3H-NA: mean 0.07 (n = 8, NS).",Pulmonary extraction of circulating noradrenaline in man. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),,0.08,70990,DB00668,Epinephrine
,3100310,pulmonary arterial-systemic arterial extraction ratio,"The pulmonary arterial-systemic arterial extraction ratio of NA was mean 0.08 (n = 9) as compared to that of 3H-NA: mean 0.07 (n = 8, NS).",Pulmonary extraction of circulating noradrenaline in man. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),,0.07,70991,DB00668,Epinephrine
,3100310,pulmonary clearances,"Likewise mean pulmonary clearances of NA and 3H-NA were not significantly different (97 ml min-1 X M-2 v. 124 ml min-1 X M-2, NS).",Pulmonary extraction of circulating noradrenaline in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),[ml] / [(M)^2·min],97,70992,DB00668,Epinephrine
,3100310,pulmonary clearances,"Likewise mean pulmonary clearances of NA and 3H-NA were not significantly different (97 ml min-1 X M-2 v. 124 ml min-1 X M-2, NS).",Pulmonary extraction of circulating noradrenaline in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),[ml] / [(M)^2·min],124,70993,DB00668,Epinephrine
,3100310,whole-body clearance,Estimated whole-body clearance of noradrenaline was mean 0.80 l min-1 X M-2 (n = 6) while the pulmonary clearance amounted to 19% of this value.,Pulmonary extraction of circulating noradrenaline in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3100310/),[l] / [(M)^2·min],0.80,70994,DB00668,Epinephrine
,16461140,AUC,"The area under the curve (AUC), maximum concentration (C(max)), and time at which C(max) was achieved (T(max)) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C(max) = 31.0 +/- 13.1 ng/mL, and T(max) = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C(max) = 50.3 +/- 17.1 ng/mL, and T(max) = 21 +/- 5 minutes).",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [min·ml],1861,72189,DB00668,Epinephrine
,16461140,C(max),"The area under the curve (AUC), maximum concentration (C(max)), and time at which C(max) was achieved (T(max)) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C(max) = 31.0 +/- 13.1 ng/mL, and T(max) = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C(max) = 50.3 +/- 17.1 ng/mL, and T(max) = 21 +/- 5 minutes).",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [ml],31.0,72190,DB00668,Epinephrine
,16461140,T(max),"The area under the curve (AUC), maximum concentration (C(max)), and time at which C(max) was achieved (T(max)) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C(max) = 31.0 +/- 13.1 ng/mL, and T(max) = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C(max) = 50.3 +/- 17.1 ng/mL, and T(max) = 21 +/- 5 minutes).",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),min,9,72191,DB00668,Epinephrine
,16461140,AUC,"The area under the curve (AUC), maximum concentration (C(max)), and time at which C(max) was achieved (T(max)) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C(max) = 31.0 +/- 13.1 ng/mL, and T(max) = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C(max) = 50.3 +/- 17.1 ng/mL, and T(max) = 21 +/- 5 minutes).",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [min·ml],2431,72192,DB00668,Epinephrine
,16461140,C(max),"The area under the curve (AUC), maximum concentration (C(max)), and time at which C(max) was achieved (T(max)) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C(max) = 31.0 +/- 13.1 ng/mL, and T(max) = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C(max) = 50.3 +/- 17.1 ng/mL, and T(max) = 21 +/- 5 minutes).",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [ml],50.3,72193,DB00668,Epinephrine
,16461140,T(max),"The area under the curve (AUC), maximum concentration (C(max)), and time at which C(max) was achieved (T(max)) did not differ significantly (P > .05) after epinephrine 40 mg (AUC = 1861 +/- 537 ng/mL/min, C(max) = 31.0 +/- 13.1 ng/mL, and T(max) = 9 +/- 2 minutes) and epinephrine 0.3 mg intramuscular (AUC = 2431 +/- 386 ng/mL/min, C(max) = 50.3 +/- 17.1 ng/mL, and T(max) = 21 +/- 5 minutes).",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),min,21,72194,DB00668,Epinephrine
,16461140,AUC,"The AUC after tablets containing epinephrine 0 mg (AUC = 472 +/- 126 ng/mL/min), epinephrine 10 mg (AUC = 335 +/- 152 ng/mL/min), and epinephrine 20 mg (AUC = 801 +/- 160 ng/mL/min) did not differ significantly from each other, but were significantly lower (P < .05) than the AUC after epinephrine 0.3 mg intramuscularly.",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [min·ml],472,72195,DB00668,Epinephrine
,16461140,AUC,"The AUC after tablets containing epinephrine 0 mg (AUC = 472 +/- 126 ng/mL/min), epinephrine 10 mg (AUC = 335 +/- 152 ng/mL/min), and epinephrine 20 mg (AUC = 801 +/- 160 ng/mL/min) did not differ significantly from each other, but were significantly lower (P < .05) than the AUC after epinephrine 0.3 mg intramuscularly.",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [min·ml],335,72196,DB00668,Epinephrine
,16461140,AUC,"The AUC after tablets containing epinephrine 0 mg (AUC = 472 +/- 126 ng/mL/min), epinephrine 10 mg (AUC = 335 +/- 152 ng/mL/min), and epinephrine 20 mg (AUC = 801 +/- 160 ng/mL/min) did not differ significantly from each other, but were significantly lower (P < .05) than the AUC after epinephrine 0.3 mg intramuscularly.",Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16461140/),[ng] / [min·ml],801,72197,DB00668,Epinephrine
,10368046,TGD,"Intratumoral administration of CDDP/epi gel (4 mg/kg) produced an average TGD time of 15.5 +/- 2.8 days, which was 5.2 - 7.4 times longer than CDDP suspension i.t. or i.p.",Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368046/),d,15.5,72338,DB00668,Epinephrine
,10368046,time,"Intratumoral administration of CDDP/epi gel (4 mg/kg) produced an average TGD time of 15.5 +/- 2.8 days, which was 5.2 - 7.4 times longer than CDDP suspension i.t. or i.p.",Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10368046/),d,15.5,72339,DB00668,Epinephrine
,27283723,plasma concentration,"The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection.","High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283723/),[ng] / [ml],226,72462,DB00668,Epinephrine
,27283723,plasma concentration,"The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection.","High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283723/),[ng] / [ml],221,72463,DB00668,Epinephrine
,27283723,plasma concentration,"The plasma concentration of dexamethasone for the CS interventions was 226 ± 47 ng/ml at 30-min and 316 ± 81.6 ng/ml at 60-min post injection, and for SS, it was 221 ± 81.6 ng/ml at 30-min and 340 ± 105 ng/ml at 60-min post injection.","High performance liquid chromatography determination of dexamethasone in plasma to evaluate its systemic absorption following intra-space pterygomandibular injection of twin-mix (mixture of 2 % lignocaine with 1:200,000 epinephrine and 4 mg dexamethasone): randomized control trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27283723/),[ng] / [ml],340,72464,DB00668,Epinephrine
,10761166,AUC0-24,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),[min·μg] / [ml],95,72570,DB00668,Epinephrine
,10761166,AUC0-24,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),min,172.5,72571,DB00668,Epinephrine
,10761166,t1/2,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),[min·μg] / [ml],176,72572,DB00668,Epinephrine
,10761166,t1/2,"AUC0-24 and t1/2 for losartan and E-3174 were 95 +/- 49.9 micrograms.min/mL and 176 +/- 82.1 micrograms.min/mL and 172.5 +/- 86.7 minutes and 628 +/- 575 minutes, respectively.",The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10761166/),min,628,72573,DB00668,Epinephrine
,1866476,half-life periods,The given half-life periods following intramuscular application range from 39 min [8] to 31 h [6].,[Pharmacokinetics of articaine in mandibular nerve block]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),min,39,73865,DB00668,Epinephrine
,1866476,half-life periods,The given half-life periods following intramuscular application range from 39 min [8] to 31 h [6].,[Pharmacokinetics of articaine in mandibular nerve block]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),h,31,73866,DB00668,Epinephrine
,1866476,maximum concentration,Blood samples from peripheral veins showed an average maximum concentration of 2.1 +/- 1.3 mg/l after 12.5 +/- 2.5 min.,[Pharmacokinetics of articaine in mandibular nerve block]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),[mg] / [l],2.1,73867,DB00668,Epinephrine
,1866476,minimum detection limit,After 8 h the value had fallen below the minimum detection limit of 0.05 mg/l.,[Pharmacokinetics of articaine in mandibular nerve block]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),[mg] / [l],0.05,73868,DB00668,Epinephrine
,1866476,half-life,"In the present study, a half-life of approximately 20 min was determined for articaine after conduction anesthesia.",[Pharmacokinetics of articaine in mandibular nerve block]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),min,20,73869,DB00668,Epinephrine
,1866476,maximum,The concentration of the resulting metabolite reaches a maximum value of 2.6 +/- 1.6 mg/l after 40 to 50 min.,[Pharmacokinetics of articaine in mandibular nerve block]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),[mg] / [l],2.6,73870,DB00668,Epinephrine
,1866476,terminal plasma half-life,"Compared to other amide-type local anesthetics, whose terminal plasma half-life varies between 1 and 3.6 h [5], the value of 20 min found for articaine is very low.",[Pharmacokinetics of articaine in mandibular nerve block]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),h,1 and 3.6,73871,DB00668,Epinephrine
,1866476,terminal plasma half-life,"Compared to other amide-type local anesthetics, whose terminal plasma half-life varies between 1 and 3.6 h [5], the value of 20 min found for articaine is very low.",[Pharmacokinetics of articaine in mandibular nerve block]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1866476/),min,20,73872,DB00668,Epinephrine
,26994624,area-under-curve (AUC),"Significant systemic absorption of epinephrine via IN route was observed only at the dose of 5 mg, and the absorption thereof was comparable to that of IM epinephrine; the average area-under-curve (AUC) values at 0-120 minutes for IN saline, IM epinephrine, and 5 mg IN epinephrine were 0.3, 18.3, and 19.4 ng.min/mL, respectively.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),[min·ng] / [ml],0.3,76730,DB00668,Epinephrine
,26994624,area-under-curve (AUC),"Significant systemic absorption of epinephrine via IN route was observed only at the dose of 5 mg, and the absorption thereof was comparable to that of IM epinephrine; the average area-under-curve (AUC) values at 0-120 minutes for IN saline, IM epinephrine, and 5 mg IN epinephrine were 0.3, 18.3, and 19.4 ng.min/mL, respectively.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),[min·ng] / [ml],18.3,76731,DB00668,Epinephrine
,26994624,area-under-curve (AUC),"Significant systemic absorption of epinephrine via IN route was observed only at the dose of 5 mg, and the absorption thereof was comparable to that of IM epinephrine; the average area-under-curve (AUC) values at 0-120 minutes for IN saline, IM epinephrine, and 5 mg IN epinephrine were 0.3, 18.3, and 19.4 ng.min/mL, respectively.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),[min·ng] / [ml],19.4,76732,DB00668,Epinephrine
,26994624,peak epinephrine concentrations,"In addition, the peak epinephrine concentrations and the time to reach them were also not significantly different between IM and 5-mg IN epinephrine; the corresponding values (mean ± SD) were 309 ± 88 pg/mL and 67 ± 43 min for IM epinephrine, and 386 ± 152 pg/mL and 70 ± 17 min for 5 mg IN epinephrine.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),[pg] / [ml],309,76733,DB00668,Epinephrine
,26994624,peak epinephrine concentrations,"In addition, the peak epinephrine concentrations and the time to reach them were also not significantly different between IM and 5-mg IN epinephrine; the corresponding values (mean ± SD) were 309 ± 88 pg/mL and 67 ± 43 min for IM epinephrine, and 386 ± 152 pg/mL and 70 ± 17 min for 5 mg IN epinephrine.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),[pg] / [ml],386,76734,DB00668,Epinephrine
,26994624,time to reach them,"In addition, the peak epinephrine concentrations and the time to reach them were also not significantly different between IM and 5-mg IN epinephrine; the corresponding values (mean ± SD) were 309 ± 88 pg/mL and 67 ± 43 min for IM epinephrine, and 386 ± 152 pg/mL and 70 ± 17 min for 5 mg IN epinephrine.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),min,67,76735,DB00668,Epinephrine
,26994624,time to reach them,"In addition, the peak epinephrine concentrations and the time to reach them were also not significantly different between IM and 5-mg IN epinephrine; the corresponding values (mean ± SD) were 309 ± 88 pg/mL and 67 ± 43 min for IM epinephrine, and 386 ± 152 pg/mL and 70 ± 17 min for 5 mg IN epinephrine.",A preliminary study of intranasal epinephrine administration as a potential route for anaphylaxis treatment. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26994624/),min,70,76736,DB00668,Epinephrine
,7699942,Cmax,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),[ng] / [ml],59.1,77484,DB00668,Epinephrine
,7699942,AUC,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),[h·ng] / [ml],288.2,77485,DB00668,Epinephrine
,7699942,Tmax,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),h,3.4,77486,DB00668,Epinephrine
,7699942,t1/2,"Pharmacokinetic parameters were as follows: Cmax, 59.1 ng/ml; AUC, 288.2 ng hr/ml; Tmax, 3.4 hr; t1/2, 5.5 hr.",[Effects of slow-release nifedipine on hemodynamics and pharmacokinetics in elderly hypertensives]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7699942/),h,5.5,77487,DB00668,Epinephrine
,11996823,clearance,After i.v. infusion the mean clearance value was 1.53+/-0.53 l/min and the mean elimination half-life was 120.5+/-73.1 min.,Spray-dryed bupivacaine-loaded microspheres: in vitro evaluation and biopharmaceutics of bupivacaine following brachial plexus administration in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996823/),[l] / [min],1.53,79281,DB00668,Epinephrine
,11996823,elimination half-life,After i.v. infusion the mean clearance value was 1.53+/-0.53 l/min and the mean elimination half-life was 120.5+/-73.1 min.,Spray-dryed bupivacaine-loaded microspheres: in vitro evaluation and biopharmaceutics of bupivacaine following brachial plexus administration in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996823/),min,120.5,79282,DB00668,Epinephrine
lower,11996823,C(max),"Following brachial plexus nerve injection, bupivacaine C(max) were lower than 100 ng/ml following either solution or microspheres administration.",Spray-dryed bupivacaine-loaded microspheres: in vitro evaluation and biopharmaceutics of bupivacaine following brachial plexus administration in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996823/),[ng] / [ml],100,79283,DB00668,Epinephrine
,4025891,peak concentration,"The initial dose (320-400 mg without epinephrine) followed by top-up injections of about 60% of the mean initial dose every 35-55 min resulted in a plasma accumulation of lidocaine: the peak concentration increased from 2.30 +/- 0.46 (mean +/- SD) microgram/ml following the first injection and 3.34 +/- 0.76 microgram/ml after the second, to 4.11 +/- 0.72 microgram/ml following the third.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],2.30,81713,DB00668,Epinephrine
,4025891,peak concentration,"The initial dose (320-400 mg without epinephrine) followed by top-up injections of about 60% of the mean initial dose every 35-55 min resulted in a plasma accumulation of lidocaine: the peak concentration increased from 2.30 +/- 0.46 (mean +/- SD) microgram/ml following the first injection and 3.34 +/- 0.76 microgram/ml after the second, to 4.11 +/- 0.72 microgram/ml following the third.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],3.34,81714,DB00668,Epinephrine
,4025891,peak concentration,"The initial dose (320-400 mg without epinephrine) followed by top-up injections of about 60% of the mean initial dose every 35-55 min resulted in a plasma accumulation of lidocaine: the peak concentration increased from 2.30 +/- 0.46 (mean +/- SD) microgram/ml following the first injection and 3.34 +/- 0.76 microgram/ml after the second, to 4.11 +/- 0.72 microgram/ml following the third.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],4.11,81715,DB00668,Epinephrine
,4025891,maximum concentrations,"The maximum concentrations of MEGX and GX were 0.66 +/- 0.22 and 0.28 +/- 0.08 microgram/ml, respectively.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],0.66,81716,DB00668,Epinephrine
,4025891,maximum concentrations,"The maximum concentrations of MEGX and GX were 0.66 +/- 0.22 and 0.28 +/- 0.08 microgram/ml, respectively.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[μg] / [ml],0.28,81717,DB00668,Epinephrine
,4025891,elimination half-life (t1/2,"Such pharmacokinetic variables as elimination half-life (t1/2, 2.33 +/- 0.43 h), apparent volume of distribution divided by bioavailability (Vd/F, 2.51 +/- 0.61 l/kg), and clearance divided by bioavailability (Cl/F, 11.65 +/- 1.21 ml X kg-1 X min-1) obtained from the female patients were in reasonable agreement with those reported from healthy females receiving the intravenous lidocaine HCl.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),h,2.33,81718,DB00668,Epinephrine
,4025891,apparent volume of distribution divided by bioavailability (Vd/F,"Such pharmacokinetic variables as elimination half-life (t1/2, 2.33 +/- 0.43 h), apparent volume of distribution divided by bioavailability (Vd/F, 2.51 +/- 0.61 l/kg), and clearance divided by bioavailability (Cl/F, 11.65 +/- 1.21 ml X kg-1 X min-1) obtained from the female patients were in reasonable agreement with those reported from healthy females receiving the intravenous lidocaine HCl.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[l] / [kg],2.51,81719,DB00668,Epinephrine
,4025891,clearance divided by bioavailability (Cl/F,"Such pharmacokinetic variables as elimination half-life (t1/2, 2.33 +/- 0.43 h), apparent volume of distribution divided by bioavailability (Vd/F, 2.51 +/- 0.61 l/kg), and clearance divided by bioavailability (Cl/F, 11.65 +/- 1.21 ml X kg-1 X min-1) obtained from the female patients were in reasonable agreement with those reported from healthy females receiving the intravenous lidocaine HCl.",Plasma concentrations of lidocaine and its principal metabolites during intermittent epidural anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025891/),[ml] / [kg·min],11.65,81720,DB00668,Epinephrine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],30.2,83715,DB00668,Epinephrine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],25.6,83716,DB00668,Epinephrine
,19840530,maximum serum concentration of morphine (Cmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],11.5,83717,DB00668,Epinephrine
,19840530,time to Cmax (tmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,0.2,83718,DB00668,Epinephrine
,19840530,time to Cmax (tmax,"Administration of EREM 3 minutes after a lidocaine-epinephrine test dose, with or without a flush, resulted in an increased mean maximum serum concentration of morphine (Cmax; flush, 30.2 +/- 8.5 ng/ml; no flush, 25.6 +/- 10.1 ng/ml; EREM alone, 11.5 +/- 7.3 ng/ml) and a decreased median time to Cmax (tmax; flush, 0.2 h; no flush, 0.2 h; EREM alone, 2.0 h) compared with administration of EREM alone, without affecting relative morphine bioavailability.",A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,2.0,83719,DB00668,Epinephrine
,19840530,Cmax,Flushing the catheter and waiting 15 minutes normalized the Cmax (11.4 +/- 6.4 ng/ml) but not the median tmax (0.5 h).,A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),[ng] / [ml],11.4,83720,DB00668,Epinephrine
,19840530,tmax,Flushing the catheter and waiting 15 minutes normalized the Cmax (11.4 +/- 6.4 ng/ml) but not the median tmax (0.5 h).,A randomized study of the serum pharmacokinetics of lower thoracic extended-release epidural morphine (DepoDur) after lidocaine-epinephrine test dose administration in patients undergoing upper abdominal surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19840530/),h,0.5,83721,DB00668,Epinephrine
,26006182,elimination half-life,Amlodipine elimination half-life during the first MARS™ session was calculated at 7.6 h.,Mixed amlodipine/valsartan overdose treated by the molecular adsorbent recirculating system (MARS™). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26006182/),h,7.6,84289,DB00668,Epinephrine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pg] / [ml],670 to 9430,87284,DB00668,Epinephrine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pM] / [l],"3660 to 51,490",87285,DB00668,Epinephrine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pg] / [ml],4360,87286,DB00668,Epinephrine
,8420716,concentrations,"Plasma epinephrine concentrations during steady-state infusions of 0.03 to 0.2 micrograms/kg/min ranged from 670 to 9430 pg/mL (3660 to 51,490 pmol/L), with a mean of 4360 +/- 3090 pg/mL (23,810 +/- 16,870 pmol/L) and were linearly related to dose.",Pharmacokinetics of exogenous epinephrine in critically ill children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[pM] / [l],"23,810",87287,DB00668,Epinephrine
,8420716,clearance rates,Epinephrine clearance rates ranged from 15.6 to 79.2 mL/kg/min (mean 29.3 +/- 16.1) and were not dependent on steady-state plasma concentrations.,Pharmacokinetics of exogenous epinephrine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),[ml] / [kg·min],29.3,87288,DB00668,Epinephrine
,8420716,clearance rates,Epinephrine clearance rate was in the same range as the clearance rates of dopamine (34.1 +/- 16.6) and dobutamine (35.9 +/- 27.8) and was linearly related to them (p < .005).,Pharmacokinetics of exogenous epinephrine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),,34.1,87289,DB00668,Epinephrine
,8420716,clearance rates,Epinephrine clearance rate was in the same range as the clearance rates of dopamine (34.1 +/- 16.6) and dobutamine (35.9 +/- 27.8) and was linearly related to them (p < .005).,Pharmacokinetics of exogenous epinephrine in critically ill children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8420716/),,35.9,87290,DB00668,Epinephrine
,1975199,elimination half-life,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),h,1.7-2.0,87894,DB00668,Epinephrine
,1975199,apparent volume of distribution,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),[l] / [kg],3.0-3.5,87895,DB00668,Epinephrine
,1975199,total plasma clearance,"Pharmacokinetic calculations revealed an elimination half-life of 1.7-2.0 h, an apparent volume of distribution of 3.0-3.5 l kg-1 and a total plasma clearance of 1.1-1.5 l h-1 kg-1.","Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1975199/),[l] / [h·kg],1.1-1.5,87896,DB00668,Epinephrine
,17535037,onset of sensory,Median onset of sensory block at surgically relevant dermatomes ranged between 5 and 10 minutes in both groups.,A Comparison of the Dynamics and Pharmacokinetics of Ropivacaine 7.5 mg/mL with and without Epinephrine Used for Epidural Anaesthesia in Urological Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535037/),min,5 and 10,87962,DB00668,Epinephrine
,17535037,duration of sensory block,Median duration of sensory block at relevant dermatomes ranged from 3.6 to 5.7h in group R and from 3.3 to 5.9h in group R+E.,A Comparison of the Dynamics and Pharmacokinetics of Ropivacaine 7.5 mg/mL with and without Epinephrine Used for Epidural Anaesthesia in Urological Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535037/),h,3.6 to 5.7,87963,DB00668,Epinephrine
,17535037,duration of sensory block,Median duration of sensory block at relevant dermatomes ranged from 3.6 to 5.7h in group R and from 3.3 to 5.9h in group R+E.,A Comparison of the Dynamics and Pharmacokinetics of Ropivacaine 7.5 mg/mL with and without Epinephrine Used for Epidural Anaesthesia in Urological Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535037/),h,3.3 to 5.9,87964,DB00668,Epinephrine
,17535037,maximum concentration,Plasma concentrations of ropivacaine peaked around 30 minutes in both groups; the mean maximum concentration was slightly higher in group R (1.4 mg/L) than in group R+E (1.1 mg/L).,A Comparison of the Dynamics and Pharmacokinetics of Ropivacaine 7.5 mg/mL with and without Epinephrine Used for Epidural Anaesthesia in Urological Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535037/),[mg] / [l],1.4,87965,DB00668,Epinephrine
,17535037,maximum concentration,Plasma concentrations of ropivacaine peaked around 30 minutes in both groups; the mean maximum concentration was slightly higher in group R (1.4 mg/L) than in group R+E (1.1 mg/L).,A Comparison of the Dynamics and Pharmacokinetics of Ropivacaine 7.5 mg/mL with and without Epinephrine Used for Epidural Anaesthesia in Urological Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17535037/),[mg] / [l],1.1,87966,DB00668,Epinephrine
,11559034,C(max),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],154.5,88271,DB00668,Epinephrine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1990.9,88272,DB00668,Epinephrine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [l],181.6,88273,DB00668,Epinephrine
,11559034,AUC(0-24h),"Thus, HHMA C(max) (154.5 microg/L) and AUC(0-24h)(1990.9 microg/L h) were similar to those obtained in previously published reports for MDMA (181.6 microg/L and 1465.9 microg/L h, respectively).","3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11559034/),[μg] / [h·l],1465.9,88274,DB00668,Epinephrine
,26065362,time of ingestion,Aldicarb concentration at admission was 2.18 μg/ml and concentration-time data best fitted a two compartmental model with first order absorption and a time of ingestion 4.5 h preadmission.,The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),h,4.5,88859,DB00668,Epinephrine
,26065362,half-life of distribution,"The half-life of distribution was 0.4 h and half-life of elimination, 13 h.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),h,0.4,88860,DB00668,Epinephrine
,26065362,half-life of elimination,"The half-life of distribution was 0.4 h and half-life of elimination, 13 h.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),h,13,88861,DB00668,Epinephrine
,26065362,IC50,"The IC50 was 0.15 μg/ml and 0.26 μg/ml for plasma and red cell cholinesterase, respectively.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),[μg] / [ml],0.15,88862,DB00668,Epinephrine
,26065362,IC50,"The IC50 was 0.15 μg/ml and 0.26 μg/ml for plasma and red cell cholinesterase, respectively.",The pharmacokinetics and pharmacodynamics of severe aldicarb toxicity after overdose. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26065362/),[μg] / [ml],0.26,88863,DB00668,Epinephrine
,11822287,t1/2 alpha,"The concentration-time date of safflor yellow in rat acute model of blood stasis syndrome was shown to fit a double-compartment open model, t1/2 alpha = 1.43 min, t1/2 beta = 95.65 min, AUC = 49,632.90 micrograms.min/ml; while the concentration-time data of safflor yellow in normal rat was shown to fit a single-compartment open model, t1/2 alpha = 66.27 min, AUC = 42,267 micrograms.min/ml.",[Pharmacokinetical study of safflor yellow on rat acute model of blood stasis syndrome]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822287/),min,1.43,90504,DB00668,Epinephrine
,11822287,t1/2 beta,"The concentration-time date of safflor yellow in rat acute model of blood stasis syndrome was shown to fit a double-compartment open model, t1/2 alpha = 1.43 min, t1/2 beta = 95.65 min, AUC = 49,632.90 micrograms.min/ml; while the concentration-time data of safflor yellow in normal rat was shown to fit a single-compartment open model, t1/2 alpha = 66.27 min, AUC = 42,267 micrograms.min/ml.",[Pharmacokinetical study of safflor yellow on rat acute model of blood stasis syndrome]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822287/),min,95.65,90505,DB00668,Epinephrine
,11822287,AUC,"The concentration-time date of safflor yellow in rat acute model of blood stasis syndrome was shown to fit a double-compartment open model, t1/2 alpha = 1.43 min, t1/2 beta = 95.65 min, AUC = 49,632.90 micrograms.min/ml; while the concentration-time data of safflor yellow in normal rat was shown to fit a single-compartment open model, t1/2 alpha = 66.27 min, AUC = 42,267 micrograms.min/ml.",[Pharmacokinetical study of safflor yellow on rat acute model of blood stasis syndrome]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822287/),[min·μg] / [ml],"49,632.90",90506,DB00668,Epinephrine
,11822287,t1/2 alpha,"The concentration-time date of safflor yellow in rat acute model of blood stasis syndrome was shown to fit a double-compartment open model, t1/2 alpha = 1.43 min, t1/2 beta = 95.65 min, AUC = 49,632.90 micrograms.min/ml; while the concentration-time data of safflor yellow in normal rat was shown to fit a single-compartment open model, t1/2 alpha = 66.27 min, AUC = 42,267 micrograms.min/ml.",[Pharmacokinetical study of safflor yellow on rat acute model of blood stasis syndrome]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822287/),min,66.27,90507,DB00668,Epinephrine
,11822287,AUC,"The concentration-time date of safflor yellow in rat acute model of blood stasis syndrome was shown to fit a double-compartment open model, t1/2 alpha = 1.43 min, t1/2 beta = 95.65 min, AUC = 49,632.90 micrograms.min/ml; while the concentration-time data of safflor yellow in normal rat was shown to fit a single-compartment open model, t1/2 alpha = 66.27 min, AUC = 42,267 micrograms.min/ml.",[Pharmacokinetical study of safflor yellow on rat acute model of blood stasis syndrome]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822287/),[min·μg] / [ml],"42,267",90508,DB00668,Epinephrine
,3624412,plasma clearance rates,The plasma clearance rates of EPI and NE were nearly identical in the young subjects (1.63 +/- 0.14 vs. 166 +/- 0.09 L/min X m2; P = NS).,Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624412/),[l] / [m2·min],1.63,91872,DB00668,Epinephrine
,3624412,plasma clearance rates,The plasma clearance rates of EPI and NE were nearly identical in the young subjects (1.63 +/- 0.14 vs. 166 +/- 0.09 L/min X m2; P = NS).,Age differences in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3624412/),[l] / [m2·min],166,91873,DB00668,Epinephrine
,12826553,C(max),"C(max) was significantly lower in Group E+ (0.93 mg x L(-1) +/- 0.29 vs 0.61 mg x L(-1) +/- 0.28, P = 0.05) and T(max) occurred later (124 min +/- 53 vs 47 min +/- 16, P = 0.003).","In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826553/),[mg] / [l],0.93,94256,DB00668,Epinephrine
,12826553,C(max),"C(max) was significantly lower in Group E+ (0.93 mg x L(-1) +/- 0.29 vs 0.61 mg x L(-1) +/- 0.28, P = 0.05) and T(max) occurred later (124 min +/- 53 vs 47 min +/- 16, P = 0.003).","In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826553/),[mg] / [l],0.61,94257,DB00668,Epinephrine
,12826553,T(max),"C(max) was significantly lower in Group E+ (0.93 mg x L(-1) +/- 0.29 vs 0.61 mg x L(-1) +/- 0.28, P = 0.05) and T(max) occurred later (124 min +/- 53 vs 47 min +/- 16, P = 0.003).","In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826553/),min,124,94258,DB00668,Epinephrine
,12826553,T(max),"C(max) was significantly lower in Group E+ (0.93 mg x L(-1) +/- 0.29 vs 0.61 mg x L(-1) +/- 0.28, P = 0.05) and T(max) occurred later (124 min +/- 53 vs 47 min +/- 16, P = 0.003).","In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826553/),min,47,94259,DB00668,Epinephrine
,12826553,Ka,Weight was a significant covariate for Cl and Vd while E significantly slowed R Ka [Group I Ka 0.025 min(-1) [coefficient of variation (CV) 21%] vs 0.078 min(-1) (CV 25%) in Group II].,"In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826553/),1/[min],0.025,94260,DB00668,Epinephrine
,12826553,Ka,Weight was a significant covariate for Cl and Vd while E significantly slowed R Ka [Group I Ka 0.025 min(-1) [coefficient of variation (CV) 21%] vs 0.078 min(-1) (CV 25%) in Group II].,"In children, the addition of epinephrine modifies the pharmacokinetics of ropivacaine injected caudally. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12826553/),1/[min],0.078,94261,DB00668,Epinephrine
,10088519,peak plasma concentrations,The peak plasma concentrations of lidocaine varied between 0.96 and 3.12 microg/ml (mean 1.49 microg/ml) and occurred between 4 and 12 hours (mean 7.3 hours) postoperatively.,Plasma concentrations of lidocaine and alpha1-acid glycoprotein during and after breast augmentation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10088519/),[μg] / [ml],1.49,96802,DB00668,Epinephrine
,8706643,peak concentration,"Free unconjugated procaine in equine urine reached a peak concentration of 23.7 ng/mL, while total (unconjugated plus conjugated) procaine peaked at 37.9 ng/mL (mean urine pH of 8.5).",Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706643/),[ng] / [ml],23.7,96908,DB00668,Epinephrine
,8706643,peak concentration,"Free unconjugated procaine in equine urine reached a peak concentration of 23.7 ng/mL, while total (unconjugated plus conjugated) procaine peaked at 37.9 ng/mL (mean urine pH of 8.5).",Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706643/),[ng] / [ml],37.9,96909,DB00668,Epinephrine
,8706643,duration of effect,There was a significant local anaesthetic (LA) effect for all doses of procaine HCl with the duration of effect ranging from 30 min (40 mg) to 60 min (320 mg).,Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706643/),min,30,96910,DB00668,Epinephrine
,8706643,duration of effect,There was a significant local anaesthetic (LA) effect for all doses of procaine HCl with the duration of effect ranging from 30 min (40 mg) to 60 min (320 mg).,Regulatory significance of procaine residues in plasma and urine samples: preliminary communication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706643/),,60,96911,DB00668,Epinephrine
,3189894,maximum arterial concentrations (Cmax),"After 15-minute IV infusions of 3.0 mg/kg ropivacaine (n = 6) and 3.4 mg/kg bupivacaine (n = 4), the maximum arterial concentrations (Cmax) of ropivacaine averaged 2.41 +/- 0.52 micrograms/ml compared with 3.35 +/- 0.16 micrograms/ml of bupivacaine.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[μg] / [ml],2.41,99510,DB00668,Epinephrine
,3189894,maximum arterial concentrations (Cmax),"After 15-minute IV infusions of 3.0 mg/kg ropivacaine (n = 6) and 3.4 mg/kg bupivacaine (n = 4), the maximum arterial concentrations (Cmax) of ropivacaine averaged 2.41 +/- 0.52 micrograms/ml compared with 3.35 +/- 0.16 micrograms/ml of bupivacaine.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[μg] / [ml],3.35,99511,DB00668,Epinephrine
,3189894,elimination half life (t 1/2 beta),The elimination half life (t 1/2 beta) of ropivacaine (25.9 +/- 1.7 min) was significantly shorter than for bupivacaine (39.1 +/- 13.3 min) after IV infusion.,"Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),min,25.9,99512,DB00668,Epinephrine
,3189894,elimination half life (t 1/2 beta),The elimination half life (t 1/2 beta) of ropivacaine (25.9 +/- 1.7 min) was significantly shorter than for bupivacaine (39.1 +/- 13.3 min) after IV infusion.,"Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),min,39.1,99513,DB00668,Epinephrine
,3189894,clearance values (Cl),"This was reflected by mean clearance values (Cl) for ropivacaine of 41.1 +/- 8.2 ml.min-1.kg-1 compared with 32.3 +/- 4.8 ml.min-1.kg-1 for bupivacaine, although the difference was not statistically significant.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[ml] / [kg·min],41.1,99514,DB00668,Epinephrine
,3189894,clearance values (Cl),"This was reflected by mean clearance values (Cl) for ropivacaine of 41.1 +/- 8.2 ml.min-1.kg-1 compared with 32.3 +/- 4.8 ml.min-1.kg-1 for bupivacaine, although the difference was not statistically significant.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[ml] / [kg·min],32.3,99515,DB00668,Epinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],63,100616,DB00668,Epinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],127,100617,DB00668,Epinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],8,100618,DB00668,Epinephrine
,1971575,maximal concentrations (Cmax),"The maximal concentrations (Cmax) of free DA in plasma after oral administration of 750 and 1500 mg of TA-870 to humans were 63 and 127 ng/ml, respectively, being higher than the concentrations of 8 and 31 ng/ml following the infusion of 1 and 3 micrograms/kg/min, the clinical doses of DA.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),[ng] / [ml],31,100619,DB00668,Epinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,40-66,100620,DB00668,Epinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,0.5,100621,DB00668,Epinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,0.6-0.9,100622,DB00668,Epinephrine
,1971575,conjugated/free ratios,"The conjugated/free ratios of urinary metabolites after TA-870 dosing were 40-66 for DA, 0.5 for HVA, 0.6-0.9 for DOPAC, and 5.0-6.2 for DEC-TA-870.","Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1971575/),,5.0-6.2,100623,DB00668,Epinephrine
,8439023,minimum effective CSF clonidine concentration,Extrapolation of CSF clonidine pharmacokinetics suggests the minimum effective CSF clonidine concentration for postoperative pain relief is 76 +/- 15 ng/ml.,Hemodynamic and analgesic actions of epidurally administered clonidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8439023/),[ng] / [ml],76,101547,DB00668,Epinephrine
,1151803,Pa,"Foetal and maternal plasma catecholamine concentrations were measured during and after hypoxia (mean maternal Pa,02 44mmHg) in chronically catheterized sheep, 118-141 days pregnant.",Plasma catecholamines in foetal and adult sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1151803/),mmhg,44,102127,DB00668,Epinephrine
,1151803,half-life,6. The half-life of adrenaline and of noradrenaline in the maternal and foetal circulation was 0.25-1 min.,Plasma catecholamines in foetal and adult sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1151803/),min,0.25-1,102128,DB00668,Epinephrine
,30629049,peak plasma concentration,The mean peak plasma concentration was 20.35 micrograms/L occurring at 120 minutes post-administration.,Is atomised intranasal cocaine systemically absorbed during endoscopic sinus surgery? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30629049/),[μg] / [l],20.35,103864,DB00668,Epinephrine
,1607003,AUC(o-t),The plasma 5-ISMN concentration-time profile was the same whether 5-ISMN was administered concomitantly with ibopamine or alone [AUC(o-t): 2.24 micrograms.,Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1607003/),μg,2.24,104283,DB00668,Epinephrine
,10077095,Maximum tissue pressure,"Maximum tissue pressure during injection was 339 +/- 63 mmHg and 27 +/- 9 mmHg using high- and low-pressure techniques, respectively.",The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10077095/),mmhg,339,104894,DB00668,Epinephrine
,10077095,Maximum tissue pressure,"Maximum tissue pressure during injection was 339 +/- 63 mmHg and 27 +/- 9 mmHg using high- and low-pressure techniques, respectively.",The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10077095/),mmhg,27,104895,DB00668,Epinephrine
greater,10077095,Peak plasma concentrations,Peak plasma concentrations greater than 1 mcg/ml were seen in 11 subjects.,The tumescent technique: the effect of high tissue pressure and dilute epinephrine on absorption of lidocaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10077095/),[mcg] / [ml],1,104896,DB00668,Epinephrine
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,249,106087,DB00668,Epinephrine
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,950,106088,DB00668,Epinephrine
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,834,106089,DB00668,Epinephrine
,21056807,AUC(0-6h),"AUC(0-6h) (mean ± SD) for CEPI closure time difference was significantly smaller after IV diclofenac 37.5 mg (249 ± 216 sec.hrs) than after ketorolac [and ASA (950 ± 287 sec.hrs and 834 ± 237 sec.hrs, respectively); P ≤ 0.0001 for both] but not after the oral diclofenac control (286 ± 265 sec.hrs; P = 0.40).","Platelet function following administration of a novel formulation of intravenous diclofenac sodium versus active comparators: a randomized, single dose, crossover study in healthy male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056807/),h·s,286,106090,DB00668,Epinephrine
,2014157,plasma t1/2,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),min,21,106641,DB00668,Epinephrine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],1682,106642,DB00668,Epinephrine
,2014157,peak plasma concentration,"After intraperitoneal injection of 50 mumols/kg, the plasma t1/2 of cocaine was 21 +/- 5 min and peak plasma concentration (1682 +/- 260 pmol/mL, measured by HPLC) was achieved in 5-10 min; a lower peak plasma concentration (486 +/- 103 pmol/mL) was achieved in 20-60 min after s.c. injection.",Effects of cocaine on rat embryo development in vivo and in cultures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2014157/),[pM] / [ml],486,106643,DB00668,Epinephrine
,12005188,Ae(Azo,"The significantly greater Ae(Azo, 0-8 h) in 4WE rats was mainly due to a significant increase in intrinsic active secretion of azosemide in renal tubules and not due to a decrease in the metabolism of azosemide.",Influence of 4-week and 8-week exercise training on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12005188/),h,0-8,107367,DB00668,Epinephrine
,8745970,Cmax,The Cmax was 859 +/- 503 ng.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),ng,859,108253,DB00668,Epinephrine
,8745970,Tmax,mL-1 after a Tmax to 47 +/- 17 min.,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,47,108254,DB00668,Epinephrine
,8745970,elimination half-life,The mean elimination half-life was 87 +/- 19 min (mean +/- SD).,[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),min,87,108255,DB00668,Epinephrine
,8745970,total clearance,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),[ml] / [min],"4,521",108256,DB00668,Epinephrine
,8745970,volume of distribution,"The total clearance and the volume of distribution were respectively 4,521 +/- 1,858 mL.min-1 and 568 +/- 273 L.",[Cocaine contact anesthesia for endonasal surgery. Kinetics and clinical tolerance of a concentrated solution]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8745970/),l,568,108257,DB00668,Epinephrine
,31522098,flow rate,"The derivatives resolved with good baseline separation on an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with mobile phase composed of methanol with 0.2% formic acid in water at a flow rate of 0.2 mL/min.",Analysis of endogenous epinephrine and norepinephrine enantiomers in rat plasma and application to a stereoselective pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31522098/),[ml] / [min],0.2,108604,DB00668,Epinephrine
more,31522098,Recoveries,Recoveries for all the analytes were more than 80.3%.,Analysis of endogenous epinephrine and norepinephrine enantiomers in rat plasma and application to a stereoselective pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31522098/),%,80.3,108605,DB00668,Epinephrine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110784,DB00668,Epinephrine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,28,110785,DB00668,Epinephrine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110786,DB00668,Epinephrine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),,23,110787,DB00668,Epinephrine
,17898657,peak concentration,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),[μg] / [ml],1.41,111384,DB00668,Epinephrine
,17898657,time to reach peak concentration,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),h,9.3,111385,DB00668,Epinephrine
,17898657,terminal half-life,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),h,6.2,111386,DB00668,Epinephrine
,17898657,area under the curve from time zero to last data point,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),[μg] / [min·ml],1379.8,111387,DB00668,Epinephrine
,17898657,area under the curve from time zero to infinity,"Pharmacokinetic analysis was peak concentration 1.41 +/- 0.4 microg/mL, time to reach peak concentration 9.3 +/- 1.6 hours, terminal half-life 6.2 +/- 1.5 hours, area under the curve from time zero to last data point 1379.8 +/- 470 microg/min/mL, and area under the curve from time zero to infinity 1530.6 +/- 471.6 microg/min/mL.",Pharmacokinetics of high-dose diluted lidocaine in local anesthesia for facelift procedures. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17898657/),[μg] / [min·ml],1530.6,111388,DB00668,Epinephrine
,9449498,maximum plasma epinephrine concentration,"In nine children who received epinephrine subcutaneously, the mean maximum plasma epinephrine concentration (+/- SEM) was 1802 +/- 214 pg/ml, achieved at a mean time of 34 +/- 14 minutes (range, 5 to 120 minutes).",Epinephrine absorption in children with a history of anaphylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449498/),[pg] / [ml],1802,111406,DB00668,Epinephrine
,9449498,maximum plasma concentration,"In eight children who received epinephrine intramuscularly, the mean maximum plasma concentration was 2136 +/- 351 pg/ml, achieved at a mean time of 8 +/- 2 minutes, which was significantly faster than the mean time at which maximum plasma concentrations were achieved after subcutaneous epinephrine injection (p < 0.05).",Epinephrine absorption in children with a history of anaphylaxis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449498/),[pg] / [ml],2136,111407,DB00668,Epinephrine
,9449498,mean time,"In eight children who received epinephrine intramuscularly, the mean maximum plasma concentration was 2136 +/- 351 pg/ml, achieved at a mean time of 8 +/- 2 minutes, which was significantly faster than the mean time at which maximum plasma concentrations were achieved after subcutaneous epinephrine injection (p < 0.05).",Epinephrine absorption in children with a history of anaphylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449498/),min,8,111408,DB00668,Epinephrine
,9449498,terminal elimination half-life,The terminal elimination half-life was 43 +/- 15 minutes.,Epinephrine absorption in children with a history of anaphylaxis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9449498/),min,43,111409,DB00668,Epinephrine
,17975237,total ropivacaine plasma concentration,The total ropivacaine plasma concentration was 3.68 microgxmL-(1).,Case report: ropivacaine neurotoxicity at clinical doses in interscalene brachial plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17975237/),ml-(1)·μg,3.68,114229,DB00668,Epinephrine
,33685510,Tmax,"Most investigators found two Cmax's with Tmax 5-10 min and 30-50 min, respectively.",The pharmacokinetics of epinephrine/adrenaline autoinjectors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685510/),min,5-10,114332,DB00668,Epinephrine
,33685510,Tmax,"Most investigators found two Cmax's with Tmax 5-10 min and 30-50 min, respectively.",The pharmacokinetics of epinephrine/adrenaline autoinjectors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33685510/),min,30-50,114333,DB00668,Epinephrine
,1513751,ED50,The ED50 of CRF for reducing pulmonary oedema was 3.2 (1.3-7.4) micrograms/kg s.c.,Epinephrine-induced pulmonary oedema in rats is inhibited by corticotropin-releasing factor. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513751/),[μg] / [kg],3.2,119929,DB00668,Epinephrine
,19505437,K(cat),"Evaluation of COMT activity in rat and mice liver homogenates revealed that both had similar methylation efficiencies (K(cat) values, respectively 7.3 and 6.4min(-1)), but rat had twice active enzyme units as the mouse (molar equivalency respectively 150 and 83).",Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19505437/),1/[min],7.3,120261,DB00668,Epinephrine
,19505437,K(cat),"Evaluation of COMT activity in rat and mice liver homogenates revealed that both had similar methylation efficiencies (K(cat) values, respectively 7.3 and 6.4min(-1)), but rat had twice active enzyme units as the mouse (molar equivalency respectively 150 and 83).",Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19505437/),1/[min],6.4,120262,DB00668,Epinephrine
,19505437,K(i),"Furthermore, nebicapone inhibited rat liver COMT with a lower K(i) than mouse liver COMT (respectively 0.2nM vs. 1.2nM).",Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19505437/),nM,0.2,120263,DB00668,Epinephrine
,19505437,K(i),"Furthermore, nebicapone inhibited rat liver COMT with a lower K(i) than mouse liver COMT (respectively 0.2nM vs. 1.2nM).",Species differences in pharmacokinetic and pharmacodynamic properties of nebicapone. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19505437/),nM,1.2,120264,DB00668,Epinephrine
,1931477,steady-state plasma bupivacaine concentration,"The mean measured steady-state plasma bupivacaine concentration was 2.1 mg l-1 (s.d. +/- 0.54, range 1.3-3.2 mg l-1).",The disposition of bupivacaine following a 72 h interpleural infusion in cholecystectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931477/),[mg] / [l],2.1,120324,DB00668,Epinephrine
,1931477,systemic clearance,"No statistically significant differences were noted and, in particular, the systemic clearance of bupivacaine (mean 10.2 l h-1 s.d +/- 3.0; range 6.3-16.0 1 h-1) remained unchanged following the long-term interpleural infusion.",The disposition of bupivacaine following a 72 h interpleural infusion in cholecystectomy patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931477/),[l] / [h],10.2,120325,DB00668,Epinephrine
below,6510884,peak concentrations,"During epidural anesthesia of longer duration (maximum 11 h), the peak concentrations remained below 5 micrograms/ml which was seen after the 9th supplementation.",[Pharmacokinetic study on the lidocaine concentration in serum during epidural anesthesia]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6510884/),[μg] / [ml],5,121773,DB00668,Epinephrine
,9356115,plasma concentration (Cp),"Dexmedetomidine was infused postoperatively by CCIP for 60 min to eight women, targeting a plasma concentration (Cp) of 600 pg/mL.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),[pg] / [ml],600,122551,DB00668,Epinephrine
,9356115,heart rate,"During the infusion, norepinephrine decreased from 2.1 +/- 0.8 to 0.7 +/- 0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2 nmol/L; heart rate decreased from 76 +/- 15 to 64 +/- 11 bpm; and systolic blood pressure decreased from 158 +/- 23 to 140 +/- 23 mm Hg.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),bpm,76,122552,DB00668,Epinephrine
,9356115,heart rate,"During the infusion, norepinephrine decreased from 2.1 +/- 0.8 to 0.7 +/- 0.3 nmol/L; epinephrine decreased from 0.7 +/- 0.5 to 0.2 +/- 0.2 nmol/L; heart rate decreased from 76 +/- 15 to 64 +/- 11 bpm; and systolic blood pressure decreased from 158 +/- 23 to 140 +/- 23 mm Hg.",Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356115/),bpm,64,122553,DB00668,Epinephrine
,25303987,maximum measured plasma concentrations,"Ranges of maximum measured plasma concentrations of total and free ropivacaine were 422-3905 and 5-186 ng ml(-1), respectively.",Early pharmacokinetic of ropivacaine without epinephrine after injection into the psoas compartment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25303987/),[ng] / [ml],422-3905,122957,DB00668,Epinephrine
,25303987,maximum measured plasma concentrations,"Ranges of maximum measured plasma concentrations of total and free ropivacaine were 422-3905 and 5-186 ng ml(-1), respectively.",Early pharmacokinetic of ropivacaine without epinephrine after injection into the psoas compartment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25303987/),[ng] / [ml],5-186,122958,DB00668,Epinephrine
,26233335,bioavailability,Intranasal bioavailability was 82%.,Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26233335/),%,82,124283,DB00668,Epinephrine
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,26,124601,DB00668,Epinephrine
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,33,124602,DB00668,Epinephrine
,7085853,Fractional extraction,Fractional extraction (arterial - venous + arterial X 100) of epinephrine across the forearm was 26 +/- 8% in the basal state and increased to 33 +/- 6% and further to 51 +/- 4% during the epinephrine infusions.,Release and clearance rates of epinephrine in man: importance of arterial measurements. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),%,51,124603,DB00668,Epinephrine
,7085853,Whole body clearance,"Whole body clearance of epinephrine, calculated from arterial measurements, was 33 +/- 3 ml/kg . min during the 0.1 microgram/min infusion and 35 +/- 3 ml/kg . min during the 2 micrograms/min epinephrine infusion, values 50% lower than the clearance rates calculated from venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],33,124604,DB00668,Epinephrine
,7085853,Whole body clearance,"Whole body clearance of epinephrine, calculated from arterial measurements, was 33 +/- 3 ml/kg . min during the 0.1 microgram/min infusion and 35 +/- 3 ml/kg . min during the 2 micrograms/min epinephrine infusion, values 50% lower than the clearance rates calculated from venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],35,124605,DB00668,Epinephrine
,7085853,whole body clearance,"Propranolol infusion resulted in a fall in whole body clearance to 20 +/- 2 ml/kg . min (P less than 0.001), suggesting that epinephrine clearance is partly dependent on a beta-adrenergic mechanism.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[ml] / [kg·min],20,124606,DB00668,Epinephrine
,7085853,Basal endogenous release rate (clearance X,"Basal endogenous release rate (clearance X basal epinephrine level) was estimated to be approximately 0.18 microgram/min, a value much less than that reported in studies using venous measurements.",Release and clearance rates of epinephrine in man: importance of arterial measurements. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7085853/),[μg] / [min],0.18,124607,DB00668,Epinephrine
,2400142,Pain score,Pain score recorded with an visual analogue scale was 5.0 +/- 1.9 before femoral block.,[Continuous block of the femoral nerve after surgery of the knee: pharmacokinetics of bupivacaine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400142/),,5.0,124815,DB00668,Epinephrine
,2400142,level at steady state,Mean plasma bupivacaine level at steady state was 1.78 +/- 0.59 micrograms.,[Continuous block of the femoral nerve after surgery of the knee: pharmacokinetics of bupivacaine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400142/),μg,1.78,124816,DB00668,Epinephrine
,2400142,Clearance,Clearance of bupivacaine was 2.59 +/- 0.91 ml.min-1.kg-1.,[Continuous block of the femoral nerve after surgery of the knee: pharmacokinetics of bupivacaine]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400142/),[ml] / [kg·min],2.59,124817,DB00668,Epinephrine
,12116053,C(max),"After administration of epinephrine 2.5 mg as a sublingual tablet, the mean (+/-SEM) C(max) was 2369+/-392 pg/ml, and the t(max) was 20.8+/-5.7 min.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),[pg] / [ml],2369,126784,DB00668,Epinephrine
,12116053,t(max),"After administration of epinephrine 2.5 mg as a sublingual tablet, the mean (+/-SEM) C(max) was 2369+/-392 pg/ml, and the t(max) was 20.8+/-5.7 min.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),min,20.8,126785,DB00668,Epinephrine
,12116053,C(max),"After administration of epinephrine 10 mg sublingually, the C(max) was 10836+/-2234 pg/ml, and the t(max) was 21.7+/-5.4 min.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),[pg] / [ml],10836,126786,DB00668,Epinephrine
,12116053,t(max),"After administration of epinephrine 10 mg sublingually, the C(max) was 10836+/-2234 pg/ml, and the t(max) was 21.7+/-5.4 min.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),min,21.7,126787,DB00668,Epinephrine
,12116053,C(max),"After IM epinephrine, the C(max) was 6445+/-4233 pg/ml, and the t(max) was 15.8+/-4.7 min.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),[pg] / [ml],6445,126788,DB00668,Epinephrine
,12116053,t(max),"After IM epinephrine, the C(max) was 6445+/-4233 pg/ml, and the t(max) was 15.8+/-4.7 min.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),min,15.8,126789,DB00668,Epinephrine
,12116053,C(max),"After IM 0.9% NaCl, the C(max) (endogenous epinephrine) was 518+/-142 pg/ml.",Is epinephrine administration by sublingual tablet feasible for the first-aid treatment of anaphylaxis? A proof-of-concept study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12116053/),[pg] / [ml],518,126790,DB00668,Epinephrine
,1572185,half-life,The half-life for the alpha phase was 2.2 mins and was 38.7 mins for the beta phase.,Plasma catecholamine concentrations after successful resuscitation in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),min,2.2,127274,DB00668,Epinephrine
,1572185,half-life,The half-life for the alpha phase was 2.2 mins and was 38.7 mins for the beta phase.,Plasma catecholamine concentrations after successful resuscitation in patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),min,38.7,127275,DB00668,Epinephrine
,1572185,plasma glucose concentrations,Median plasma glucose concentrations were between 8.2 mmol/L (147.7 mg/dL; range 5.8 to 11.2 mmol/L [104.5 to 201.8 mg/dL]) at 1 min and 13.9 mmol/L (250.4 mg/dL; range 9.7 to 16.6 mmol/L [174.8 to 299.1 mg/dL]) at 30 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],8.2,127276,DB00668,Epinephrine
,1572185,plasma glucose concentrations,Median plasma glucose concentrations were between 8.2 mmol/L (147.7 mg/dL; range 5.8 to 11.2 mmol/L [104.5 to 201.8 mg/dL]) at 1 min and 13.9 mmol/L (250.4 mg/dL; range 9.7 to 16.6 mmol/L [174.8 to 299.1 mg/dL]) at 30 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],13.9,127277,DB00668,Epinephrine
,1572185,Lactate,Lactate values were between 11.4 mmol/L (range 4.7 to 16.5) at 1 min and 5.2 mmol/L (range 2.7 to 12.5) at 60 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],11.4,127278,DB00668,Epinephrine
,1572185,Lactate,Lactate values were between 11.4 mmol/L (range 4.7 to 16.5) at 1 min and 5.2 mmol/L (range 2.7 to 12.5) at 60 mins.,Plasma catecholamine concentrations after successful resuscitation in patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572185/),[mM] / [l],5.2,127279,DB00668,Epinephrine
,2253294,peak plasma concentration (Cmax),The mean peak plasma concentration (Cmax) was 1.6 +/- 0.6 mg.L-1 and 1.3 +/- 0.4 mg.L-1 after administration of ropivacaine with and without epinephrine.,Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253294/),[mg] / [l],1.6,127968,DB00668,Epinephrine
,2253294,peak plasma concentration (Cmax),The mean peak plasma concentration (Cmax) was 1.6 +/- 0.6 mg.L-1 and 1.3 +/- 0.4 mg.L-1 after administration of ropivacaine with and without epinephrine.,Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253294/),[mg] / [l],1.3,127969,DB00668,Epinephrine
,2253294,time to peak plasma concentration (tmax),The median time to peak plasma concentration (tmax) was 0.75 hr and 0.88 hr and the mean area under the plasma concentration curve AUC0-12h was 7.7 +/- 3.6 and 7.0 +/- 3.4 mg.l hr-1.,Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253294/),h,0.75,127970,DB00668,Epinephrine
,2253294,time to peak plasma concentration (tmax),The median time to peak plasma concentration (tmax) was 0.75 hr and 0.88 hr and the mean area under the plasma concentration curve AUC0-12h was 7.7 +/- 3.6 and 7.0 +/- 3.4 mg.l hr-1.,Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253294/),h,0.88,127971,DB00668,Epinephrine
,2253294,area under the plasma concentration curve AUC0-12h,The median time to peak plasma concentration (tmax) was 0.75 hr and 0.88 hr and the mean area under the plasma concentration curve AUC0-12h was 7.7 +/- 3.6 and 7.0 +/- 3.4 mg.l hr-1.,Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253294/),[l·mg] / [h],7.7,127972,DB00668,Epinephrine
,2253294,area under the plasma concentration curve AUC0-12h,The median time to peak plasma concentration (tmax) was 0.75 hr and 0.88 hr and the mean area under the plasma concentration curve AUC0-12h was 7.7 +/- 3.6 and 7.0 +/- 3.4 mg.l hr-1.,Plasma concentrations of ropivacaine given with or without epinephrine for brachial plexus block. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253294/),[l·mg] / [h],7.0,127973,DB00668,Epinephrine
,7818055,maximum bupivacaine concentration,"There was no clinical evidence of bupivacaine toxicity although the maximum bupivacaine concentration ranged from 0.74-6.52 mg/l, mean 2.90 (SEM 0.44) mg/l and vascular uptake was rapid in two patients.",Pharmacokinetics of bupivacaine enantiomers during interpleural infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818055/),[mg] / [l],2.90,130154,DB00668,Epinephrine
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],"13,",130386,DB00668,Epinephrine
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],"16,166",130387,DB00668,Epinephrine
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],"10,372",130388,DB00668,Epinephrine
,10470765,plasma concentrations,"At both 90 secs and 5 mins after drug administration, intravenous and intraosseous administration of vasopressin resulted in comparable mean (+/-SEM) coronary perfusion pressure (43+/-4 vs. 44+/-3 and 30+/-2 vs. 37+/-2 mm Hg, respectively) and vasopressin plasma concentrations (13,706+/-1,857 vs. 16,166+/-3,114 pg/mL and 10,372+/-883 vs. 8246+/-2211 pg/mL, respectively).",Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),[pg] / [ml],8246,130389,DB00668,Epinephrine
,10470765,arterial,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),mm,92,130390,DB00668,Epinephrine
,10470765,arterial,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),mm,129,130391,DB00668,Epinephrine
,10470765,coronary perfusion pressure,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),hg·mm,84,130392,DB00668,Epinephrine
,10470765,coronary perfusion pressure,All animals in both groups were successfully resuscitated; pigs that received intraosseous vasopressin had a significantly higher (p < .05) mean arterial (92+/-6 vs. 129+/-12 mm Hg) and coronary perfusion pressure (84+/-11 vs. 119+/-11 mm Hg) at 5 mins of return of spontaneous circulation.,Intraosseous vasopressin improves coronary perfusion pressure rapidly during cardiopulmonary resuscitation in pigs. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10470765/),hg·mm,119,130393,DB00668,Epinephrine
,7574011,V1,"Using mixed-effects nonlinear regression (for n = 28), the following volumes were determined for the three compartments: V1 = 11.1 L, V2 = 16.9 L, and V3 = 363 L.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),l,11.1,131035,DB00668,Epinephrine
,7574011,V2,"Using mixed-effects nonlinear regression (for n = 28), the following volumes were determined for the three compartments: V1 = 11.1 L, V2 = 16.9 L, and V3 = 363 L.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),l,16.9,131036,DB00668,Epinephrine
,7574011,V3,"Using mixed-effects nonlinear regression (for n = 28), the following volumes were determined for the three compartments: V1 = 11.1 L, V2 = 16.9 L, and V3 = 363 L.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),l,363,131037,DB00668,Epinephrine
,7574011,Cl1,"Similarly, the following clearances were estimated for the three compartments: Cl1 = 0.067 L/min, Cl2 = 1.05 L/min, and Cl3 = 0.31 L/min.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),[l] / [min],0.067,131038,DB00668,Epinephrine
,7574011,Cl2,"Similarly, the following clearances were estimated for the three compartments: Cl1 = 0.067 L/min, Cl2 = 1.05 L/min, and Cl3 = 0.31 L/min.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),[l] / [min],1.05,131039,DB00668,Epinephrine
,7574011,Cl3,"Similarly, the following clearances were estimated for the three compartments: Cl1 = 0.067 L/min, Cl2 = 1.05 L/min, and Cl3 = 0.31 L/min.",A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),[l] / [min],0.31,131040,DB00668,Epinephrine
,7574011,half-times,The short context-sensitive half-times of 6.7 or 10.2 min after 1- or 10-min bolus infusions underscore the need for prompt institution of a maintenance infusion when milrinone concentrations must be maintained.,A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),min,6.7,131041,DB00668,Epinephrine
,7574011,half-times,The short context-sensitive half-times of 6.7 or 10.2 min after 1- or 10-min bolus infusions underscore the need for prompt institution of a maintenance infusion when milrinone concentrations must be maintained.,A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7574011/),min,10.2,131042,DB00668,Epinephrine
,2015726,maximal increase,"Twelve milligrams of yohimbine moderately but significantly accelerated supine heart rate (mean maximal increase, 7 +/- 3 beats/min).",The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2015726/),[beats] / [min],7,131264,DB00668,Epinephrine
,1616166,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of R(+) was 1.54 +/- 0.34 micrograms/mL, whereas that of the S(-) isomer was 2.34 +/- 0.51 micrograms/mL (P = 0.00050).",Clinical pharmacokinetics of R(+)- and S(-)-mepivacaine after high doses of racemic mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1616166/),[μg] / [ml],1.54,132107,DB00668,Epinephrine
,1616166,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of R(+) was 1.54 +/- 0.34 micrograms/mL, whereas that of the S(-) isomer was 2.34 +/- 0.51 micrograms/mL (P = 0.00050).",Clinical pharmacokinetics of R(+)- and S(-)-mepivacaine after high doses of racemic mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1616166/),[μg] / [ml],2.34,132108,DB00668,Epinephrine
,1616166,elimination half-life (T1/2),"The elimination half-life (T1/2) was identical for both isomers (3 h), which means that the calculated total body clearance and the calculated steady-state volume of the distribution of R(+) are, respectively, 1.7 and 1.5 times larger than that of the S(-) isomer.",Clinical pharmacokinetics of R(+)- and S(-)-mepivacaine after high doses of racemic mepivacaine with epinephrine in the combined psoas compartment/sciatic nerve block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1616166/),h,3,132109,DB00668,Epinephrine
,28270248,time to ROSC,"Analysis of Variance (ANOVA) indicated the mean time to ROSC for HIO and IV was 621.20 seconds (SD=204.21 seconds) and 554.50 seconds (SD=213.96 seconds), respectively, with no significant difference between the groups (U=11; P=.22).",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,621.20,135705,DB00668,Epinephrine
,28270248,time to ROSC,"Analysis of Variance (ANOVA) indicated the mean time to ROSC for HIO and IV was 621.20 seconds (SD=204.21 seconds) and 554.50 seconds (SD=213.96 seconds), respectively, with no significant difference between the groups (U=11; P=.22).",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,554.50,135706,DB00668,Epinephrine
,28270248,maximum plasma concentration (Cmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),[pg] / [ml],71753.9,135707,DB00668,Epinephrine
,28270248,time to maximum concentration (Tmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),[pg] / [ml],61853.7,135708,DB00668,Epinephrine
,28270248,time to maximum concentration (Tmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,111.42,135709,DB00668,Epinephrine
,28270248,time to maximum concentration (Tmax),"Multivariate Analysis of Variance (MANOVA) revealed the maximum plasma concentration (Cmax) and time to maximum concentration (Tmax) of vasopressin in the HIO and IV groups was 71753.9 pg/mL (SD=26744.58 pg/mL) and 61853.7 pg/mL (SD=22745.04 pg/mL); 111.42 seconds (SD=51.3 seconds) and 114.55 seconds (SD=55.02 seconds), respectively.",The Resuscitative and Pharmacokinetic Effects of Humeral Intraosseous Vasopressin in a Swine Model of Ventricular Fibrillation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28270248/),seconds,114.55,135710,DB00668,Epinephrine
,31696528,plasma unbound fraction,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.09,135973,DB00668,Epinephrine
,31696528,plasma unbound fraction,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.06,135974,DB00668,Epinephrine
,31696528,plasma ratio,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.47,135975,DB00668,Epinephrine
,31696528,plasma ratio,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.39,135976,DB00668,Epinephrine
,2006723,peak concentration,The addition of epinephrine yielded only minor advantages from a pharmacokinetic point of view (median peak concentration of bupivacaine 1.8 micrograms/ml vs 2.0 micrograms/ml for bupivacaine alone).,[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μg] / [ml],1.8,143907,DB00668,Epinephrine
,2006723,peak concentration,The addition of epinephrine yielded only minor advantages from a pharmacokinetic point of view (median peak concentration of bupivacaine 1.8 micrograms/ml vs 2.0 micrograms/ml for bupivacaine alone).,[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μg] / [ml],2.0,143908,DB00668,Epinephrine
above,2006723,maximum total plasma concentrations,"Even though maximum total plasma concentrations of bupivacaine above 2 micrograms/ml were found in some patients, there were no signs of CNS toxicity, most probably because of the increased protein binding of bupivacaine following trauma.",[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μg] / [ml],2,143909,DB00668,Epinephrine
below,2006723,maximum free plasma concentrations,"Accordingly, the maximum free plasma concentrations in all patients were below the threshold level of 0.24 micron/ml.",[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μn] / [ml],0.24,143910,DB00668,Epinephrine
,2378770,peak plasma concentrations,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),[μg] / [ml],2.57,146426,DB00668,Epinephrine
,2378770,peak plasma concentrations,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),[μg] / [ml],3.22,146427,DB00668,Epinephrine
,2378770,time to maximum concentration,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),min,25,146428,DB00668,Epinephrine
,2378770,time to maximum concentration,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),min,15,146429,DB00668,Epinephrine
,21318594,absolute bioavailability,"Following intranasal administration, peak plasma concentrations of dexmedetomidine were reached in 38 (15-60) min and its absolute bioavailability was 65% (35-93%) (medians and ranges).",Bioavailability of dexmedetomidine after intranasal administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21318594/),%,65,148902,DB00668,Epinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],178,149399,DB00668,Epinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],205,149400,DB00668,Epinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],193,149401,DB00668,Epinephrine
,3774414,MCR,"The results demonstrate that MCR of NE in term fetuses (178 +/- 28 ml X kg-1 min-1) is similar to preterm fetuses (205 +/- 22 ml X kg-1 min-1) as is MCR for E (193 +/- 28 versus 170 +/- 33 ml X kg-1 min-1, respectively).",Metabolic clearance and plasma appearance rates of catecholamines in preterm and term fetal sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3774414/),[ml] / [kg·min],170,149402,DB00668,Epinephrine
,2354553,steady state concentrations,2. In patients and volunteers steady state concentrations of free DA showing fairly large inter-individual variations (12.4-73.4 micrograms/L) were reached within 10 min of the beginning of the infusion.,Dopamine infusion in healthy subjects and critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[μg] / [l],12.4-73.4,150239,DB00668,Epinephrine
,2354553,steady state concentrations,In patients steady state concentrations of conjugated DA (63-80 micrograms/L) were reached within 5-10 h of DA infusion.,Dopamine infusion in healthy subjects and critically ill patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[μg] / [l],63-80,150240,DB00668,Epinephrine
,2354553,distribution volumes,The large distribution volumes of 19.8-75 L/kg indicate that DA has been taken up by peripheral tissues.,Dopamine infusion in healthy subjects and critically ill patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[l] / [kg],19.8-75,150241,DB00668,Epinephrine
,2354553,clearance,5. Substantial inter-individual variations in the patients' clearance of free DA (3.9-16.5 L/kg per h) may partly explain the variability in haemodynamic responses to DA infusion reported in clinical studies.,Dopamine infusion in healthy subjects and critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354553/),[l] / [h·kg],3.9-16.5,150242,DB00668,Epinephrine
,3780129,peak mean,"The peak mean (+/- SE) plasma epinephrine levels were 1.50 (+/- 0.61) and 4.22 (+/- 1.93) nmol/L 1 minute after each dose, respectively.",Systemic absorption of inhaled epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780129/),nm,1.50,150574,DB00668,Epinephrine
,3780129,peak mean,"The peak mean (+/- SE) plasma epinephrine levels were 1.50 (+/- 0.61) and 4.22 (+/- 1.93) nmol/L 1 minute after each dose, respectively.",Systemic absorption of inhaled epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780129/),nm,4.22,150575,DB00668,Epinephrine
,3780129,peak plasma epinephrine level,"This caused a peak plasma epinephrine level of 2.43 (+/- 0.47) nmol/L at 10 minutes, and this was still raised at 2.05 (+/- 0.41) nmol/L after 40 minutes.",Systemic absorption of inhaled epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780129/),[nM] / [l],2.43,150576,DB00668,Epinephrine
,3780129,peak plasma epinephrine level,"This caused a peak plasma epinephrine level of 2.43 (+/- 0.47) nmol/L at 10 minutes, and this was still raised at 2.05 (+/- 0.41) nmol/L after 40 minutes.",Systemic absorption of inhaled epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3780129/),[nM] / [l],2.05,150577,DB00668,Epinephrine
,15096108,peak concentration,"Rapid uptake of lidocaine produced a peak concentration of 1.45 +/- 0.36 microg/mL (mean +/- SD, range 0.80-1.86 microg/mL) by 0.37 +/- 0.26 h (range 0.11-0.81) after administration.",Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096108/),[μg] / [ml],1.45,151705,DB00668,Epinephrine
,15096108,absorption half-life,The absorption half-life was 0.13 +/- 0.1 h.,Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096108/),h,0.13,151706,DB00668,Epinephrine
,15096108,elimination half-life,Plasma concentrations decreased rapidly and the elimination half-life was 1.17 +/- 0.11 h.,Pharmacokinetics of combined intraperitoneal and incisional lidocaine in the dog following ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096108/),h,1.17,151707,DB00668,Epinephrine
,26615448,absorption half-live,Inhaled epinephrine was available almost immediately and more rapidly than via the intramuscular route (absorption half-live 29 min).,Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26615448/),min,29,156201,DB00668,Epinephrine
,26615448,elimination half-life,Epinephrine plasma concentrations declined rapidly after terminating inhalation (elimination half-life 4.1 min) offering the option to stop exposure in case of adverse events.,Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26615448/),min,4.1,156202,DB00668,Epinephrine
,26615448,Bioavailability,Bioavailability after inhalation (4.7%) was subject to high interindividual and interoccasional variability highlighting that training of inhalation would be essential for patients.,Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26615448/),%,4.7,156203,DB00668,Epinephrine
,27442605,V,"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),l,63.4,159028,DB00668,Epinephrine
,27442605,maximum rate [Vm],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [h],9.57,159029,DB00668,Epinephrine
,27442605,Michaelis constant [Km],"Final parameter estimates were V, 63.4 L, maximum rate [Vm], 9.57 mg h-1, Michaelis constant [Km], 1.97 mg L-1.",Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),[mg] / [l],1.97,159030,DB00668,Epinephrine
,27442605,elimination half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,20,159031,DB00668,Epinephrine
,27442605,half-life,Predicted elimination half-life decreased from 20 h over time until there was first order elimination with a half-life 9 h.,Zero-order metoprolol pharmacokinetics after therapeutic doses: severe toxicity and cardiogenic shock. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27442605/),h,9,159032,DB00668,Epinephrine
,24859764,IC50,"The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro.",Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859764/),μM,6.6,162152,DB00668,Epinephrine
,24859764,IC50,"The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro.",Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859764/),μM,37,162153,DB00668,Epinephrine
,24859764,IC50,"The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro.",Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859764/),μM,16,162154,DB00668,Epinephrine
,24859764,IC50,Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation.,Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859764/),μM,3.3,162155,DB00668,Epinephrine
,24859764,IC50,Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation.,Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24859764/),μM,2.7,162156,DB00668,Epinephrine
,32423275,Cmax,The Cmax occurred at ∼2 minutes and was significantly higher in the epinephrine HFA group (0.18 ng/mL) compared with the CFC version (0.046 ng/mL) at normal dose.,Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423275/),[ng] / [ml],0.18,162323,DB00668,Epinephrine
,32423275,Cmax,The Cmax occurred at ∼2 minutes and was significantly higher in the epinephrine HFA group (0.18 ng/mL) compared with the CFC version (0.046 ng/mL) at normal dose.,Pharmacokinetic Study of Epinephrine Hydrofluoroalkane (Primatene MIST) Metered-Dose Inhaler. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32423275/),[ng] / [ml],0.046,162324,DB00668,Epinephrine
,18370545,onset time,The mean onset time of surgical analgesia of both lidocaine and prilocaine was 10 minutes.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,10,167805,DB00668,Epinephrine
,18370545,elimination phase half-life (t((1/2)alpha)),Lidocaine was biexponentially eliminated with a rapid elimination phase half-life (t((1/2)alpha)) of 9.95 +/- 14.3 minutes and a terminal elimination phase half-life (t((1/2)beta)) of 2.86 +/- 1.55 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,9.95,167806,DB00668,Epinephrine
,18370545,terminal elimination phase half-life (t((1/2)beta)),Lidocaine was biexponentially eliminated with a rapid elimination phase half-life (t((1/2)alpha)) of 9.95 +/- 14.3 minutes and a terminal elimination phase half-life (t((1/2)beta)) of 2.86 +/- 1.55 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.86,167807,DB00668,Epinephrine
,18370545,time to reach maximum plasma concentration (tmax),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.3,167808,DB00668,Epinephrine
,18370545,maximum plasma concentration (C(max)),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[mg] / [l],0.32,167809,DB00668,Epinephrine
,18370545,t((1/2)beta),Lidocaine was metabolised to MEGX (monoethylglycylxylidide); time to reach maximum plasma concentration (tmax) 2.3 +/- 0.8 hours; maximum plasma concentration (C(max)) 0.32 +/- 0.13 mg/L; t((1/2)beta) 2.4 +/- 2.4 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.4,167810,DB00668,Epinephrine
,18370545,total body clearance,Lidocaine total body clearance was 67.8 +/- 28.8 L/h.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[l] / [h],67.8,167811,DB00668,Epinephrine
,18370545,t((1/2)alpha),Prilocaine was rapidly and biexponentially eliminated with a t((1/2)alpha) of 9.4 +/- 18.4 minutes and a t((1/2)beta) of 2.12 +/- 1.28 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),min,9.4,167812,DB00668,Epinephrine
,18370545,t((1/2)beta),Prilocaine was rapidly and biexponentially eliminated with a t((1/2)alpha) of 9.4 +/- 18.4 minutes and a t((1/2)beta) of 2.12 +/- 1.28 hours.,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),h,2.12,167813,DB00668,Epinephrine
,18370545,total body clearance,The total body clearance of prilocaine (150 +/- 53 L/h) was higher than that of lidocaine (p = 0.0255).,Comparison of the effects and disposition kinetics of lidocaine and (+/-)prilocaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370545/),[l] / [h],150,167814,DB00668,Epinephrine
,21871857,Peak arterial blood concentrations,"Peak arterial blood concentrations were achieved faster for sternal IO vs. tibial IO administration (53±11 s vs. 107±27 s, p=0.03).",Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871857/),s,53,170378,DB00668,Epinephrine
,21871857,Peak arterial blood concentrations,"Peak arterial blood concentrations were achieved faster for sternal IO vs. tibial IO administration (53±11 s vs. 107±27 s, p=0.03).",Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871857/),s,107,170379,DB00668,Epinephrine
,21871857,Time to peak blood concentration,"Time to peak blood concentration was similar for sternal IO and CV administration (97±17 s vs. 70±12 s, respectively; p=0.17) with total dose delivered of sternal being 86% of the dose delivered via CV (p=0.22).",Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871857/),s,97,170380,DB00668,Epinephrine
,21871857,Time to peak blood concentration,"Time to peak blood concentration was similar for sternal IO and CV administration (97±17 s vs. 70±12 s, respectively; p=0.17) with total dose delivered of sternal being 86% of the dose delivered via CV (p=0.22).",Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21871857/),s,70,170381,DB00668,Epinephrine
,8796829,clearance rate,"Fetal-placental cocaine clearance rate was independent of dose (337 +/- 39 mL/kg/minute), indicating that it is a first-order pharmacokinetic process.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[ml] / [kg·min],337,173366,DB00668,Epinephrine
,8796829,heart rate,"There were significant increases in fetal heart rate (from 169 +/- 11 to 242 +/- 36 beats per minute), mean blood pressure (from 53 +/- 4 to 63 +/- 5 mmHg), and systolic blood pressure (from 68 +/- 2 to 80 +/- 5 mmHg), with a corresponding increase in catecholamine levels seen in the fetuses infused with 0.2 mg/kg/minute.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[beats] / [min],169,173367,DB00668,Epinephrine
,8796829,heart rate,"There were significant increases in fetal heart rate (from 169 +/- 11 to 242 +/- 36 beats per minute), mean blood pressure (from 53 +/- 4 to 63 +/- 5 mmHg), and systolic blood pressure (from 68 +/- 2 to 80 +/- 5 mmHg), with a corresponding increase in catecholamine levels seen in the fetuses infused with 0.2 mg/kg/minute.",Ovine fetal-placental cocaine pharmacokinetics during continuous cocaine infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8796829/),[beats] / [min],242,173368,DB00668,Epinephrine
,1572184,plasma clearance rates,Dobutamine plasma clearance rates ranged from 40 to 130 mL/kg/min.,Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1572184/),[ml] / [kg·min],40 to 130,173638,DB00668,Epinephrine
,1493849,half life,"Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and 18 min, and the elimination half life ranged between 0.25 and 2.5 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),min,0.4 and 18,174457,DB00668,Epinephrine
,1493849,elimination half life,"Pharmacokinetic analysis showed that distribution was rapid, with a half life between 0.4 and 18 min, and the elimination half life ranged between 0.25 and 2.5 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),h,0.25 and 2.5,174458,DB00668,Epinephrine
,1493849,volume of distribution (Vss),"The volume of distribution (Vss) was 74 l, (range 26 to 127 l).",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),l,74,174459,DB00668,Epinephrine
,1493849,Total plasma clearance,"Total plasma clearance was 117 l.h-1, which exceeds the hepatic plasma flow.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),[l] / [h],117,174460,DB00668,Epinephrine
,1493849,half life,"The data also suggested the existence of a slower elimination phase, with a half life of 13 h.",Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1493849/),h,13,174461,DB00668,Epinephrine
,2378769,maximum arterial,"Mean maximum arterial and venous concentrations in eight of 11 patients were 1.90 (SD 0.36) and 1.65 (0.48) mg litre-1 and occurred at 22 (10) min and 25 (10) min, respectively.",Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),[mg] / [l],1.90,175133,DB00668,Epinephrine
,2378769,venous concentrations,"Mean maximum arterial and venous concentrations in eight of 11 patients were 1.90 (SD 0.36) and 1.65 (0.48) mg litre-1 and occurred at 22 (10) min and 25 (10) min, respectively.",Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),[mg] / [l],1.65,175134,DB00668,Epinephrine
,2378769,systemic venous plasma clearance,Mean systemic venous plasma clearance (0.15 (0.08) litre h-1 kg-1) was less and the mean elimination half-life (6.85 (2.29) h) and mean body residence time (9.99 (3.00) h) were longer than reported previously for interpleural bupivacaine--possibly because of continued slow absorption of the drug from its absorption site.,Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),[l] / [h·kg],0.15,175135,DB00668,Epinephrine
,2378769,elimination half-life,Mean systemic venous plasma clearance (0.15 (0.08) litre h-1 kg-1) was less and the mean elimination half-life (6.85 (2.29) h) and mean body residence time (9.99 (3.00) h) were longer than reported previously for interpleural bupivacaine--possibly because of continued slow absorption of the drug from its absorption site.,Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),h,6.85,175136,DB00668,Epinephrine
,2378769,body residence time,Mean systemic venous plasma clearance (0.15 (0.08) litre h-1 kg-1) was less and the mean elimination half-life (6.85 (2.29) h) and mean body residence time (9.99 (3.00) h) were longer than reported previously for interpleural bupivacaine--possibly because of continued slow absorption of the drug from its absorption site.,Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),h,9.99,175137,DB00668,Epinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,12.0,176883,DB00668,Epinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,10.7,176884,DB00668,Epinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,11.4,176885,DB00668,Epinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,16.2,176886,DB00668,Epinephrine
,8418710,contribution,"The calculated contribution values after CPB were 12.0, 10.7, 11.4, 16.2, and 16.7% at the doses of 3.0, 4.0, 5.0, 6.0, and 7.0 micrograms.",Quantitative analysis of pulmonary clearance of exogenous dopamine after cardiopulmonary bypass in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8418710/),%,16,176887,DB00668,Epinephrine
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1000,176980,DB00668,Epinephrine
,15735610,clearance,"Nicotine clearance was 1000 +/- 315 mL/min and 1047 +/- 271 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.06; 90% confidence interval, 0.87-1.29).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],1047,176981,DB00668,Epinephrine
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],44,176982,DB00668,Epinephrine
,15735610,clearance,"Cotinine clearance was 44 +/- 20 mL/min and 55 +/- 42 mL/min in the follicular and luteal phases, respectively (geometric mean ratio, 1.13; 90% confidence interval, 0.90-1.41).",Influence of menstrual cycle on cytochrome P450 2A6 activity and cardiovascular effects of nicotine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15735610/),[ml] / [min],55,176983,DB00668,Epinephrine
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],63,177505,DB00668,Epinephrine
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],108,177506,DB00668,Epinephrine
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],158,177507,DB00668,Epinephrine
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],146,177508,DB00668,Epinephrine
,23167288,Tabs,"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,0.15,177557,DB00668,Epinephrine
,23167288,Tabs(LATE),"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,2.34,177558,DB00668,Epinephrine
,23167288,volume of distribution,The population parameter estimate for volume of distribution was 157 l 70 kg(-1).,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·kg],157,177559,DB00668,Epinephrine
,23167288,Clearance,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],6.5,177560,DB00668,Epinephrine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),month,1.6,177561,DB00668,Epinephrine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],18.5,177562,DB00668,Epinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.111,179686,DB00668,Epinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.117,179687,DB00668,Epinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,24,179688,DB00668,Epinephrine
,9252564,pulmonary fractional extraction,"The pulmonary fractional extraction of norepinephrine was similar in 1-h (0.111 +/- 0.021) and 4-h (0.117 +/- 0.023) lambs and constituted 24 +/- 5 and 32 +/- 9% of total body norepinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,32,179689,DB00668,Epinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.035,179690,DB00668,Epinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,0.036,179691,DB00668,Epinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,8,179692,DB00668,Epinephrine
,9252564,fractional extraction,"Pulmonary removal of epinephrine was less pronounced with a fractional extraction of 0.035 +/- 0.017 in 1-h and 0.036 +/- 0.013 in 4-h lambs, which corresponded to 8 +/- 4 and 9 +/- 3% of total body epinephrine clearance, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,9,179693,DB00668,Epinephrine
,9252564,Pulmonary spillover,"Pulmonary spillover of norepinephrine into the circulation was similar in 1-h (79 +/- 26 ng.min-1.kg-1) and 4-h (82 +/- 18 ng.min-1.kg-1) lambs, and this comprised 27 +/- 8 and 42 +/- 8% of total body norepinephrine spillover, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),[ng] / [kg·min],79,179694,DB00668,Epinephrine
,9252564,Pulmonary spillover,"Pulmonary spillover of norepinephrine into the circulation was similar in 1-h (79 +/- 26 ng.min-1.kg-1) and 4-h (82 +/- 18 ng.min-1.kg-1) lambs, and this comprised 27 +/- 8 and 42 +/- 8% of total body norepinephrine spillover, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),[ng] / [kg·min],82,179695,DB00668,Epinephrine
,9252564,Pulmonary spillover,"Pulmonary spillover of norepinephrine into the circulation was similar in 1-h (79 +/- 26 ng.min-1.kg-1) and 4-h (82 +/- 18 ng.min-1.kg-1) lambs, and this comprised 27 +/- 8 and 42 +/- 8% of total body norepinephrine spillover, respectively.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),,27,179696,DB00668,Epinephrine
,9252564,spillover,"Pulmonary epinephrine spillover was not detectable at 1 h, but it occurred in all 4-h lambs, averaging 4.7 +/- 0.8 ng.min-1.kg-1 or 20 +/- 6% of epinephrine total body spillover.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),[ng] / [kg·min],4.7,179697,DB00668,Epinephrine
,9252564,spillover,"Pulmonary epinephrine spillover was not detectable at 1 h, but it occurred in all 4-h lambs, averaging 4.7 +/- 0.8 ng.min-1.kg-1 or 20 +/- 6% of epinephrine total body spillover.",Pulmonary clearance and release of norepinephrine and epinephrine in newborn lambs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9252564/),%,20,179698,DB00668,Epinephrine
,17503047,Area Under the Curve (AUC),"The best predictive parameter for renal failure was the total Pt 24-h Area Under the Curve (AUC) with a threshold value of 25 mg h/l RR = 0.31 (95% CI 0.13 - 0.49, P < 0.01).",Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17503047/),,25,179800,DB00668,Epinephrine
,32302068,plasma epinephrine concentration,"IN epinephrine (5 mg) demonstrated significantly greater plasma epinephrine concentration at 1 minute as compared with IM epinephrine (0.3 mg) (1.68 ± 0.65 ng/mL vs 0.21 ± 0.08 ng/mL, P = .03).",Intranasal epinephrine in dogs: Pharmacokinetic and heart rate effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32302068/),[ng] / [ml],1.68,180677,DB00668,Epinephrine
,32302068,plasma epinephrine concentration,"IN epinephrine (5 mg) demonstrated significantly greater plasma epinephrine concentration at 1 minute as compared with IM epinephrine (0.3 mg) (1.68 ± 0.65 ng/mL vs 0.21 ± 0.08 ng/mL, P = .03).",Intranasal epinephrine in dogs: Pharmacokinetic and heart rate effects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32302068/),[ng] / [ml],0.21,180678,DB00668,Epinephrine
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],0.3 to 97.3,181080,DB00668,Epinephrine
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],6.7,181081,DB00668,Epinephrine
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],402.8,181082,DB00668,Epinephrine
,8541435,total dose,Over a period of 69.2 +/- 39.8 min during resection of the tumor the total dose was 7017 +/- 12433 micrograms.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),μg,7017,181083,DB00668,Epinephrine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,8.6,183621,DB00668,Epinephrine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,13.0,183622,DB00668,Epinephrine
,6589939,duration of analgesia,"The mean duration of analgesia after E.D. administration was dose-related (8.6 +/- 2.0 h, 13.0 +/- 3.5 h, and 15.6 +/- 2.6 h; means +/- SEM for the 2, 4 and 6 mg groups, respectively), which was comparable to that achieved after I.T. administration of 0.25 to 0.50 mg M. M. concentrations in plasma after E.D. administration were comparable in variability and magnitude to those found after I.M. administration.",Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),h,15.6,183623,DB00668,Epinephrine
,6589939,CSF/plasma concentration ratio,This is to be compared with a CSF/plasma concentration ratio around 100 after E.D. administration.,Pharmacokinetic aspects of spinal morphine analgesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6589939/),,100,183624,DB00668,Epinephrine
,18582256,maximum diltiazem concentration,The maximum diltiazem concentration (577 microg.l(-1)) was recorded 7 h post ingestion which was followed by an erratic and prolonged elimination phase.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),[μg] / [l],577,184005,DB00668,Epinephrine
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,19.4,184006,DB00668,Epinephrine
,18582256,maximum clearance,The maximum clearance of diltiazem due to haemoperfusion was calculated to be 19.4 and 15.1 ml.,Lessons learnt in the pharmacokinetic analysis of the effect of haemoperfusion for acute overdose with sustained-release diltiazem. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18582256/),ml,15.1,184007,DB00668,Epinephrine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],8.0,185266,DB00668,Epinephrine
,2357862,peak plasma caffeine concentration,"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),[μg] / [ml],2.1,185267,DB00668,Epinephrine
,2357862,t[24],"In subjects receiving 400 mg caffeine plus 75 mg phenylpropanolamine, the mean (+/- SEM) peak plasma caffeine concentration of 8.0 +/- 2.2 micrograms/ml was significantly greater than after 400 mg caffeine alone (2.1 +/- 0.3 micrograms/ml; t[24] = 2.4; p less than 0.01).",Phenylpropanolamine increases plasma caffeine levels. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2357862/),,2.4,185268,DB00668,Epinephrine
,3942298,area under the concentration time curve,The calculated area under the concentration time curve in preeclamptic patients (18.5 +/- 4.7 micrograms X hr X ml-1) was significantly greater than in normotensive mothers (14.1 +/- 1.3 micrograms X hr X ml-1) (P less than 0.02).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[h·μg] / [ml],18.5,185516,DB00668,Epinephrine
,3942298,area under the concentration time curve,The calculated area under the concentration time curve in preeclamptic patients (18.5 +/- 4.7 micrograms X hr X ml-1) was significantly greater than in normotensive mothers (14.1 +/- 1.3 micrograms X hr X ml-1) (P less than 0.02).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[h·μg] / [ml],14.1,185517,DB00668,Epinephrine
,3942298,Total maternal body clearance,Total maternal body clearance in preeclamptic patients (24.5 +/- 7.1 L/hr) was significantly lower than in normotensives (31.1 +/- 4.4 L/hr) (P less than 0.05).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[l] / [h],24.5,185518,DB00668,Epinephrine
,3942298,Total maternal body clearance,Total maternal body clearance in preeclamptic patients (24.5 +/- 7.1 L/hr) was significantly lower than in normotensives (31.1 +/- 4.4 L/hr) (P less than 0.05).,The pharmacokinetics and maternal and neonatal effects of epidural lidocaine in preeclampsia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3942298/),[l] / [h],31.1,185519,DB00668,Epinephrine
,15096431,peak concentration (C(max)),The mean +/- SD peak concentration (C(max)) was 0.71 +/- 0.33 micro g/mL and the half-life was 0.96 hours.,Effect of perioperative administration of ropivacaine with epinephrine on postoperative pediatric adenotonsillectomy recovery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096431/),[μg] / [ml],0.71,186035,DB00668,Epinephrine
,15096431,half-life,The mean +/- SD peak concentration (C(max)) was 0.71 +/- 0.33 micro g/mL and the half-life was 0.96 hours.,Effect of perioperative administration of ropivacaine with epinephrine on postoperative pediatric adenotonsillectomy recovery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15096431/),h,0.96,186036,DB00668,Epinephrine
,15861085,time to reach peak lidocaine concentration,"The average time to reach peak lidocaine concentration after neck injection was 5.8 hours, whereas peak lidocaine concentration after thigh injection did not occur until 12.0 hours.",Rapid absorption of tumescent lidocaine above the clavicles: a prospective clinical study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15861085/),h,5.8,187607,DB00668,Epinephrine
,15861085,peak concentration,"The average peak concentration after neck injection was 16 percent greater than that after thigh injection (0.94 microg/ml versus 0.81 microg/ml), with the difference approaching significance (p = 0.06).",Rapid absorption of tumescent lidocaine above the clavicles: a prospective clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15861085/),[μg] / [ml],0.94,187608,DB00668,Epinephrine
,15861085,peak concentration,"The average peak concentration after neck injection was 16 percent greater than that after thigh injection (0.94 microg/ml versus 0.81 microg/ml), with the difference approaching significance (p = 0.06).",Rapid absorption of tumescent lidocaine above the clavicles: a prospective clinical study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15861085/),[μg] / [ml],0.81,187609,DB00668,Epinephrine
,9331518,relative bioavailability,The relative bioavailability of selegiline was slightly reduced (by 29%; p = 0.008) when citalopram was coadministered compared with selegiline alone.,Lack of adverse interactions between concomitantly administered selegiline and citalopram. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331518/),,29,188189,DB00668,Epinephrine
,23292159,area under the curve AUC0-t(last),"Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L).",Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23292159/),[h·ng] / [l],282,189151,DB00668,Epinephrine
,23292159,area under the curve AUC0-t(last),"Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L).",Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23292159/),[h·ng] / [l],236,189152,DB00668,Epinephrine
,23292159,area under the curve AUC0-t(last),"Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L).",Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23292159/),[h·ng] / [l],204,189153,DB00668,Epinephrine
,23292159,area under the curve AUC0-t(last),"Mean exposure to epinephrine decreased from the 8 mg dose to the 4 mg inhalative dose, and further with the 0.3 mg intramuscular dose, with active treatments showing significantly higher concentrations than placebo (geometric mean area under the curve AUC0-t(last) values: 282, 236, 204 and 81.6 hr*ng/L).",Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23292159/),[h·ng] / [l],81.6,189154,DB00668,Epinephrine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,21.5,189217,DB00668,Epinephrine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,12.2,189218,DB00668,Epinephrine
,27669443,Peak [CAF],"Peak [CAF] was greater in TETRA (21.5 μM) compared with AB (12.2 μM) and PARA (15.1 μM), and mean peak [CAF] occurred at 70, 80, and 80 min, respectively.",Spinal Cord Injury Level Influences Acute Plasma Caffeine Responses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669443/),μM,15.1,189219,DB00668,Epinephrine
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.19-1.22,190047,DB00668,Epinephrine
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.39-1.63,190048,DB00668,Epinephrine
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.28-0.60,190049,DB00668,Epinephrine
,31425209,peak plasma concentration,"The peak plasma concentration for S (-) ketorolac was found to be lower than that of R (+) ketorolac, for both THA (0.19-1.22 mg/L vs 0.39-1.63 mg/L, respectively) and TKA (0.28-0.60 mg/L vs 0.48-0.88 mg/L, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[mg] / [l],0.48-0.88,190050,DB00668,Epinephrine
,31425209,clearance,"The clearance of the S (-) ketorolac enantiomer was higher than R (+) ketorolac (4.50 ± 2.27 vs 1.40 ± 0.694 L/h, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[l] / [h],4.50,190051,DB00668,Epinephrine
,31425209,clearance,"The clearance of the S (-) ketorolac enantiomer was higher than R (+) ketorolac (4.50 ± 2.27 vs 1.40 ± 0.694 L/h, respectively).",Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425209/),[l] / [h],1.40,190052,DB00668,Epinephrine
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,8.8,190327,DB00668,Epinephrine
,7678675,pulmonary extractions,"Statistically significant pulmonary extractions were observed for NA (8.8%) and DA (24.0%), but not for A and ISO.",Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,24.0,190328,DB00668,Epinephrine
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,63,190329,DB00668,Epinephrine
,7678675,systemic extraction,The systemic extraction was lowest for ISO (63%) and highest for DA (75%).,Plasma clearances and extractions of four catecholamines in the anesthetized rabbit: the role of amine removal by blood cells. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7678675/),%,75,190330,DB00668,Epinephrine
,17082283,peak concentrations,"Plasma concentration curves of articaine over time were similar for both solutions, with peak concentrations and times to maximum concentration being 2,037 nanograms per milliliter and 22 minutes for A100 and 2,145 ng/mL and 22 minutes for A200.","The pharmacokinetics and cardiovascular effects of high-dose articaine with 1:100,000 and 1:200,000 epinephrine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17082283/),[nanograms] / [milliliter],"2,037",192388,DB00668,Epinephrine
,17082283,peak concentrations,"Plasma concentration curves of articaine over time were similar for both solutions, with peak concentrations and times to maximum concentration being 2,037 nanograms per milliliter and 22 minutes for A100 and 2,145 ng/mL and 22 minutes for A200.","The pharmacokinetics and cardiovascular effects of high-dose articaine with 1:100,000 and 1:200,000 epinephrine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17082283/),[ng] / [ml],"2,145",192389,DB00668,Epinephrine
,17082283,times to maximum concentration,"Plasma concentration curves of articaine over time were similar for both solutions, with peak concentrations and times to maximum concentration being 2,037 nanograms per milliliter and 22 minutes for A100 and 2,145 ng/mL and 22 minutes for A200.","The pharmacokinetics and cardiovascular effects of high-dose articaine with 1:100,000 and 1:200,000 epinephrine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17082283/),min,22,192390,DB00668,Epinephrine
,29369957,peak ropivacaine concentration,"The median peak ropivacaine concentration was 0.57 μg/mL, with a range of 0.32 to 0.88 μg/mL, and occurred between 6 and 24 hours.",Plasma Ropivacaine Concentrations Following Local Infiltration Analgesia in Total Knee Arthroplasty: A Pharmacokinetic Study to Determine Safety Following Fixed-Dose Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29369957/),[μg] / [ml],0.57,198879,DB00668,Epinephrine
below,29369957,peak total ropivacaine concentration,The peak total ropivacaine concentration was below quoted toxic concentrations (2.2 μg/mL) in all patients.,Plasma Ropivacaine Concentrations Following Local Infiltration Analgesia in Total Knee Arthroplasty: A Pharmacokinetic Study to Determine Safety Following Fixed-Dose Administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29369957/),[μg] / [ml],2.2,198880,DB00668,Epinephrine
,8843047,Peak plasma concentration,Peak plasma concentration was 1.83 +/- 0.17 mg/l.,Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),[mg] / [l],1.83,203216,DB00668,Epinephrine
,8843047,time taken to reach the maximum concentration,"Pharmacokinetic parameters determined from an independent compartment model were not different from those observed after an epidural administration of lidocaine via the sacrococcygeal space in children, except for a wide variability in the time taken to reach the maximum concentration (27.3 +/- 7.4 min) and a shorter half-life of elimination (82.8 +/- 7.0 min).",Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),min,27.3,203217,DB00668,Epinephrine
,8843047,half-life of elimination,"Pharmacokinetic parameters determined from an independent compartment model were not different from those observed after an epidural administration of lidocaine via the sacrococcygeal space in children, except for a wide variability in the time taken to reach the maximum concentration (27.3 +/- 7.4 min) and a shorter half-life of elimination (82.8 +/- 7.0 min).",Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),min,82.8,203218,DB00668,Epinephrine
,8843047,total body clearance,The total body clearance of lidocaine was similar in piglets (17.3 +/- 1.6 ml/min/kg) to that in children.,Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),[ml] / [kg·min],17.3,203219,DB00668,Epinephrine
,8843047,volume of distribution,The shorter half-life of elimination was therefore attributed to a smaller volume of distribution in piglets (2.0 +/- 0.2 l/kg).,Pharmacokinetics of lidocaine with epinephrine in piglets following epidural anaesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8843047/),[l] / [kg],2.0,203220,DB00668,Epinephrine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],36.5,204004,DB00668,Epinephrine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],73.8,204005,DB00668,Epinephrine
,6723754,steady state levels,"Dopamine reached a steady state level within 15 to 30 min after commencement of the infusion; the steady state levels averaged 36.5 micrograms/l at 200 micrograms/min, 73.8 micrograms/l at 400 micrograms/min and 207 micrograms/l at 800 micrograms/min.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),[μg] / [l],207,204006,DB00668,Epinephrine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],5.81,204007,DB00668,Epinephrine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],5.51,204008,DB00668,Epinephrine
,6723754,total clearances,"The corresponding total clearances were 5.81/ min, 5.51/min and 3.91/min suggesting non-linear kinetics.",Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723754/),1/[min],3.91,204009,DB00668,Epinephrine
,2441162,terminal half-life (t1/2),The pharmacokinetics of S-9780 fitted a three-compartment model with a terminal half-life (t1/2) of 31 h.,"Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2441162/),h,31,204335,DB00668,Epinephrine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],526,204683,DB00668,Epinephrine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],376,204684,DB00668,Epinephrine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],70,204685,DB00668,Epinephrine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],56,204686,DB00668,Epinephrine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],3.8,205627,DB00668,Epinephrine
,10454044,Cmax,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[μg] / [ml],2.5,205628,DB00668,Epinephrine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,3.3,205629,DB00668,Epinephrine
,10454044,distribution half-lives,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,5.9,205630,DB00668,Epinephrine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],1.5,205631,DB00668,Epinephrine
,10454044,central compartment volumes of distribution,"Bolus dose cocaine administration, simultaneously with catecholamine infusion, resulted in significantly higher Cmax levels for cocaine (3.8 compared with 2.5 microg mL(-1)) and lower distribution half-lives (3.3 compared with 5.9 min) and central compartment volumes of distribution (1.5 compared with 2.1 L kg(-1)) compared with saline infusion.",Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[l] / [kg],2.1,205632,DB00668,Epinephrine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,26.3,205633,DB00668,Epinephrine
,10454044,elimination half-lives,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),min,25.0,205634,DB00668,Epinephrine
,10454044,systemic clearances,Benzoylecgonine formation was significantly reduced in rats receiving catecholamines whereas the elimination half-lives (26.3 compared with 25.0 min) and systemic clearances (146 compared with 146 mL kg(-1) min(-1)) were not different.,Influence of infused catecholamines on the pharmacokinetics of cocaine and benzoylecgonine formation after bolus dose or continuous cocaine administration in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454044/),[ml] / [kg·min],146,205635,DB00668,Epinephrine
,28902942,peak of plasma concentrations,The peak of plasma concentrations appeared difference (Group LG: 1.39 ± 0.23 mg/L; Group LS: 1.47 ± 0.29 mg/L and Group LE: 0.99 ± 0.08 mg/L).,A study on reducing the absorption of lidocaine from the airway in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902942/),[mg] / [l],1.39,206195,DB00668,Epinephrine
,28902942,peak of plasma concentrations,The peak of plasma concentrations appeared difference (Group LG: 1.39 ± 0.23 mg/L; Group LS: 1.47 ± 0.29 mg/L and Group LE: 0.99 ± 0.08 mg/L).,A study on reducing the absorption of lidocaine from the airway in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902942/),[mg] / [l],1.47,206196,DB00668,Epinephrine
,28902942,peak of plasma concentrations,The peak of plasma concentrations appeared difference (Group LG: 1.39 ± 0.23 mg/L; Group LS: 1.47 ± 0.29 mg/L and Group LE: 0.99 ± 0.08 mg/L).,A study on reducing the absorption of lidocaine from the airway in cats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28902942/),[mg] / [l],0.99,206197,DB00668,Epinephrine
,23038415,maximum arterial levobupivacaine concentrations,"The mean maximum arterial levobupivacaine concentrations with epinephrine were 0.36 (95% bootstrap confidence interval [95% CI], 0.30-0.42) μg/mL and 0.63 (95% CI, 0.49-0.85) μg/mL without epinephrine (P = 0.014, difference in means of 0.27 [95% CI, 0.12-0.46]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.36,206873,DB00668,Epinephrine
,23038415,maximum arterial levobupivacaine concentrations,"The mean maximum arterial levobupivacaine concentrations with epinephrine were 0.36 (95% bootstrap confidence interval [95% CI], 0.30-0.42) μg/mL and 0.63 (95% CI, 0.49-0.85) μg/mL without epinephrine (P = 0.014, difference in means of 0.27 [95% CI, 0.12-0.46]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.63,206874,DB00668,Epinephrine
,23038415,maximal venous levobupivacaine concentration,"The mean maximal venous levobupivacaine concentration was 0.32 (95% CI, 0.28-0.39) μg/mL and 0.49 (95% CI, 0.37-0.68) μg/mL, with and without epinephrine, respectively (P = 0.006, difference in means of 0.17 [95% CI, 0.08-0.33]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.32,206875,DB00668,Epinephrine
,23038415,maximal venous levobupivacaine concentration,"The mean maximal venous levobupivacaine concentration was 0.32 (95% CI, 0.28-0.39) μg/mL and 0.49 (95% CI, 0.37-0.68) μg/mL, with and without epinephrine, respectively (P = 0.006, difference in means of 0.17 [95% CI, 0.08-0.33]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.49,206876,DB00668,Epinephrine
,23038415,duration of the blockade,"The mean duration of the blockade was 10.2 hours (95% CI, 8.5-12.5 hours) with epinephrine and 10.3 hours (95% CI, 8.7-12.4 hours) without epinephrine (P = 1.000).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),h,10.2,206877,DB00668,Epinephrine
,23038415,duration of the blockade,"The mean duration of the blockade was 10.2 hours (95% CI, 8.5-12.5 hours) with epinephrine and 10.3 hours (95% CI, 8.7-12.4 hours) without epinephrine (P = 1.000).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),h,10.3,206878,DB00668,Epinephrine
,9259064,PaO2,"higher volumes of diluent (5 and 10 ml) caused a significant decrease of PaO2, from 147 +/- 8 to 106 +/- 10 torr, compared with the lower volumes of diluent (1 and 2 ml), from 136 +/- 10 to 135 +/- 7 torr (P < 0.05).",Epinephrine pharmacokinetics and pharmacodynamics following endotracheal administration in dogs: the role of volume of diluent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9259064/),torr,147,207839,DB00668,Epinephrine
,9259064,PaO2,"higher volumes of diluent (5 and 10 ml) caused a significant decrease of PaO2, from 147 +/- 8 to 106 +/- 10 torr, compared with the lower volumes of diluent (1 and 2 ml), from 136 +/- 10 to 135 +/- 7 torr (P < 0.05).",Epinephrine pharmacokinetics and pharmacodynamics following endotracheal administration in dogs: the role of volume of diluent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9259064/),torr,106,207840,DB00668,Epinephrine
,9259064,PaO2,"higher volumes of diluent (5 and 10 ml) caused a significant decrease of PaO2, from 147 +/- 8 to 106 +/- 10 torr, compared with the lower volumes of diluent (1 and 2 ml), from 136 +/- 10 to 135 +/- 7 torr (P < 0.05).",Epinephrine pharmacokinetics and pharmacodynamics following endotracheal administration in dogs: the role of volume of diluent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9259064/),torr,136,207841,DB00668,Epinephrine
,9259064,PaO2,"higher volumes of diluent (5 and 10 ml) caused a significant decrease of PaO2, from 147 +/- 8 to 106 +/- 10 torr, compared with the lower volumes of diluent (1 and 2 ml), from 136 +/- 10 to 135 +/- 7 torr (P < 0.05).",Epinephrine pharmacokinetics and pharmacodynamics following endotracheal administration in dogs: the role of volume of diluent. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9259064/),torr,135,207842,DB00668,Epinephrine
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,5.0,208111,DB00668,Epinephrine
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,3.1,208112,DB00668,Epinephrine
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],345,208113,DB00668,Epinephrine
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],248,208114,DB00668,Epinephrine
,23013208,Total Cmax,"Total Cmax was 2.81 (0.94) μg ml(-1) vs. 2.16 (0.21) μg ml(-1) (95% CI -0.23, 1.53).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[μg] / [ml],2.81,208299,DB00668,Epinephrine
,23013208,Total Cmax,"Total Cmax was 2.81 (0.94) μg ml(-1) vs. 2.16 (0.21) μg ml(-1) (95% CI -0.23, 1.53).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[μg] / [ml],2.16,208300,DB00668,Epinephrine
,23013208,tmax,"tmax was 1.17 (0.30) h vs. 1.67 (0.94) h (95% CI -1.40, 0.40).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),h,1.17,208301,DB00668,Epinephrine
,23013208,tmax,"tmax was 1.17 (0.30) h vs. 1.67 (0.94) h (95% CI -1.40, 0.40).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),h,1.67,208302,DB00668,Epinephrine
,23013208,concentration,"The highest free ropivacaine concentration per patient was 0.16 (0.08) μg ml(-1) vs. 0.12 (0.04) μg ml(-1) (95% CI -0.04, 0.12).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[μg] / [ml],0.16,208303,DB00668,Epinephrine
,23013208,concentration,"The highest free ropivacaine concentration per patient was 0.16 (0.08) μg ml(-1) vs. 0.12 (0.04) μg ml(-1) (95% CI -0.04, 0.12).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[μg] / [ml],0.12,208304,DB00668,Epinephrine
,23013208,t(1/2),"t(1/2) was 6.82 (2.26) h vs. 5.48 (1.69) h (95% CI -1.23, 3.91).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),h,6.82,208305,DB00668,Epinephrine
,23013208,t(1/2),"t(1/2) was 6.82 (2.26) h vs. 5.48 (1.69) h (95% CI -1.23, 3.91).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),h,5.48,208306,DB00668,Epinephrine
,23013208,AUC,"AUC was 28.35 (5.92) μg ml(-1) h vs. 29.12 (7.34) μg ml(-1) h (95% CI -9.35, 7.81).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[h·μg] / [ml],28.35,208307,DB00668,Epinephrine
,23013208,AUC,"AUC was 28.35 (5.92) μg ml(-1) h vs. 29.12 (7.34) μg ml(-1) h (95% CI -9.35, 7.81).",Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[h·μg] / [ml],29.12,208308,DB00668,Epinephrine
,23013208,Free serum concentrations,Free serum concentrations of ropivacaine with and without epinephrine remained well below the assumed threshold of 0.56 μg ml(-1) for systemic toxicity.,Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23013208/),[μg] / [ml],0.56,208309,DB00668,Epinephrine
,16021436,t(1/2)alpha,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,13.5,211876,DB00668,Epinephrine
,16021436,t(1/2)beta,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,192.5,211877,DB00668,Epinephrine
,16021436,t(1/2)gamma,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,620,211878,DB00668,Epinephrine
,16021436,AUC(0-infinity),"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[min·ng] / [milliliter],137.404,211879,DB00668,Epinephrine
,16021436,C(l)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [min],464.984,211880,DB00668,Epinephrine
,16021436,V(d)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),l,299.974,211881,DB00668,Epinephrine
,16021436,C(l)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [kg·min],6.875,211882,DB00668,Epinephrine
,16021436,V(d)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[l] / [kg],4.441,211883,DB00668,Epinephrine
,16021436,latency,"The latency between drug administration and birth was 28.5 min, with a maternal and fetal plasma concentration of 0.310 and 0.245 ng/ml, respectively, at a median fetal/maternal ratio of 0.892.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,28.5,211884,DB00668,Epinephrine
,10599952,onset time of sensory block,The mean onset time of sensory block of the median nerve of both lidocaine and articaine were approximately 10 min.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),min,10,212028,DB00668,Epinephrine
,10599952,t1/2alpha,Lidocaine is biexponentially eliminated with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),min,9.95,212029,DB00668,Epinephrine
,10599952,t1/2beta,Lidocaine is biexponentially eliminated with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,2.86,212030,DB00668,Epinephrine
,10599952,t(max),Lidocaine is metabolized into MEGX (mono-ethyl-glycyl-xilidide) (t(max) 2.31 +/- 0.84 h; C(max) 0.32 +/- 0.13 mg/l; t1/2beta 2.36 +/- 2.35 h).,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,2.31,212031,DB00668,Epinephrine
,10599952,C(max),Lidocaine is metabolized into MEGX (mono-ethyl-glycyl-xilidide) (t(max) 2.31 +/- 0.84 h; C(max) 0.32 +/- 0.13 mg/l; t1/2beta 2.36 +/- 2.35 h).,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[mg] / [l],0.32,212032,DB00668,Epinephrine
,10599952,t1/2beta,Lidocaine is metabolized into MEGX (mono-ethyl-glycyl-xilidide) (t(max) 2.31 +/- 0.84 h; C(max) 0.32 +/- 0.13 mg/l; t1/2beta 2.36 +/- 2.35 h).,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,2.36,212033,DB00668,Epinephrine
,10599952,total body clearance,Lidocaine total body clearance was 67.9 +/- 28.9 l/h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[l] / [h],67.9,212034,DB00668,Epinephrine
,10599952,t1/2beta,Articaine is rapidly and monoexponentially eliminated with a t1/2beta of 0.95 +/- 0.39 h.,Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),h,0.95,212035,DB00668,Epinephrine
,10599952,total body clearance,"The total body clearance of articaine is higher than that of lidocaine, 1,133 +/- 582 l/h vs 67.9 +/- 28.9 l/h, respectively (p < 0.0001).",Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[l] / [h],"1,133",212036,DB00668,Epinephrine
,10599952,total body clearance,"The total body clearance of articaine is higher than that of lidocaine, 1,133 +/- 582 l/h vs 67.9 +/- 28.9 l/h, respectively (p < 0.0001).",Similar motor block effects with different disposition kinetics between lidocaine and (+ or -) articaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10599952/),[l] / [h],67.9,212037,DB00668,Epinephrine
,7650234,Cmax,The drug was quickly absorbed into the plasma in the control group (Cmax = 2.76 +/- 0.10 microgram/mL at 0.33 +/- 0.14 hours after administration); whereas drug access to CSF was decreased and occurred slowly (Cmax = 0.32 +/- 0.07 microgram/mL at 1.66 +/- 1.35 hours).,The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),[μg] / [ml],2.76,214079,DB00668,Epinephrine
,7650234,Cmax,The drug was quickly absorbed into the plasma in the control group (Cmax = 2.76 +/- 0.10 microgram/mL at 0.33 +/- 0.14 hours after administration); whereas drug access to CSF was decreased and occurred slowly (Cmax = 0.32 +/- 0.07 microgram/mL at 1.66 +/- 1.35 hours).,The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),[μg] / [ml],0.32,214080,DB00668,Epinephrine
,7650234,half-lives,"The drug was eliminated more quickly from plasma than from CSF, with half-lives of 1.71 +/- 0.43 hours and 3.86 +/- 1.27 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,1.71,214081,DB00668,Epinephrine
,7650234,half-lives,"The drug was eliminated more quickly from plasma than from CSF, with half-lives of 1.71 +/- 0.43 hours and 3.86 +/- 1.27 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,3.86,214082,DB00668,Epinephrine
,7650234,tmax,The simultaneous administration of adrenalin delayed absorption (tmax = 0.91 +/- 0.52 hours).,The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,0.91,214083,DB00668,Epinephrine
,7650234,elimination half-lives,"The drug elimination half-lives in plasma and CSF of this group increased to 3.22 +/- 1.22 hours and 8.71 +/- 3.28 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,3.22,214084,DB00668,Epinephrine
,7650234,elimination half-lives,"The drug elimination half-lives in plasma and CSF of this group increased to 3.22 +/- 1.22 hours and 8.71 +/- 3.28 hours, respectively.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,8.71,214085,DB00668,Epinephrine
,7650234,duration,"The duration of the analgesia, evaluated as the time until the patient needed another dose, increased from 8.2 +/- 1.5 hours in the control group to 9.7 +/- 1.3 hours in the group that received adrenalin.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,8.2,214086,DB00668,Epinephrine
,7650234,duration,"The duration of the analgesia, evaluated as the time until the patient needed another dose, increased from 8.2 +/- 1.5 hours in the control group to 9.7 +/- 1.3 hours in the group that received adrenalin.",The influence of adrenalin on the pharmacokinetics of interpleurally administered lidocaine in patients with pancreatic neoplasia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650234/),h,9.7,214087,DB00668,Epinephrine
,9052295,elimination half-life,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,113.9,214660,DB00668,Epinephrine
,9052295,elimination half-life,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,110.4,214661,DB00668,Epinephrine
,9052295,plasma clearance,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[ml] / [kg·min],6.1,214662,DB00668,Epinephrine
,9052295,plasma clearance,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[ml] / [kg·min],13.6,214663,DB00668,Epinephrine
,9052295,volume of distribution,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[l] / [kg],0.98,214664,DB00668,Epinephrine
,9052295,volume of distribution,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[l] / [kg],1.67,214665,DB00668,Epinephrine
,9052295,time to peak concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,31,214666,DB00668,Epinephrine
,9052295,time to peak concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,40.5,214667,DB00668,Epinephrine
,9052295,peak Ma concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[μg] / [ml],6.4,214668,DB00668,Epinephrine
,9052295,peak Ma concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[μg] / [ml],0.8,214669,DB00668,Epinephrine
,9425973,Arterial plasma me,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",8.0,214759,DB00668,Epinephrine
,9425973,Arterial plasma me,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",5.8,214760,DB00668,Epinephrine
,9425973,concentrations,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",8.0,214761,DB00668,Epinephrine
,9425973,concentrations,"Arterial plasma mepivacaine concentrations were higher after extrasheath injection [8.0 (6.3-9.7) vs 5.8 (4.5-7.0), microg/mL, means (95% confidence intervals), P < .05].",Failed axillary brachial plexus block techniques result in high plasma concentrations of mepivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9425973/),"[,·μg] / [ml]",5.8,214762,DB00668,Epinephrine
,3300758,Blood loss,Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/- 16 ml; placebo 114 +/- 20 ml).,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),ml,104,215212,DB00668,Epinephrine
,3300758,Blood loss,Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/- 16 ml; placebo 114 +/- 20 ml).,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),ml,114,215213,DB00668,Epinephrine
,3300758,time after ingestion to peak concentration,The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml-1.,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),min,105,215214,DB00668,Epinephrine
,3300758,concentration,The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml-1.,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),[ng] / [ml],7.8,215215,DB00668,Epinephrine
,15505444,BIS,"In a randomized, prospective design, 20 patients received propofol at a target concentration of 3 microg/ml, whereas in 20 patients propofol was titrated to maintain a BIS value of 40-50.",Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505444/),,40-50,216645,DB00668,Epinephrine
,3213936,peak plasma concentrations,"Although the endogenous release of epinephrine produced peak plasma concentrations of 214 +/- 86 ng/ml (mean +/- SEM) during cardiac massage, only 5 animals were successfully resuscitated in group A.",[Pharmacokinetics and dynamics of endogenously released and therapeutically administered adrenaline in resuscitation. A comparative animal experimental study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3213936/),[ng] / [ml],214,218951,DB00668,Epinephrine
,3213936,peak plasma concentrations,"All animals in groups B and C were successfully resuscitated and peak plasma concentrations of epinephrine were achieved with comparable onset times (317 +/- 53 ng/ml after 2.5 min in group B, 634 +/- 202 ng/ml after 3 min in group C).",[Pharmacokinetics and dynamics of endogenously released and therapeutically administered adrenaline in resuscitation. A comparative animal experimental study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3213936/),[ng] / [ml],317,218952,DB00668,Epinephrine
,3213936,peak plasma concentrations,"All animals in groups B and C were successfully resuscitated and peak plasma concentrations of epinephrine were achieved with comparable onset times (317 +/- 53 ng/ml after 2.5 min in group B, 634 +/- 202 ng/ml after 3 min in group C).",[Pharmacokinetics and dynamics of endogenously released and therapeutically administered adrenaline in resuscitation. A comparative animal experimental study]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3213936/),[ng] / [ml],634,218953,DB00668,Epinephrine
,3213936,onset times,"All animals in groups B and C were successfully resuscitated and peak plasma concentrations of epinephrine were achieved with comparable onset times (317 +/- 53 ng/ml after 2.5 min in group B, 634 +/- 202 ng/ml after 3 min in group C).",[Pharmacokinetics and dynamics of endogenously released and therapeutically administered adrenaline in resuscitation. A comparative animal experimental study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3213936/),[ng] / [ml],317,218954,DB00668,Epinephrine
,3213936,onset times,"All animals in groups B and C were successfully resuscitated and peak plasma concentrations of epinephrine were achieved with comparable onset times (317 +/- 53 ng/ml after 2.5 min in group B, 634 +/- 202 ng/ml after 3 min in group C).",[Pharmacokinetics and dynamics of endogenously released and therapeutically administered adrenaline in resuscitation. A comparative animal experimental study]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3213936/),[ng] / [ml],634,218955,DB00668,Epinephrine
,3213936,bioavailability,"The mean bioavailability with this route of administration, however, was 40% (5-71%).",[Pharmacokinetics and dynamics of endogenously released and therapeutically administered adrenaline in resuscitation. A comparative animal experimental study]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3213936/),%,40,218956,DB00668,Epinephrine
,2316876,Peak lidocaine serum concentrations,"Peak lidocaine serum concentrations, 1.9 +/- 0.7 micrograms/mL, were present 9 +/- 3 min after injection of the loading dose.",Continuous intercostal blockade with lidocaine after thoracic surgery. Clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316876/),[μg] / [ml],1.9,219268,DB00668,Epinephrine
,2316876,Serum concentrations,"Serum concentrations of lidocaine under steady state conditions averaged 4.8 +/- 0.9 micrograms/mL (range, 3.5-5.8 micrograms/mL).",Continuous intercostal blockade with lidocaine after thoracic surgery. Clinical and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316876/),[μg] / [ml],4.8,219269,DB00668,Epinephrine
,31452900,peak concentration,"After inhalation, the peak concentration of thymol in mouse serum was 42.3 ng/mL (Cmax ) and occurred at 2 minutes (tmax ).",Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452900/),[ng] / [ml],42.3,219700,DB00668,Epinephrine
,31452900,Cmax,"After inhalation, the peak concentration of thymol in mouse serum was 42.3 ng/mL (Cmax ) and occurred at 2 minutes (tmax ).",Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452900/),[ng] / [ml],42.3,219701,DB00668,Epinephrine
,31452900,tmax,"After inhalation, the peak concentration of thymol in mouse serum was 42.3 ng/mL (Cmax ) and occurred at 2 minutes (tmax ).",Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452900/),min,2,219702,DB00668,Epinephrine
,31452900,AUC of,The AUC of the inhaled thymol at 0-60 minutes (AUC0-60) was 464 ng/mL/min.,Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452900/),[ng] / [min·ml],464,219703,DB00668,Epinephrine
,31452900,bioavailability,"In fact, the bioavailability for the net inhalation of thymol was 74% and 77% relative to that for IV injection per AUC0-60min and AUC0-infinite, respectively.",Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452900/),%,74,219704,DB00668,Epinephrine
,31452900,bioavailability,"In fact, the bioavailability for the net inhalation of thymol was 74% and 77% relative to that for IV injection per AUC0-60min and AUC0-infinite, respectively.",Pharmacokinetic study of thymol after intravenous injection and high-dose inhalation in mouse model. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31452900/),%,77,219705,DB00668,Epinephrine
,19622169,half-life,The corresponding half-life was 3.5 minutes.,Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19622169/),min,3.5,220582,DB00668,Epinephrine
,18547152,Tmax,The phentolamine Tmax occurred earlier following the intravenous administration of 1Piv (7 minutes than following its submucosal administration in treatment 1L1P (15 minutes) or 4L2P (11 minutes).,Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547152/),min,7,220621,DB00668,Epinephrine
,18547152,Tmax,The phentolamine Tmax occurred earlier following the intravenous administration of 1Piv (7 minutes than following its submucosal administration in treatment 1L1P (15 minutes) or 4L2P (11 minutes).,Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547152/),min,15,220622,DB00668,Epinephrine
,18547152,Tmax,The phentolamine Tmax occurred earlier following the intravenous administration of 1Piv (7 minutes than following its submucosal administration in treatment 1L1P (15 minutes) or 4L2P (11 minutes).,Pharmacokinetics of lidocaine with epinephrine following local anesthesia reversal with phentolamine mesylate. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18547152/),min,11,220623,DB00668,Epinephrine
,10780953,VO(2 max),"Seven fit male subjects (26 +/- 2 yr, body mass index 23 +/- 0.5 kg/m(2), VO(2 max) 65 +/- 5 ml x kg(-1) x min(-1)) underwent 40 min of postabsorptive cycle ergometer exercise (145 +/- 14 W) once without [control (CON)] and once with Epi infusion [EPI (0.1 microg x kg(-1) x min(-1))] from 30 to 40 min.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[ml] / [kg·min],65,221477,DB00668,Epinephrine
,10780953,Epi levels,"Epi levels reached 9.4 +/- 0.8 nM (20x rest, 10x CON).",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),nM,9.4,221478,DB00668,Epinephrine
,10780953,R(a),R(a) increased approximately 70% to 3.75 +/- 0.53 in CON but to 8.57 +/- 0.58 mg x kg(-1) x min(-1) in EPI (P < 0.001).,Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[mg] / [kg·min],3.75,221479,DB00668,Epinephrine
,10780953,R(a),R(a) increased approximately 70% to 3.75 +/- 0.53 in CON but to 8.57 +/- 0.58 mg x kg(-1) x min(-1) in EPI (P < 0.001).,Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),[mg] / [kg·min],8.57,221480,DB00668,Epinephrine
,10780953,peak R(d),"In EPI, peak R(d) (5.55 +/- 0.54 vs.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,5.55,221481,DB00668,Epinephrine
,10780953,R(a)-to-R(d),"The R(a)-to-R(d) imbalance in EPI caused hyperglycemia (7.12 +/- 0.22 vs. 5.59 +/- 0.22 mM, P = 0.001) until minute 60 of recovery.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,7,221482,DB00668,Epinephrine
,10780953,R(a)-to-R(d),"The R(a)-to-R(d) imbalance in EPI caused hyperglycemia (7.12 +/- 0.22 vs. 5.59 +/- 0.22 mM, P = 0.001) until minute 60 of recovery.",Epinephrine infusion during moderate intensity exercise increases glucose production and uptake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10780953/),,5,221483,DB00668,Epinephrine
,12805913,t1/2alpha,Lidocaine is eliminated biexponentially with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),min,9.95,225154,DB00668,Epinephrine
,12805913,t1/2beta,Lidocaine is eliminated biexponentially with a t1/2alpha of 9.95 +/- 14.3 min and a t1/2beta of 2.86 +/- 1.55 h.,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.86,225155,DB00668,Epinephrine
,12805913,tmax,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.31,225156,DB00668,Epinephrine
,12805913,Cmax,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.32,225157,DB00668,Epinephrine
,12805913,t1/2beta,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,2.36,225158,DB00668,Epinephrine
,12805913,total body clearance,Lidocaine is metabolised into MEGX (tmax 2.31 +/- 0.84 h; Cmax 0.32 +/- 0.13 mg l(-1); t1/2beta 2.36 +/- 2.35 h; total body clearance was 67.9 +/- 28.9 l h(-1)).,Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],67.9,225159,DB00668,Epinephrine
,12805913,t1/2,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,4.78,225160,DB00668,Epinephrine
,12805913,Cmax,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],3.89,225161,DB00668,Epinephrine
,12805913,tmax,"Mepivacaine is eliminated rapidly and monoexponentially with a t1/2 of 4.78 +/- 2.38 h, a Cmax of 3.89 +/- 0.83 mg l(-1), and a tmax of 0.41 +/- 0.19 h.",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,0.41,225162,DB00668,Epinephrine
,12805913,total body clearance,"The total body clearance of mepivacaine is 50% of that of lidocaine, 26.9 +/- 10.6 l h(-1) vs. 67.9 +/- 28.9 l h-1, respectively (p < 0.0001).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],26.9,225163,DB00668,Epinephrine
,12805913,total body clearance,"The total body clearance of mepivacaine is 50% of that of lidocaine, 26.9 +/- 10.6 l h(-1) vs. 67.9 +/- 28.9 l h-1, respectively (p < 0.0001).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[l] / [h],67.9,225164,DB00668,Epinephrine
,12805913,Cmax,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.45,225165,DB00668,Epinephrine
,12805913,t1/2beta,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,6.48,225166,DB00668,Epinephrine
,12805913,Cmax,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),[mg] / [l],0.56,225167,DB00668,Epinephrine
,12805913,t1/2beta,"(+/-)mepivacaine is metabolised into (+/-)4-OHmepivacaine (Cmax 0.45 +/- 0.25 mg l(-1); t1/2beta 6.48 +/- 6.57 h) and (+/-)2,6-pipecoloxylidide (Cmax 0.56 +/- 0.30 mg l(-1); t1/2beta 1.48 +/- 0.74 h).",Similar motor block effects and disposition kinetics between lidocaine and (+/-)mepivacaine in patients undergoing axillary brachial plexus block during day case surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12805913/),h,1.48,225168,DB00668,Epinephrine
,1513725,plasma,The plasma epinephrine clearance rate was 186 +/- 17 ml/kg/min by the intraosseous route versus 174 +/- 11 ml/kg/min by the intravenous route.,Intraosseous versus intravenous epinephrine infusions in lambs: pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513725/),[ml] / [kg·min],186,227397,DB00668,Epinephrine
,1513725,plasma,The plasma epinephrine clearance rate was 186 +/- 17 ml/kg/min by the intraosseous route versus 174 +/- 11 ml/kg/min by the intravenous route.,Intraosseous versus intravenous epinephrine infusions in lambs: pharmacokinetics and pharmacodynamics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513725/),[ml] / [kg·min],174,227398,DB00668,Epinephrine
,1513725,threshold,"The plasma epinephrine threshold, or lowest plasma level beyond which discernible increases in blood pressure occur, was slightly lower after intravenous than after intraosseous drug administration, 2.0 +/- 0.6 ng/ml versus 4.0 +/- 0.9 ng/ml of epinephrine.",Intraosseous versus intravenous epinephrine infusions in lambs: pharmacokinetics and pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1513725/),[ng] / [ml],4.0,227399,DB00668,Epinephrine
,1797482,bioavailability,The estimated bioavailability of subcutaneous insulin was 103.0 +/- 10.5% of the injected dose.,Intravenous insulin infusion to simulate subcutaneous absorption. Bioavailability and metabolic sequelae. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1797482/),%,103.0,228476,DB00668,Epinephrine
,8873850,extraction ratio,"Results showed a high dialyser extraction ratio averaging 38.3%, but a low dialysis clearance of 67 ml/min.",Effect of dialysis on exogenous dopamine in haemodialysed critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873850/),%,38.3,229730,DB00668,Epinephrine
,8873850,clearance,"Results showed a high dialyser extraction ratio averaging 38.3%, but a low dialysis clearance of 67 ml/min.",Effect of dialysis on exogenous dopamine in haemodialysed critically ill patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873850/),[ml] / [min],67,229731,DB00668,Epinephrine
,8873850,fraction removed by dial,The fraction removed by dialysis is 2.5%.,Effect of dialysis on exogenous dopamine in haemodialysed critically ill patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8873850/),%,2.5,229732,DB00668,Epinephrine
,7340377,duration of anal,"The duration of analgesia was significantly longer, on average, with morphine (28 h) than with bupivacaine (4.3 h) when the drugs were given by the lumbar route.",A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,28,230195,DB00668,Epinephrine
,7340377,duration of anal,"The duration of analgesia was significantly longer, on average, with morphine (28 h) than with bupivacaine (4.3 h) when the drugs were given by the lumbar route.",A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,4.3,230196,DB00668,Epinephrine
,7340377,duration of pain relief,Thoracic administration of morphine also resulted in a significantly longer duration of pain relief (on average 9.8 h) than that of bupivacaine (3.8 h).,A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,9.8,230197,DB00668,Epinephrine
,7340377,duration of pain relief,Thoracic administration of morphine also resulted in a significantly longer duration of pain relief (on average 9.8 h) than that of bupivacaine (3.8 h).,A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,3.8,230198,DB00668,Epinephrine
,28066882,Highest ropivacaine,Highest ropivacaine concentration (Cmax ) was 1.06 μg/ml [0.34]; highest unbound ropivacaine concentration (Cu max ) was 0.09 μg/ml [0.05].,Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),[μg] / [ml],1.06,230671,DB00668,Epinephrine
,28066882,concentration (Cmax ),Highest ropivacaine concentration (Cmax ) was 1.06 μg/ml [0.34]; highest unbound ropivacaine concentration (Cu max ) was 0.09 μg/ml [0.05].,Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),[μg] / [ml],1.06,230672,DB00668,Epinephrine
,28066882,highest unbound ropivacaine concentration (Cu max ),Highest ropivacaine concentration (Cmax ) was 1.06 μg/ml [0.34]; highest unbound ropivacaine concentration (Cu max ) was 0.09 μg/ml [0.05].,Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),[μg] / [ml],0.09,230673,DB00668,Epinephrine
,28066882,time to reach the maximum concentration,"The corresponding time to reach the maximum concentration for total ropivacaine was 312 min [120] after tourniquet release, and for the unbound fraction 265 [110] min after tourniquet release.",Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),min,312,230674,DB00668,Epinephrine
,28066882,unbound fraction,"The corresponding time to reach the maximum concentration for total ropivacaine was 312 min [120] after tourniquet release, and for the unbound fraction 265 [110] min after tourniquet release.",Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),min,265,230675,DB00668,Epinephrine
,28066882,systemic toxic,"Although great inter-individual variability was found between the maximum ropivacaine concentrations, both maximum total and unbound serum concentrations of ropivacaine remained well below the assumed systemic toxic thresholds of 4.3 and 0.56 μg/ml.",Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),,4.3,230676,DB00668,Epinephrine
,28066882,systemic toxic,"Although great inter-individual variability was found between the maximum ropivacaine concentrations, both maximum total and unbound serum concentrations of ropivacaine remained well below the assumed systemic toxic thresholds of 4.3 and 0.56 μg/ml.",Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28066882/),,0,230677,DB00668,Epinephrine
,29909577,apparent volume,"The estimates (between subject variability; relative standard error, %) of apparent volume, apparent clearance, tumescent absorption rate, and instillation absorption rate were 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and 2.56 (135.3; 44.9%) h-1, respectively.",Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29909577/),,195.0,232436,DB00668,Epinephrine
,29909577,apparent clearance,"The estimates (between subject variability; relative standard error, %) of apparent volume, apparent clearance, tumescent absorption rate, and instillation absorption rate were 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and 2.56 (135.3; 44.9%) h-1, respectively.",Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29909577/),[l] / [h],24.7,232437,DB00668,Epinephrine
,29909577,instillation absorption rate,"The estimates (between subject variability; relative standard error, %) of apparent volume, apparent clearance, tumescent absorption rate, and instillation absorption rate were 195.0 (46.3; 14.5%) L, 24.7 (48.9; 13.3%) L h-1, 0.28 (39.6; 13.8%) h-1, and 2.56 (135.3; 44.9%) h-1, respectively.",Population pharmacokinetic model for tumescent lidocaine in women undergoing breast cancer surgery. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29909577/),,2.56,232438,DB00668,Epinephrine
,28214793,time,Median time (interquartile range) to achieve ROSC was significantly longer in the ETT group (including those that received RA epinephrine) compared to the intravenous group (4.5 [2.9-7.4] versus 2 [1.9-3] minutes; P=0.02).,Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28214793/),min,4.5,234216,DB00668,Epinephrine
,28214793,time,Median time (interquartile range) to achieve ROSC was significantly longer in the ETT group (including those that received RA epinephrine) compared to the intravenous group (4.5 [2.9-7.4] versus 2 [1.9-3] minutes; P=0.02).,Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28214793/),min,2,234217,DB00668,Epinephrine
,28214793,peak plasma epinephrine concentrations,RA and low UVC epinephrine administration achieved comparable peak plasma epinephrine concentrations (470±250 versus 450±190 ng/mL) by 1 minute compared to ETT values of 130±60 ng/mL at 5 minutes; P=0.03.,Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28214793/),[ng] / [ml],470,234218,DB00668,Epinephrine
,28214793,peak plasma epinephrine concentrations,RA and low UVC epinephrine administration achieved comparable peak plasma epinephrine concentrations (470±250 versus 450±190 ng/mL) by 1 minute compared to ETT values of 130±60 ng/mL at 5 minutes; P=0.03.,Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28214793/),[ng] / [ml],450,234219,DB00668,Epinephrine
,28214793,peak plasma epinephrine concentrations,RA and low UVC epinephrine administration achieved comparable peak plasma epinephrine concentrations (470±250 versus 450±190 ng/mL) by 1 minute compared to ETT values of 130±60 ng/mL at 5 minutes; P=0.03.,Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28214793/),[ng] / [ml],130,234220,DB00668,Epinephrine
,28214793,peak epinephrine concentration,"Following ROSC with ETT epinephrine alone, there was a delayed peak epinephrine concentration (652±240 ng/mL).",Evaluation of Timing and Route of Epinephrine in a Neonatal Model of Asphyxial Arrest. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28214793/),[ng] / [ml],652,234221,DB00668,Epinephrine
,952693,Spread of,Spread of sensory analgesia to four segments above and below the site of injection was faster with etidocaine (13 +/- 3 min) (mean +/- SD) than with bupivacaine (22 +/- 8 min).,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,13,235381,DB00668,Epinephrine
,952693,Spread of,Spread of sensory analgesia to four segments above and below the site of injection was faster with etidocaine (13 +/- 3 min) (mean +/- SD) than with bupivacaine (22 +/- 8 min).,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,22,235382,DB00668,Epinephrine
,952693,regression of,"The onset of motor blockade tended to be faster with etidocaine (5.8 +/- 3.0 min), than with bupivacaine (10.0 +/- 3.5 min); regression of motor blockade by one unit was longer with etidocaine (306 +/- 103 min) than bupivacaine (238 +/- 75 min).","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,306,235383,DB00668,Epinephrine
,952693,regression of,"The onset of motor blockade tended to be faster with etidocaine (5.8 +/- 3.0 min), than with bupivacaine (10.0 +/- 3.5 min); regression of motor blockade by one unit was longer with etidocaine (306 +/- 103 min) than bupivacaine (238 +/- 75 min).","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,238,235384,DB00668,Epinephrine
,952693,maximum arterial plasma concentration,"The mean maximum arterial plasma concentration of etidocaine was 1.52 +/- 0.64 mug/ml, at 14 +/- 2 min and of bupivacaine was 1.35 +/- 0.63 mug/ml, achieved at 20 +/- 4 min.","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),[μg] / [ml],1.52,235385,DB00668,Epinephrine
,952693,maximum arterial plasma concentration,"The mean maximum arterial plasma concentration of etidocaine was 1.52 +/- 0.64 mug/ml, at 14 +/- 2 min and of bupivacaine was 1.35 +/- 0.63 mug/ml, achieved at 20 +/- 4 min.","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),[μg] / [ml],1.35,235386,DB00668,Epinephrine
,952693,fast,The systemic absorption of both drugs occurred in a biphasic pattern with a fast and slow half-life of 0.3 and approximately 8 h respectively.,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),h,0.3,235387,DB00668,Epinephrine
,952693,half-life,The systemic absorption of both drugs occurred in a biphasic pattern with a fast and slow half-life of 0.3 and approximately 8 h respectively.,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),h,0.3,235388,DB00668,Epinephrine
,952693,half-life,The systemic absorption of both drugs occurred in a biphasic pattern with a fast and slow half-life of 0.3 and approximately 8 h respectively.,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),h,8,235389,DB00668,Epinephrine
,10910841,peak plasma epinephrine concentration,The peak plasma epinephrine concentration was significantly larger after treatment with E + water (26.5 +/- 7.9 ng/mL) than after E + saline (2.1 +/- 0.7 ng/mL).,A comparison of distilled water and normal saline as diluents for endobronchial administration of epinephrine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10910841/),[ng] / [ml],26.5,237062,DB00668,Epinephrine
,10910841,peak plasma epinephrine concentration,The peak plasma epinephrine concentration was significantly larger after treatment with E + water (26.5 +/- 7.9 ng/mL) than after E + saline (2.1 +/- 0.7 ng/mL).,A comparison of distilled water and normal saline as diluents for endobronchial administration of epinephrine in the dog. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10910841/),[ng] / [ml],2.1,237063,DB00668,Epinephrine
,1467100,half-life,"Mean half-life was 72.9 (SEM 9.9) min, similar to that found previously in adults and children.",Pharmacokinetics of lignocaine in children after infiltration for cleft palate surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467100/),min,72.9,237824,DB00668,Epinephrine
,1467100,clearance,However differences in mean clearance (24.6 (2.04) ml kg-1 min-1) and volume of distribution (0.80 (0.07) litre kg-1) were found between this and previous studies.,Pharmacokinetics of lignocaine in children after infiltration for cleft palate surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467100/),[ml] / [kg·min],24.6,237825,DB00668,Epinephrine
,1467100,volume of distribution,However differences in mean clearance (24.6 (2.04) ml kg-1 min-1) and volume of distribution (0.80 (0.07) litre kg-1) were found between this and previous studies.,Pharmacokinetics of lignocaine in children after infiltration for cleft palate surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1467100/),[l] / [kg],0.80,237826,DB00668,Epinephrine
,16952812,C(max),"The lumbar-plexus block C(max) was less (986 +/- 221 ng/mL) than for the combined blocks (1,560 +/- 351 ng/mL, P = .0004).",Combined lumbar-plexus and sciatic-nerve blocks: an analysis of plasma ropivacaine concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952812/),[ng] / [ml],986,244330,DB00668,Epinephrine
,16952812,C(max),"The lumbar-plexus block C(max) was less (986 +/- 221 ng/mL) than for the combined blocks (1,560 +/- 351 ng/mL, P = .0004).",Combined lumbar-plexus and sciatic-nerve blocks: an analysis of plasma ropivacaine concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952812/),[ng] / [ml],"1,560",244331,DB00668,Epinephrine
,16952812,T(max),"The T(max) was greater for the lumbar plexus (80 +/- 49 min) than for the combined blocks (38 +/- 22 min, P = .03).",Combined lumbar-plexus and sciatic-nerve blocks: an analysis of plasma ropivacaine concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952812/),min,80,244332,DB00668,Epinephrine
,16952812,T(max),"The T(max) was greater for the lumbar plexus (80 +/- 49 min) than for the combined blocks (38 +/- 22 min, P = .03).",Combined lumbar-plexus and sciatic-nerve blocks: an analysis of plasma ropivacaine concentrations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16952812/),min,38,244333,DB00668,Epinephrine
,3236225,percent of dose systemically absorbed,"Based on the area under the plasma concentration curve from zero to 120 min, the percent of dose systemically absorbed was 36.1 +/- 4.4% for YAGFM, at least 3.3 +/- 0.2% for inulin, and 58.5 +/- 4.4% for epinephrine.","Systemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3236225/),%,36.1,246215,DB00668,Epinephrine
,3236225,percent of dose systemically absorbed,"Based on the area under the plasma concentration curve from zero to 120 min, the percent of dose systemically absorbed was 36.1 +/- 4.4% for YAGFM, at least 3.3 +/- 0.2% for inulin, and 58.5 +/- 4.4% for epinephrine.","Systemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3236225/),%,3.,246216,DB00668,Epinephrine
,3236225,percent of dose systemically absorbed,"Based on the area under the plasma concentration curve from zero to 120 min, the percent of dose systemically absorbed was 36.1 +/- 4.4% for YAGFM, at least 3.3 +/- 0.2% for inulin, and 58.5 +/- 4.4% for epinephrine.","Systemic absorption of ocularly administered enkephalinamide and inulin in the albino rabbit: extent, pathways, and vehicle effects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3236225/),%,58.5,246217,DB00668,Epinephrine
,1688484,Time to placement,"Time to placement of the intraosseous needle varied from 15 seconds to 5 minutes, with a mean of 60 seconds.","Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688484/),min,5,247741,DB00668,Epinephrine
,1688484,Time to placement,"Time to placement of the intraosseous needle varied from 15 seconds to 5 minutes, with a mean of 60 seconds.","Comparison study of intraosseous, central intravenous, and peripheral intravenous infusions of emergency drugs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688484/),seconds,60,247742,DB00668,Epinephrine
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],5.6,247758,DB00668,Epinephrine
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],1.6,247759,DB00668,Epinephrine
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],5.5,247760,DB00668,Epinephrine
,10233203,"area under serum drug concentration (AUC (0, 2 h)","During the first 2 h after the 200 mg dose, dental extraction resulted in a significant reduction of the area under serum drug concentration (AUC (0, 2 h) mg l-1 h) from 5.6+/-2.9 to 1.6+/-1.8 (P<0.01) and from 5.5+/-3.0 to 2.1+/-2.0 (P<0.05) for S and R-ibuprofen, respectively.",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],2.1,247761,DB00668,Epinephrine
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],14.2,247762,DB00668,Epinephrine
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],7.2,247763,DB00668,Epinephrine
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),,14.4,247764,DB00668,Epinephrine
,10233203,"AUC (0, 2 h)","Similar observations were made following the 600 mg dose for AUC (0, 2 h) of S-ibuprofen (from 14.2+/-6.1 to 7.2+/-5.5 mg l-1 h, P<0.05) with no significant difference for R-ibuprofen (from 14.4+/-9.5 to 5.8+/-7. 1).",Pain-mediated altered absorption and metabolism of ibuprofen: an explanation for decreased serum enantiomer concentration after dental surgery. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10233203/),[h·mg] / [l],5.8,247765,DB00668,Epinephrine
,32528643,time to peak concentration,"There were numerical trends toward higher peak epinephrine concentrations (0.52 vs 0.35 ng/mL; geometric mean ratio, 1.40; 90% CI 117.6-164.6%) and more rapid exposure (time to peak concentration, 20 vs 50 min) for EpiPen vs IM syringe at mid-AL thigh across STMD groups.",Epinephrine delivery via EpiPen® Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32528643/),min,20,249068,DB00668,Epinephrine
,32528643,time to peak concentration,"There were numerical trends toward higher peak epinephrine concentrations (0.52 vs 0.35 ng/mL; geometric mean ratio, 1.40; 90% CI 117.6-164.6%) and more rapid exposure (time to peak concentration, 20 vs 50 min) for EpiPen vs IM syringe at mid-AL thigh across STMD groups.",Epinephrine delivery via EpiPen® Auto-Injector or manual syringe across participants with a wide range of skin-to-muscle distances. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32528643/),min,50,249069,DB00668,Epinephrine
,8250719,maximum concentration,The mean of maximum concentration of HCS was 26.38 mg/L.,[Pharmacokinetics and pharmacodynamics of hydrocortisone in asthmatic children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250719/),[mg] / [l],26.38,250413,DB00668,Epinephrine
,8250719,half-life,The concentration of HCS decreased rapidly with a half-life of 0.09 hr (5.38 min).,[Pharmacokinetics and pharmacodynamics of hydrocortisone in asthmatic children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250719/),h,0.09,250414,DB00668,Epinephrine
,8250719,half-life,"The concentration of hydrocortisone reached to a peak value of 4.96 mg/L after 10 min, and then decreased with a half-life of 1.24 hour.",[Pharmacokinetics and pharmacodynamics of hydrocortisone in asthmatic children]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8250719/),h,1.24,250415,DB00668,Epinephrine
,11152032,total bupivacaine,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],742,251947,DB00668,Epinephrine
,11152032,total bupivacaine,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],400.5,251948,DB00668,Epinephrine
,11152032,concentration,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],742,251949,DB00668,Epinephrine
,11152032,concentration,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],400.5,251950,DB00668,Epinephrine
,11152032,apparent,"The median ""apparent"" terminal half-life (t1/2) was significantly longer in the ""adrenaline"" group (363 min; range 238-537 min) compared to the ""plain"" group (n=6) (165 min; range 104-264 min), P=0.0087.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),min,363,251951,DB00668,Epinephrine
,11152032,apparent,"The median ""apparent"" terminal half-life (t1/2) was significantly longer in the ""adrenaline"" group (363 min; range 238-537 min) compared to the ""plain"" group (n=6) (165 min; range 104-264 min), P=0.0087.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),min,165,251952,DB00668,Epinephrine
,2550167,t1/2,"In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day.",Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550167/),h,18 to 24,253025,DB00668,Epinephrine
,2550167,t1/2,"In a single-blind randomized study, 10 healthy men took a placebo for 1 week and then took nadolol one time a day (t1/2, 18 to 24 hours) or propranolol three times a day (t1/2, 4 to 6 hours) in doses that were increased weekly for 4 weeks to reach 240 mg per day.",Beta-blockade disappearance rate predicts beta-adrenergic hypersensitivity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2550167/),h,4 to 6,253026,DB00668,Epinephrine
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],341,256101,DB00668,Epinephrine
,1672843,time of peak plasma drug concentration,"Maximum reduction in ST-segment depression was found 4 and 8 h after IS-5-MN intake both after one-week and long-term therapy at the time of peak plasma drug concentration (341 +/- 95 and 405 +/- 125 ng/ml, respectively).","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],405,256102,DB00668,Epinephrine
below,1672843,residual plasma concentration,"At a residual plasma concentration below 100 ng/ml, ST depression was not significantly improved 24 h after drug intake compared with placebo.","Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),,100,256103,DB00668,Epinephrine
,1672843,Maximum IS-5-MN plasma concentrations,Maximum IS-5-MN plasma concentrations at a mean of 445 +/- 116 ng/ml were reached after 5.8 +/- 2.9 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),[ng] / [ml],445,256104,DB00668,Epinephrine
,1672843,Beta-phase half-life of elimination,Beta-phase half-life of elimination was 9 +/- 3 h.,"Hemodynamic, anti-ischemic, and neurohumoral effects of slow-release isosorbide-5-mononitrate in patients with coronary artery disease after short- and long-term therapy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1672843/),h,9,256105,DB00668,Epinephrine
,7315181,t 1/2 alpha,Elimination of dopamine from plasma after termination of infusion had a biphasic course with t 1/2 alpha around 1 min and t 1/2 beta about 9 min in both groups.,Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315181/),min,1,256330,DB00668,Epinephrine
,7315181,t 1/2 beta,Elimination of dopamine from plasma after termination of infusion had a biphasic course with t 1/2 alpha around 1 min and t 1/2 beta about 9 min in both groups.,Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7315181/),min,9,256331,DB00668,Epinephrine
,18162599,affinity (K(A)),The pharmacokinetic-pharmacodynamic relationship of isoprenaline was first characterized with the operational model of agonism using the literature value for the affinity (K(A)) of isoprenaline (3.2 x 10(-8) M; left atria WKY rats).,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,3.2 x 10(-8),257983,DB00668,Epinephrine
,18162599,baseline (E(0)),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),,374,257984,DB00668,Epinephrine
,18162599,maximal effect (E(max)),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),[beats] / [min],130,257985,DB00668,Epinephrine
,18162599,efficacy (tau),"Resulting estimates for baseline (E(0)), maximal effect (E(max)), and efficacy (tau) were 374 (1.9%), 130 (5.9%), and 247 (33%) beats per minute, respectively.",Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),[beats] / [min],247,257986,DB00668,Epinephrine
,18162599,affinity (K(B)),The estimated in vivo affinity (K(B)) of S(-)-atenolol for the beta(1) -receptor was 4.6 x 10(-8) M.,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,4.6 x 10(-8),257987,DB00668,Epinephrine
,18162599,affinity,The obtained estimate for in vivo affinity of S(-)-atenolol (4.6 x 10(-8) M) is comparable to literature values for the in vitro affinity in functional assays.,Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18162599/),M,4.6 x 10(-8),257988,DB00668,Epinephrine
,8352818,urinary recovery,"The 24-h urinary recovery of the 3 metabolites considered together, expressed as a percentage of the dose of SIM2055 administered, was 78 +/- 6 with the 100 mg dose, 66 +/- 11 with the 200 mg dose and 55 +/- 6 with the 300 mg dose (mean +/- S. D.).",Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352818/),,78,258850,DB00668,Epinephrine
,8352818,urinary recovery,"The 24-h urinary recovery of the 3 metabolites considered together, expressed as a percentage of the dose of SIM2055 administered, was 78 +/- 6 with the 100 mg dose, 66 +/- 11 with the 200 mg dose and 55 +/- 6 with the 300 mg dose (mean +/- S. D.).",Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352818/),,66,258851,DB00668,Epinephrine
,8352818,urinary recovery,"The 24-h urinary recovery of the 3 metabolites considered together, expressed as a percentage of the dose of SIM2055 administered, was 78 +/- 6 with the 100 mg dose, 66 +/- 11 with the 200 mg dose and 55 +/- 6 with the 300 mg dose (mean +/- S. D.).",Kinetics and pharmacodynamic effects of a novel prodrug of N-methyldopamine at single dose in healthy volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8352818/),,55,258852,DB00668,Epinephrine
,3428692,Whole body clearance,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[l] / [min],1.6,260300,DB00668,Epinephrine
,3428692,Whole body clearance,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[l] / [min],1.7,260301,DB00668,Epinephrine
,3428692,overall appearance rate,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],4.2,260302,DB00668,Epinephrine
,3428692,overall appearance rate,"Whole body clearance of 3H-NA equal in the two groups (1.6 v 1.7 l/min, ns), while as the overall appearance rate of NA was significantly higher in alcoholic cirrhosis (4.2 v 2.6 nmol/min, p less than 0.02) indicating an enhanced sympathoadrenal activity in this group.",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],2.6,260303,DB00668,Epinephrine
,3428692,hepatic intestinal spillover rate,"The hepatic intestinal clearances of A, NA, and 3H-NA were not significantly different in patients and controls, but the estimated hepatic intestinal spillover rate of NA was 0.24 nmol/min in patients as compared with 0.0 nmol/min in controls (p less than 0.02).",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],0.24,260304,DB00668,Epinephrine
,3428692,hepatic intestinal spillover rate,"The hepatic intestinal clearances of A, NA, and 3H-NA were not significantly different in patients and controls, but the estimated hepatic intestinal spillover rate of NA was 0.24 nmol/min in patients as compared with 0.0 nmol/min in controls (p less than 0.02).",Hepatic intestinal uptake and release of catecholamines in alcoholic cirrhosis. Evidence of enhanced hepatic intestinal sympathetic nervous activity. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428692/),[nM] / [min],0.0,260305,DB00668,Epinephrine
,12401633,maximum total plasma ropivacaine concentration,"Mean (+/- SD) maximum total plasma ropivacaine concentration was smaller in the epinephrine group (arterial, 0.92 +/- 0.32 microg/mL; venous, 0.82 +/- 0.33 microg/mL) compared with the plain group (1.31 +/- 0.39 microg/mL and 1.31 +/- 0.50 microg/mL, respectively; P = 0.01).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),[μg] / [ml],0.92,261032,DB00668,Epinephrine
,12401633,maximum total plasma ropivacaine concentration,"Mean (+/- SD) maximum total plasma ropivacaine concentration was smaller in the epinephrine group (arterial, 0.92 +/- 0.32 microg/mL; venous, 0.82 +/- 0.33 microg/mL) compared with the plain group (1.31 +/- 0.39 microg/mL and 1.31 +/- 0.50 microg/mL, respectively; P = 0.01).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),[μg] / [ml],0.82,261033,DB00668,Epinephrine
,12401633,maximum total plasma ropivacaine concentration,"Mean (+/- SD) maximum total plasma ropivacaine concentration was smaller in the epinephrine group (arterial, 0.92 +/- 0.32 microg/mL; venous, 0.82 +/- 0.33 microg/mL) compared with the plain group (1.31 +/- 0.39 microg/mL and 1.31 +/- 0.50 microg/mL, respectively; P = 0.01).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),[μg] / [ml],1.31,261034,DB00668,Epinephrine
,12401633,maximum total plasma ropivacaine concentration,"Mean (+/- SD) maximum total plasma ropivacaine concentration was smaller in the epinephrine group (arterial, 0.92 +/- 0.32 microg/mL; venous, 0.82 +/- 0.33 microg/mL) compared with the plain group (1.31 +/- 0.39 microg/mL and 1.31 +/- 0.50 microg/mL, respectively; P = 0.01).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),[μg] / [ml],1.31,261035,DB00668,Epinephrine
,12401633,Time to maximum total plasma ropivacaine concentration,"Time to maximum total plasma ropivacaine concentration was not significantly different between groups (mean +/- SD; arterial, 16 +/- 2 min; venous, 23 +/- 2 min in the epinephrine group versus 9 +/- 2 min and 12 +/- 3 min, respectively, in the plain group; P = 0.08).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),min,16,261036,DB00668,Epinephrine
,12401633,Time to maximum total plasma ropivacaine concentration,"Time to maximum total plasma ropivacaine concentration was not significantly different between groups (mean +/- SD; arterial, 16 +/- 2 min; venous, 23 +/- 2 min in the epinephrine group versus 9 +/- 2 min and 12 +/- 3 min, respectively, in the plain group; P = 0.08).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),min,23,261037,DB00668,Epinephrine
,12401633,Time to maximum total plasma ropivacaine concentration,"Time to maximum total plasma ropivacaine concentration was not significantly different between groups (mean +/- SD; arterial, 16 +/- 2 min; venous, 23 +/- 2 min in the epinephrine group versus 9 +/- 2 min and 12 +/- 3 min, respectively, in the plain group; P = 0.08).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),min,9,261038,DB00668,Epinephrine
,12401633,Time to maximum total plasma ropivacaine concentration,"Time to maximum total plasma ropivacaine concentration was not significantly different between groups (mean +/- SD; arterial, 16 +/- 2 min; venous, 23 +/- 2 min in the epinephrine group versus 9 +/- 2 min and 12 +/- 3 min, respectively, in the plain group; P = 0.08).",The effect of the addition of epinephrine on early systemic absorption of epidural ropivacaine in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401633/),min,12,261039,DB00668,Epinephrine
,31477360,heart rate,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],115,265920,DB00668,Epinephrine
,31477360,respirations,"Vital signs were: BP, 66 mmHg/palpation; heart rate, 115/min; respirations 18/min; oxygen saturation, 100% on room air.",Toxicokinetics of hydroxychloroquine following a massive overdose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),1/[min],18,265921,DB00668,Epinephrine
,31477360,half-life,Serial concentrations demonstrated apparent first-order elimination with a half-life of 11.6 h.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265922,DB00668,Epinephrine
,31477360,apparent,The apparent 11.6 hour half-life of hydroxychloroquine was shorter than previously described.,Toxicokinetics of hydroxychloroquine following a massive overdose. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31477360/),h,11.6,265923,DB00668,Epinephrine
,26275090,peak plasma NeoSTX concentration,"Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),[pg] / [ml],67,267497,DB00668,Epinephrine
,26275090,peak plasma NeoSTX concentration,"Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),[pg] / [ml],134,267498,DB00668,Epinephrine
,26275090,peak plasma NeoSTX concentration,"Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),[pg] / [ml],164,267499,DB00668,Epinephrine
,26275090,time to near-complete recovery,"Median time to near-complete recovery for 10 μg NeoSTX-Bup-Epi was almost five-fold longer compared with Bup (50 vs. 10 h, P = 0.007).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),h,50,267500,DB00668,Epinephrine
,26275090,time to near-complete recovery,"Median time to near-complete recovery for 10 μg NeoSTX-Bup-Epi was almost five-fold longer compared with Bup (50 vs. 10 h, P = 0.007).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),h,10,267501,DB00668,Epinephrine
,32245384,Cmax,"There were no significant differences in Cmax and AUC1-90 between histamine and saline groups after IN epinephrine delivery (3.5 vs 1.7 ng/mL, p = 0.06, and 117 vs 59 ng/mL*minutes, p = 0.09, respectively).",Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32245384/),[ng] / [ml],3.5,269932,DB00668,Epinephrine
,32245384,Cmax,"There were no significant differences in Cmax and AUC1-90 between histamine and saline groups after IN epinephrine delivery (3.5 vs 1.7 ng/mL, p = 0.06, and 117 vs 59 ng/mL*minutes, p = 0.09, respectively).",Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32245384/),[ng] / [ml],1.7,269933,DB00668,Epinephrine
,32245384,AUC1-90,"There were no significant differences in Cmax and AUC1-90 between histamine and saline groups after IN epinephrine delivery (3.5 vs 1.7 ng/mL, p = 0.06, and 117 vs 59 ng/mL*minutes, p = 0.09, respectively).",Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32245384/),[ng] / [min·ml],117,269934,DB00668,Epinephrine
,32245384,AUC1-90,"There were no significant differences in Cmax and AUC1-90 between histamine and saline groups after IN epinephrine delivery (3.5 vs 1.7 ng/mL, p = 0.06, and 117 vs 59 ng/mL*minutes, p = 0.09, respectively).",Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32245384/),[ng] / [min·ml],59,269935,DB00668,Epinephrine
,32245384,Tmax,"After receiving IN epinephrine, the histamine group had a significantly lower Tmax versus the saline group (6 vs 70 min, respectively; p = 0.02).",Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32245384/),min,6,269936,DB00668,Epinephrine
,32245384,Tmax,"After receiving IN epinephrine, the histamine group had a significantly lower Tmax versus the saline group (6 vs 70 min, respectively; p = 0.02).",Intranasal epinephrine effects on epinephrine pharmacokinetics and heart rate in a nasal congestion canine model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32245384/),min,70,269937,DB00668,Epinephrine
,7648772,maximal increase,"The maximal increase in heart rate during isoproterenol infusion after entacapone administration (40 +/- 11 beats/min, mean +/- SD) was statistically greater (p = 0.0496) than after placebo administration (27 +/- 7 beats/min).",The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],40,270060,DB00668,Epinephrine
,7648772,maximal increase,"The maximal increase in heart rate during isoproterenol infusion after entacapone administration (40 +/- 11 beats/min, mean +/- SD) was statistically greater (p = 0.0496) than after placebo administration (27 +/- 7 beats/min).",The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],27,270061,DB00668,Epinephrine
,7648772,heart rate,The increase in heart rate during epinephrine infusion was 25 +/- 13 beats/min after entacapone administration and 14 +/- 9 beats/min after placebo administration (p = 0.127).,The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],25,270062,DB00668,Epinephrine
,7648772,heart rate,The increase in heart rate during epinephrine infusion was 25 +/- 13 beats/min after entacapone administration and 14 +/- 9 beats/min after placebo administration (p = 0.127).,The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7648772/),[beats] / [min],14,270063,DB00668,Epinephrine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,136,271167,DB00668,Epinephrine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,144,271168,DB00668,Epinephrine
,17640955,elimination half-life (t(1/2)),"Curiously, the approximate elimination half-life (t(1/2)) of MDMA at 18 degrees C (136 min) and 31 degrees C (144 min) was increased compared with 24 degrees C (90 min) and is most likely because of volume of distribution changes induced by core temperature alterations.","Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640955/),min,90,271169,DB00668,Epinephrine
,2687065,plasma clearance,In patients with (n = 8) and without (n = 8) neuropathy forearm venous plasma noradrenaline and adrenaline concentrations as well as plasma clearance of adrenaline based on arterial sampling (1.7 vs 2.1 l/min) were not significantly different.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),[l] / [min],1.7,272186,DB00668,Epinephrine
,2687065,plasma clearance,In patients with (n = 8) and without (n = 8) neuropathy forearm venous plasma noradrenaline and adrenaline concentrations as well as plasma clearance of adrenaline based on arterial sampling (1.7 vs 2.1 l/min) were not significantly different.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),[l] / [min],2.1,272187,DB00668,Epinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,2.7,272188,DB00668,Epinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,2.2,272189,DB00668,Epinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,3.7,272190,DB00668,Epinephrine
,2687065,initial disappearance time (T 1/2),"The initial disappearance time (T 1/2) after the infusion of the tritium labelled adrenaline had been stopped was significantly prolonged in Type 1 diabetic patients with neuropathy compared to those without (after 20 min infusion 2.7 vs 2.2 min, p less than 0.02, after 75 min infusion 3.7 vs 2.9 min, p less than 0.05).",Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,2.9,272191,DB00668,Epinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,6.5,272192,DB00668,Epinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,4.7,272193,DB00668,Epinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,18,272194,DB00668,Epinephrine
,2687065,sojourn time,The corresponding values for the mean sojourn time of adrenaline in plasma were 6.5 vs 4.7 min (p less than 0.05) after 20 min infusion and 18 vs 10 min (p less than 0.05) after 75 min of infusion.,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),min,10,272195,DB00668,Epinephrine
,2687065,space of distribution,The unchanged plasma clearance and the prolonged initial halftime and mean sojourn time of adrenaline in plasma suggest that adrenaline is distributed in a larger volume in Type 1 diabetic patients with neuropathy as compared to patients without neuropathy (estimated space of distribution 29 vs 20 l).,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),l,29,272196,DB00668,Epinephrine
,2687065,space of distribution,The unchanged plasma clearance and the prolonged initial halftime and mean sojourn time of adrenaline in plasma suggest that adrenaline is distributed in a larger volume in Type 1 diabetic patients with neuropathy as compared to patients without neuropathy (estimated space of distribution 29 vs 20 l).,Plasma adrenaline kinetics in type 1 (insulin-dependent) diabetic patients with and without autonomic neuropathy. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2687065/),l,20,272197,DB00668,Epinephrine
